Background  ||| S:24 E:43 ||| NNP
Cytosolic  ||| S:43 E:53 ||| NNP
PLA  ||| S:53 E:66 ||| NNP
2  ||| S:66 E:68 ||| CD
specifically  ||| S:68 E:81 ||| CD
hydrolyzes  ||| S:81 E:101 ||| CD
sn-2  ||| S:101 E:106 ||| CD
arachidonate  ||| S:106 E:119 ||| NN
from  ||| S:119 E:124 ||| IN
phospholipid  ||| S:124 E:145 ||| NNS
providing  ||| S:145 E:155 ||| VBG
the  ||| S:155 E:159 ||| DT
precursors  ||| S:159 E:170 ||| NN
for  ||| S:170 E:174 ||| IN
many  ||| S:174 E:179 ||| JJ
different  ||| S:179 E:189 ||| JJ
lipid  ||| S:189 E:195 ||| NNS
mediators  ||| S:195 E:213 ||| VBP
including  ||| S:213 E:223 ||| VBG
prostaglandins  ||| S:223 E:238 ||| NNS
and  ||| S:238 E:242 ||| CC
leukotrienes  ||| S:242 E:255 ||| NNS
[  ||| S:255 E:257 ||| -LRB-
1  ||| S:257 E:259 ||| CD
2  ||| S:259 E:261 ||| CD
]  ||| S:261 E:263 ||| -RRB-
.  ||| S:263 E:265 ||| .
These  ||| S:265 E:279 ||| DT
lipid  ||| S:279 E:285 ||| JJ
metabolites  ||| S:285 E:297 ||| NNS
play  ||| S:297 E:302 ||| VBP
a  ||| S:302 E:304 ||| DT
role  ||| S:304 E:309 ||| NN
in  ||| S:309 E:312 ||| IN
acute  ||| S:312 E:318 ||| JJ
inflammatory  ||| S:318 E:339 ||| JJ
responses  ||| S:339 E:349 ||| NNS
and  ||| S:349 E:353 ||| CC
also  ||| S:353 E:358 ||| RB
regulate  ||| S:358 E:367 ||| VB
normal  ||| S:367 E:374 ||| JJ
physiological  ||| S:374 E:388 ||| JJ
processes ||| S:388 E:397 ||| NNS
.  ||| S:397 E:407 ||| .
Certain  ||| S:407 E:415 ||| JJ
prostaglandins  ||| S:415 E:430 ||| NNS
are  ||| S:430 E:434 ||| VBP
required  ||| S:434 E:443 ||| VBN
for  ||| S:443 E:447 ||| IN
female  ||| S:447 E:454 ||| JJ
reproduction  ||| S:454 E:475 ||| NN
and  ||| S:475 E:479 ||| CC
kidney  ||| S:479 E:486 ||| NN
function  ||| S:486 E:495 ||| NN
[  ||| S:495 E:497 ||| -LRB-
3  ||| S:497 E:499 ||| CD
4  ||| S:499 E:501 ||| CD
5  ||| S:501 E:503 ||| CD
]  ||| S:503 E:505 ||| -RRB-
.  ||| S:505 E:507 ||| .
Because  ||| S:507 E:515 ||| IN
of  ||| S:515 E:518 ||| IN
its  ||| S:518 E:522 ||| PRP$
important  ||| S:522 E:540 ||| JJ
role  ||| S:540 E:545 ||| NN
in  ||| S:545 E:548 ||| IN
controlling  ||| S:548 E:560 ||| VBG
levels  ||| S:560 E:567 ||| NNS
of  ||| S:567 E:570 ||| IN
arachidonic  ||| S:570 E:582 ||| JJ
acid  ||| S:582 E:587 ||| NN
( ||| S:587 E:588 ||| -LRB-
AA ||| S:588 E:590 ||| NN
) ||| S:590 E:591 ||| -RRB-
,  ||| S:591 E:593 ||| ,
much  ||| S:593 E:606 ||| JJ
attention  ||| S:606 E:616 ||| NN
has  ||| S:616 E:620 ||| VBZ
been  ||| S:620 E:625 ||| VBN
focused  ||| S:625 E:633 ||| VBN
on  ||| S:633 E:636 ||| IN
the  ||| S:636 E:640 ||| DT
regulation  ||| S:640 E:651 ||| NN
of  ||| S:651 E:654 ||| IN
cPLA  ||| S:654 E:668 ||| JJ
2  ||| S:668 E:670 ||| CD
activation ||| S:670 E:680 ||| NN
,  ||| S:680 E:682 ||| ,
with  ||| S:682 E:687 ||| IN
particular  ||| S:687 E:698 ||| JJ
emphasis  ||| S:698 E:715 ||| NN
on  ||| S:715 E:718 ||| IN
the  ||| S:718 E:722 ||| DT
role  ||| S:722 E:727 ||| NN
of  ||| S:727 E:730 ||| IN
its  ||| S:730 E:734 ||| PRP$
phosphorylation  ||| S:734 E:750 ||| NN
and  ||| S:750 E:754 ||| CC
Ca  ||| S:754 E:757 ||| NNP
2+-mediated  ||| S:757 E:777 ||| FW
translocation  ||| S:777 E:791 ||| FW
[  ||| S:791 E:793 ||| -LRB-
6  ||| S:793 E:795 ||| CD
7  ||| S:795 E:797 ||| CD
8  ||| S:797 E:799 ||| CD
]  ||| S:799 E:801 ||| -RRB-
.  ||| S:801 E:811 ||| .
cPLA  ||| S:811 E:825 ||| SYM
2  ||| S:825 E:827 ||| CD
is  ||| S:827 E:830 ||| VBZ
regulated  ||| S:830 E:840 ||| VBN
by  ||| S:840 E:843 ||| IN
controlling  ||| S:843 E:855 ||| VBG
its  ||| S:855 E:867 ||| PRP$
cellular  ||| S:867 E:876 ||| JJ
localization  ||| S:876 E:889 ||| NN
and  ||| S:889 E:893 ||| CC
access  ||| S:893 E:900 ||| NN
to  ||| S:900 E:903 ||| TO
membrane-phospholipid  ||| S:903 E:933 ||| JJ
substrate ||| S:933 E:942 ||| NN
.  ||| S:942 E:944 ||| .
An  ||| S:944 E:947 ||| DT
amino  ||| S:947 E:953 ||| JJ
terminal ||| S:953 E:961 ||| NN
,  ||| S:961 E:963 ||| ,
calcium-dependent  ||| S:963 E:981 ||| JJ
lipid  ||| S:981 E:995 ||| NN
binding  ||| S:995 E:1003 ||| NNS
( ||| S:1003 E:1004 ||| -LRB-
CaLB  ||| S:1004 E:1009 ||| NNP
or  ||| S:1009 E:1012 ||| CC
C2 ||| S:1012 E:1014 ||| CD
)  ||| S:1014 E:1016 ||| -RRB-
domain  ||| S:1016 E:1023 ||| NN
regulates  ||| S:1023 E:1033 ||| VBZ
Ca  ||| S:1033 E:1036 ||| NNP
2+-mediated  ||| S:1036 E:1048 ||| NNP
cPLA  ||| S:1048 E:1062 ||| NNP
2  ||| S:1062 E:1064 ||| CD
translocation  ||| S:1064 E:1078 ||| NN
to  ||| S:1078 E:1081 ||| TO
intracellular  ||| S:1081 E:1103 ||| VB
membranes  ||| S:1103 E:1113 ||| NNS
[  ||| S:1113 E:1115 ||| -LRB-
9  ||| S:1115 E:1117 ||| CD
]  ||| S:1117 E:1119 ||| -RRB-
.  ||| S:1119 E:1121 ||| .
In  ||| S:1121 E:1124 ||| IN
vitro ||| S:1124 E:1129 ||| NN
,  ||| S:1129 E:1131 ||| ,
membrane  ||| S:1131 E:1140 ||| JJ
docking  ||| S:1140 E:1148 ||| NN
via  ||| S:1148 E:1152 ||| IN
the  ||| S:1152 E:1156 ||| DT
C2  ||| S:1156 E:1167 ||| JJ
domain  ||| S:1167 E:1174 ||| NN
is  ||| S:1174 E:1177 ||| VBZ
necessary  ||| S:1177 E:1187 ||| JJ
and  ||| S:1187 E:1191 ||| CC
sufficient  ||| S:1191 E:1202 ||| JJ
for  ||| S:1202 E:1206 ||| IN
catalysis  ||| S:1206 E:1216 ||| NN
and  ||| S:1216 E:1228 ||| CC
release  ||| S:1228 E:1236 ||| NN
of  ||| S:1236 E:1239 ||| IN
AA  ||| S:1239 E:1242 ||| NN
[  ||| S:1242 E:1244 ||| -LRB-
10  ||| S:1244 E:1247 ||| CD
]  ||| S:1247 E:1249 ||| -RRB-
.  ||| S:1249 E:1251 ||| .
Binding  ||| S:1251 E:1259 ||| VBG
of  ||| S:1259 E:1262 ||| IN
calcium  ||| S:1262 E:1270 ||| JJ
ions  ||| S:1270 E:1275 ||| NN
by  ||| S:1275 E:1278 ||| IN
the  ||| S:1278 E:1282 ||| DT
cPLA  ||| S:1282 E:1296 ||| JJ
2  ||| S:1296 E:1298 ||| CD
C2  ||| S:1298 E:1301 ||| CD
domain  ||| S:1301 E:1308 ||| NN
is  ||| S:1308 E:1311 ||| VBZ
essential  ||| S:1311 E:1321 ||| JJ
for  ||| S:1321 E:1325 ||| IN
the  ||| S:1325 E:1329 ||| DT
lipid  ||| S:1329 E:1343 ||| JJ
association  ||| S:1343 E:1355 ||| NN
in  ||| S:1355 E:1358 ||| IN
vitro  ||| S:1358 E:1364 ||| NNS
[  ||| S:1364 E:1366 ||| -LRB-
11  ||| S:1366 E:1369 ||| CD
12  ||| S:1369 E:1372 ||| CD
]  ||| S:1372 E:1374 ||| -RRB-
and  ||| S:1374 E:1378 ||| CC
translocation  ||| S:1378 E:1392 ||| NN
in  ||| S:1392 E:1395 ||| IN
vivo  ||| S:1395 E:1400 ||| NNS
[  ||| S:1400 E:1410 ||| -LRB-
13  ||| S:1410 E:1413 ||| CD
14  ||| S:1413 E:1416 ||| CD
]  ||| S:1416 E:1418 ||| -RRB-
.  ||| S:1418 E:1420 ||| .
In  ||| S:1420 E:1423 ||| IN
response  ||| S:1423 E:1432 ||| NN
to  ||| S:1432 E:1435 ||| TO
an  ||| S:1435 E:1438 ||| DT
increase  ||| S:1438 E:1447 ||| NN
in  ||| S:1447 E:1450 ||| IN
[ ||| S:1450 E:1451 ||| -LRB-
Ca  ||| S:1451 E:1454 ||| NNP
2+ ||| S:1454 E:1456 ||| NNP
]  ||| S:1456 E:1467 ||| -RRB-
i  ||| S:1467 E:1469 ||| FW
,  ||| S:1469 E:1471 ||| ,
cPLA  ||| S:1471 E:1485 ||| JJ
2  ||| S:1485 E:1487 ||| CD
translocates  ||| S:1487 E:1500 ||| NN
to  ||| S:1500 E:1503 ||| TO
the  ||| S:1503 E:1507 ||| DT
Golgi  ||| S:1507 E:1513 ||| NNP
and  ||| S:1513 E:1517 ||| CC
ER ||| S:1517 E:1519 ||| NNP
,  ||| S:1519 E:1529 ||| ,
however  ||| S:1529 E:1537 ||| RB
translocation  ||| S:1537 E:1551 ||| VBN
to  ||| S:1551 E:1554 ||| TO
Golgi  ||| S:1554 E:1560 ||| NNP
occurs  ||| S:1560 E:1567 ||| VBZ
at  ||| S:1567 E:1570 ||| IN
a  ||| S:1570 E:1572 ||| DT
lower  ||| S:1572 E:1578 ||| JJR
[ ||| S:1578 E:1579 ||| -LRB-
Ca  ||| S:1579 E:1582 ||| NNP
2+ ||| S:1582 E:1584 ||| NNP
]  ||| S:1584 E:1595 ||| -RRB-
i  ||| S:1595 E:1597 ||| FW
[  ||| S:1597 E:1599 ||| -LRB-
15  ||| S:1599 E:1602 ||| CD
]  ||| S:1602 E:1604 ||| -RRB-
.  ||| S:1604 E:1614 ||| .
Protein  ||| S:1614 E:1622 ||| NN
kinase  ||| S:1622 E:1629 ||| NN
pathways  ||| S:1629 E:1638 ||| NNS
play  ||| S:1638 E:1643 ||| VBP
major  ||| S:1643 E:1649 ||| JJ
roles  ||| S:1649 E:1655 ||| NNS
in  ||| S:1655 E:1658 ||| IN
cPLA  ||| S:1658 E:1672 ||| JJ
2  ||| S:1672 E:1674 ||| CD
activation ||| S:1674 E:1684 ||| NN
,  ||| S:1684 E:1686 ||| ,
and  ||| S:1686 E:1690 ||| CC
regulation  ||| S:1690 E:1701 ||| NN
by  ||| S:1701 E:1704 ||| IN
the  ||| S:1704 E:1716 ||| DT
mitogen-activated  ||| S:1716 E:1734 ||| JJ
protein  ||| S:1734 E:1742 ||| NN
kinase  ||| S:1742 E:1749 ||| NN
kinase  ||| S:1749 E:1756 ||| NNS
( ||| S:1756 E:1757 ||| -LRB-
MEK ||| S:1757 E:1760 ||| NNP
)  ||| S:1760 E:1770 ||| -RRB-
/ ||| S:1770 E:1771 ||| FW
extracellular-signal  ||| S:1771 E:1792 ||| FW
regulated  ||| S:1792 E:1802 ||| FW
kinase  ||| S:1802 E:1809 ||| FW
( ||| S:1809 E:1810 ||| -LRB-
ERK ||| S:1810 E:1813 ||| NNP
)  ||| S:1813 E:1815 ||| -RRB-
signaling  ||| S:1815 E:1833 ||| VBG
pathway  ||| S:1833 E:1841 ||| NN
has  ||| S:1841 E:1845 ||| VBZ
received  ||| S:1845 E:1854 ||| VBN
particular  ||| S:1854 E:1865 ||| JJ
attention.  ||| S:1865 E:1876 ||| NNP
cPLA  ||| S:1876 E:1890 ||| NNP
2  ||| S:1890 E:1892 ||| CD
is  ||| S:1892 E:1895 ||| VBZ
phosphorylated  ||| S:1895 E:1910 ||| VBN
by  ||| S:1910 E:1913 ||| IN
mitogen  ||| S:1913 E:1921 ||| JJ
activated  ||| S:1921 E:1939 ||| JJ
protein  ||| S:1939 E:1947 ||| NN
( ||| S:1947 E:1948 ||| -LRB-
MAP ||| S:1948 E:1951 ||| NNP
)  ||| S:1951 E:1953 ||| -RRB-
kinases ||| S:1953 E:1960 ||| NN
,  ||| S:1960 E:1962 ||| ,
including  ||| S:1962 E:1972 ||| VBG
p42 ||| S:1972 E:1975 ||| NNP
/ ||| S:1975 E:1976 ||| NNP
p44  ||| S:1976 E:1980 ||| NNP
ERKs  ||| S:1980 E:1985 ||| NNP
and  ||| S:1985 E:1989 ||| CC
p38 ||| S:1989 E:1992 ||| NNP
,  ||| S:1992 E:1994 ||| ,
on  ||| S:1994 E:2005 ||| IN
Ser  ||| S:2005 E:2009 ||| NNP
505in  ||| S:2009 E:2015 ||| FW
vitro  ||| S:2015 E:2021 ||| FW
[  ||| S:2021 E:2023 ||| -LRB-
16  ||| S:2023 E:2026 ||| CD
17  ||| S:2026 E:2029 ||| CD
]  ||| S:2029 E:2031 ||| -RRB-
and  ||| S:2031 E:2035 ||| CC
in  ||| S:2035 E:2038 ||| IN
response  ||| S:2038 E:2047 ||| NN
to  ||| S:2047 E:2050 ||| TO
receptor  ||| S:2050 E:2067 ||| VB
stimulation  ||| S:2067 E:2079 ||| NNS
[  ||| S:2079 E:2081 ||| -LRB-
16  ||| S:2081 E:2084 ||| CD
18  ||| S:2084 E:2087 ||| CD
19  ||| S:2087 E:2090 ||| CD
20  ||| S:2090 E:2093 ||| CD
21  ||| S:2093 E:2096 ||| CD
]  ||| S:2096 E:2098 ||| -RRB-
.  ||| S:2098 E:2100 ||| .
In  ||| S:2100 E:2103 ||| IN
addition  ||| S:2103 E:2112 ||| NN
to  ||| S:2112 E:2123 ||| TO
phosphorylation  ||| S:2123 E:2139 ||| VB
by  ||| S:2139 E:2142 ||| IN
MAP  ||| S:2142 E:2146 ||| NNP
kinase ||| S:2146 E:2152 ||| NN
,  ||| S:2152 E:2154 ||| ,
it  ||| S:2154 E:2157 ||| PRP
has  ||| S:2157 E:2161 ||| VBZ
been  ||| S:2161 E:2166 ||| VBN
shown  ||| S:2166 E:2172 ||| VBN
that  ||| S:2172 E:2177 ||| IN
cPLA  ||| S:2177 E:2191 ||| JJ
2  ||| S:2191 E:2193 ||| CD
is  ||| S:2193 E:2196 ||| VBZ
also  ||| S:2196 E:2201 ||| RB
phosphorylated  ||| S:2201 E:2216 ||| VBN
on  ||| S:2216 E:2219 ||| IN
Ser  ||| S:2219 E:2223 ||| NNP
727by  ||| S:2223 E:2237 ||| NNP
MAPK-interacting  ||| S:2237 E:2254 ||| NNP
kinase  ||| S:2254 E:2261 ||| VBD
I  ||| S:2261 E:2263 ||| PRP
( ||| S:2263 E:2264 ||| -LRB-
MNKI ||| S:2264 E:2268 ||| NNP
)  ||| S:2268 E:2270 ||| -RRB-
[  ||| S:2270 E:2272 ||| -LRB-
22  ||| S:2272 E:2275 ||| CD
]  ||| S:2275 E:2277 ||| -RRB-
and  ||| S:2277 E:2281 ||| CC
on  ||| S:2281 E:2284 ||| IN
Ser  ||| S:2284 E:2288 ||| NNP
515by  ||| S:2288 E:2302 ||| FW
calcium ||| S:2302 E:2309 ||| FW
/ ||| S:2309 E:2310 ||| FW
calmodulin-dependent  ||| S:2310 E:2331 ||| FW
protein  ||| S:2331 E:2339 ||| FW
kinase  ||| S:2339 E:2346 ||| FW
II  ||| S:2346 E:2349 ||| NNP
[  ||| S:2349 E:2351 ||| -LRB-
23  ||| S:2351 E:2354 ||| CD
]  ||| S:2354 E:2356 ||| -RRB-
.  ||| S:2356 E:2366 ||| .
Phosphorylation  ||| S:2366 E:2382 ||| NNP
of  ||| S:2382 E:2385 ||| IN
these  ||| S:2385 E:2391 ||| DT
sites  ||| S:2391 E:2397 ||| NNS
may  ||| S:2397 E:2401 ||| MD
also  ||| S:2401 E:2406 ||| RB
play  ||| S:2406 E:2411 ||| VB
a  ||| S:2411 E:2413 ||| DT
role  ||| S:2413 E:2418 ||| NN
in  ||| S:2418 E:2429 ||| IN
regulating  ||| S:2429 E:2440 ||| VBG
cPLA  ||| S:2440 E:2454 ||| JJ
2  ||| S:2454 E:2456 ||| CD
function  ||| S:2456 E:2465 ||| NN
in  ||| S:2465 E:2468 ||| IN
certain  ||| S:2468 E:2476 ||| JJ
cell  ||| S:2476 E:2481 ||| NN
models ||| S:2481 E:2487 ||| NNS
.  ||| S:2487 E:2497 ||| .
Phosphorylation  ||| S:2497 E:2513 ||| NNP
of  ||| S:2513 E:2516 ||| IN
Ser  ||| S:2516 E:2520 ||| NNP
505has  ||| S:2520 E:2527 ||| VBZ
been  ||| S:2527 E:2532 ||| VBN
extensively  ||| S:2532 E:2544 ||| RB
studied  ||| S:2544 E:2560 ||| VBN
because  ||| S:2560 E:2568 ||| IN
it  ||| S:2568 E:2571 ||| PRP
is  ||| S:2571 E:2574 ||| VBZ
readily  ||| S:2574 E:2582 ||| RB
detected  ||| S:2582 E:2591 ||| VBN
due  ||| S:2591 E:2595 ||| JJ
to  ||| S:2595 E:2598 ||| TO
a  ||| S:2598 E:2600 ||| DT
characteristic  ||| S:2600 E:2623 ||| JJ
electrophoretic  ||| S:2623 E:2639 ||| JJ
mobility  ||| S:2639 E:2648 ||| JJ
shift  ||| S:2648 E:2654 ||| NN
when  ||| S:2654 E:2659 ||| WRB
analyzed  ||| S:2659 E:2668 ||| VBN
by  ||| S:2668 E:2671 ||| IN
SDS-PAGE  ||| S:2671 E:2680 ||| NNP
[  ||| S:2680 E:2690 ||| -LRB-
13  ||| S:2690 E:2693 ||| CD
16  ||| S:2693 E:2696 ||| CD
]  ||| S:2696 E:2698 ||| -RRB-
.  ||| S:2698 E:2700 ||| .
The  ||| S:2700 E:2704 ||| DT
importance  ||| S:2704 E:2715 ||| NN
of  ||| S:2715 E:2718 ||| IN
Ser  ||| S:2718 E:2722 ||| NNP
505phosphorylation  ||| S:2722 E:2741 ||| NNP
in  ||| S:2741 E:2752 ||| IN
regulating  ||| S:2752 E:2763 ||| VBG
cPLA  ||| S:2763 E:2777 ||| JJ
2  ||| S:2777 E:2779 ||| CD
has  ||| S:2779 E:2783 ||| VBZ
been  ||| S:2783 E:2788 ||| VBN
demonstrated  ||| S:2788 E:2801 ||| VBN
in  ||| S:2801 E:2804 ||| IN
different  ||| S:2804 E:2822 ||| JJ
cells  ||| S:2822 E:2828 ||| NNS
and  ||| S:2828 E:2832 ||| CC
in  ||| S:2832 E:2835 ||| IN
vitro  ||| S:2835 E:2841 ||| JJ
models  ||| S:2841 E:2848 ||| NNS
by  ||| S:2848 E:2851 ||| IN
using  ||| S:2851 E:2857 ||| VBG
cPLA  ||| S:2857 E:2871 ||| JJ
2  ||| S:2871 E:2873 ||| CD
containing  ||| S:2873 E:2884 ||| VBG
a  ||| S:2884 E:2886 ||| DT
S505A  ||| S:2886 E:2892 ||| JJ
mutation  ||| S:2892 E:2901 ||| NN
[  ||| S:2901 E:2903 ||| -LRB-
16  ||| S:2903 E:2906 ||| CD
22  ||| S:2906 E:2909 ||| CD
]  ||| S:2909 E:2919 ||| -RRB-
.  ||| S:2919 E:2921 ||| .
However ||| S:2921 E:2928 ||| RB
,  ||| S:2928 E:2930 ||| ,
the  ||| S:2930 E:2934 ||| DT
mechanism  ||| S:2934 E:2944 ||| NN
whereby  ||| S:2944 E:2952 ||| WRB
Ser  ||| S:2952 E:2956 ||| NNP
505phosphorylation  ||| S:2956 E:2983 ||| NNP
regulates  ||| S:2983 E:2993 ||| VBZ
cPLA  ||| S:2993 E:3007 ||| JJ
2  ||| S:3007 E:3009 ||| CD
function  ||| S:3009 E:3018 ||| NN
has  ||| S:3018 E:3022 ||| VBZ
been  ||| S:3022 E:3027 ||| VBN
elusive ||| S:3027 E:3034 ||| JJ
.  ||| S:3034 E:3036 ||| .
In  ||| S:3036 E:3039 ||| IN
vitro  ||| S:3039 E:3053 ||| JJ
studies  ||| S:3053 E:3061 ||| NNS
have  ||| S:3061 E:3066 ||| VBP
demonstrated  ||| S:3066 E:3079 ||| VBN
that  ||| S:3079 E:3084 ||| IN
dephosphorylated  ||| S:3084 E:3101 ||| JJ
cPLA  ||| S:3101 E:3115 ||| JJ
2  ||| S:3115 E:3117 ||| CD
is  ||| S:3117 E:3120 ||| VBZ
catalytically  ||| S:3120 E:3134 ||| JJ
active  ||| S:3134 E:3141 ||| JJ
and  ||| S:3141 E:3145 ||| CC
that  ||| S:3145 E:3150 ||| IN
Ser  ||| S:3150 E:3162 ||| NNP
505phosphorylation  ||| S:3162 E:3181 ||| NNP
increases  ||| S:3181 E:3191 ||| VBZ
activity  ||| S:3191 E:3200 ||| NN
by  ||| S:3200 E:3203 ||| IN
only  ||| S:3203 E:3208 ||| RB
~30  ||| S:3208 E:3212 ||| CD
percent  ||| S:3212 E:3220 ||| NN
[  ||| S:3220 E:3230 ||| -LRB-
24  ||| S:3230 E:3233 ||| CD
]  ||| S:3233 E:3235 ||| -RRB-
.  ||| S:3235 E:3237 ||| .
In  ||| S:3237 E:3240 ||| IN
contrast ||| S:3240 E:3248 ||| NN
,  ||| S:3248 E:3250 ||| ,
cells  ||| S:3250 E:3256 ||| NNS
expressing  ||| S:3256 E:3267 ||| VBG
the  ||| S:3267 E:3271 ||| DT
cPLA  ||| S:3271 E:3285 ||| JJ
2  ||| S:3285 E:3287 ||| CD
S505A  ||| S:3287 E:3293 ||| CD
mutation  ||| S:3293 E:3302 ||| NNS
fail  ||| S:3302 E:3307 ||| VBP
to  ||| S:3307 E:3310 ||| TO
release  ||| S:3310 E:3318 ||| VB
AA  ||| S:3318 E:3321 ||| NN
in  ||| S:3321 E:3332 ||| IN
response  ||| S:3332 E:3341 ||| NN
to  ||| S:3341 E:3344 ||| TO
a  ||| S:3344 E:3346 ||| DT
low  ||| S:3346 E:3350 ||| JJ
dose  ||| S:3350 E:3355 ||| NN
of  ||| S:3355 E:3358 ||| IN
calcium  ||| S:3358 E:3366 ||| JJ
ionophore ||| S:3366 E:3375 ||| NN
,  ||| S:3375 E:3377 ||| ,
but  ||| S:3377 E:3381 ||| CC
release  ||| S:3381 E:3397 ||| VB
similar  ||| S:3397 E:3405 ||| JJ
amounts  ||| S:3405 E:3413 ||| NNS
of  ||| S:3413 E:3416 ||| IN
AA  ||| S:3416 E:3419 ||| NN
as  ||| S:3419 E:3422 ||| IN
cells  ||| S:3422 E:3428 ||| NNS
expressing  ||| S:3428 E:3439 ||| VBG
wild-type  ||| S:3439 E:3449 ||| JJ
cPLA  ||| S:3449 E:3463 ||| JJ
2  ||| S:3463 E:3465 ||| CD
in  ||| S:3465 E:3468 ||| IN
response  ||| S:3468 E:3477 ||| NN
to  ||| S:3477 E:3480 ||| TO
high  ||| S:3480 E:3485 ||| JJ
dose  ||| S:3485 E:3490 ||| NN
ionophore  ||| S:3490 E:3500 ||| NNS
[  ||| S:3500 E:3510 ||| -LRB-
22  ||| S:3510 E:3513 ||| CD
]  ||| S:3513 E:3515 ||| -RRB-
.  ||| S:3515 E:3517 ||| .
From  ||| S:3517 E:3522 ||| IN
these  ||| S:3522 E:3528 ||| DT
studies ||| S:3528 E:3535 ||| NNS
,  ||| S:3535 E:3537 ||| ,
it  ||| S:3537 E:3540 ||| PRP
has  ||| S:3540 E:3544 ||| VBZ
been  ||| S:3544 E:3549 ||| VBN
suggested  ||| S:3549 E:3559 ||| VBN
that  ||| S:3559 E:3564 ||| IN
cPLA  ||| S:3564 E:3578 ||| JJ
2  ||| S:3578 E:3580 ||| CD
Ser  ||| S:3580 E:3584 ||| NNP
505phosphorylation  ||| S:3584 E:3603 ||| NNP
may  ||| S:3603 E:3607 ||| MD
have  ||| S:3607 E:3612 ||| VB
a  ||| S:3612 E:3614 ||| DT
role  ||| S:3614 E:3627 ||| NN
in  ||| S:3627 E:3630 ||| IN
regulating  ||| S:3630 E:3641 ||| VBG
translocation  ||| S:3641 E:3655 ||| NNS
[  ||| S:3655 E:3657 ||| -LRB-
22  ||| S:3657 E:3660 ||| CD
]  ||| S:3660 E:3662 ||| -RRB-
.  ||| S:3662 E:3664 ||| .
A  ||| S:3664 E:3666 ||| DT
previous  ||| S:3666 E:3675 ||| JJ
study  ||| S:3675 E:3689 ||| NN
demonstrated  ||| S:3689 E:3702 ||| VBD
translocation  ||| S:3702 E:3716 ||| VBN
of  ||| S:3716 E:3719 ||| IN
cPLA  ||| S:3719 E:3733 ||| JJ
2  ||| S:3733 E:3735 ||| CD
S505A  ||| S:3735 E:3741 ||| CD
in  ||| S:3741 E:3744 ||| IN
response  ||| S:3744 E:3753 ||| NN
to  ||| S:3753 E:3756 ||| TO
Ca  ||| S:3756 E:3759 ||| NNP
2+ionophore ||| S:3759 E:3770 ||| NNP
,  ||| S:3770 E:3780 ||| ,
but  ||| S:3780 E:3784 ||| CC
did  ||| S:3784 E:3788 ||| VBD
not  ||| S:3788 E:3792 ||| RB
address  ||| S:3792 E:3800 ||| VB
the  ||| S:3800 E:3804 ||| DT
kinetics  ||| S:3804 E:3813 ||| NN
of  ||| S:3813 E:3816 ||| IN
translocation ||| S:3816 E:3829 ||| NN
,  ||| S:3829 E:3839 ||| ,
translocation  ||| S:3839 E:3853 ||| VBG
in  ||| S:3853 E:3856 ||| IN
response  ||| S:3856 E:3865 ||| NN
to  ||| S:3865 E:3868 ||| TO
a  ||| S:3868 E:3870 ||| DT
physiological  ||| S:3870 E:3884 ||| JJ
agonist ||| S:3884 E:3891 ||| NN
,  ||| S:3891 E:3893 ||| ,
or  ||| S:3893 E:3904 ||| CC
differences  ||| S:3904 E:3916 ||| NNS
in  ||| S:3916 E:3919 ||| IN
targeting  ||| S:3919 E:3929 ||| VBG
[  ||| S:3929 E:3931 ||| -LRB-
25  ||| S:3931 E:3934 ||| CD
]  ||| S:3934 E:3936 ||| -RRB-
.  ||| S:3936 E:3946 ||| .
To  ||| S:3946 E:3949 ||| TO
better  ||| S:3949 E:3956 ||| RB
understand  ||| S:3956 E:3967 ||| VB
the  ||| S:3967 E:3971 ||| DT
regulation  ||| S:3971 E:3982 ||| NN
of  ||| S:3982 E:3985 ||| IN
cPLA  ||| S:3985 E:3999 ||| JJ
2  ||| S:3999 E:4001 ||| CD
by  ||| S:4001 E:4004 ||| IN
the  ||| S:4004 E:4008 ||| DT
MEK1 ||| S:4008 E:4012 ||| NNP
/ ||| S:4012 E:4013 ||| NNP
ERK  ||| S:4013 E:4017 ||| NNP
pathway  ||| S:4017 E:4025 ||| NN
and  ||| S:4025 E:4029 ||| CC
Ca  ||| S:4029 E:4032 ||| NNP
2+ ||| S:4032 E:4034 ||| NNP
,  ||| S:4034 E:4036 ||| ,
we  ||| S:4036 E:4047 ||| PRP
investigated  ||| S:4047 E:4060 ||| VBD
the  ||| S:4060 E:4064 ||| DT
effect  ||| S:4064 E:4071 ||| NN
of  ||| S:4071 E:4074 ||| IN
MEK  ||| S:4074 E:4078 ||| NNP
inhibitors  ||| S:4078 E:4089 ||| NN
on  ||| S:4089 E:4092 ||| IN
AA  ||| S:4092 E:4095 ||| NN
release ||| S:4095 E:4102 ||| NN
,  ||| S:4102 E:4112 ||| ,
cPLA  ||| S:4112 E:4126 ||| JJ
2  ||| S:4126 E:4128 ||| CD
phosphorylation  ||| S:4128 E:4144 ||| NN
of  ||| S:4144 E:4147 ||| IN
Ser  ||| S:4147 E:4151 ||| NNP
505 ||| S:4151 E:4154 ||| CD
,  ||| S:4154 E:4156 ||| ,
cPLA  ||| S:4156 E:4170 ||| JJ
2  ||| S:4170 E:4172 ||| CD
translocation  ||| S:4172 E:4186 ||| JJ
kinetics ||| S:4186 E:4194 ||| NN
,  ||| S:4194 E:4196 ||| ,
and  ||| S:4196 E:4200 ||| CC
[ ||| S:4200 E:4201 ||| -LRB-
Ca  ||| S:4201 E:4204 ||| NNP
2+ ||| S:4204 E:4206 ||| NNP
]  ||| S:4206 E:4217 ||| -RRB-
i  ||| S:4217 E:4219 ||| FW
increase  ||| S:4219 E:4228 ||| NN
in  ||| S:4228 E:4231 ||| IN
Madin-Darby  ||| S:4231 E:4243 ||| JJ
canine  ||| S:4243 E:4250 ||| JJ
kidney  ||| S:4250 E:4265 ||| NN
( ||| S:4265 E:4266 ||| -LRB-
MDCK ||| S:4266 E:4270 ||| NNP
)  ||| S:4270 E:4272 ||| -RRB-
cells ||| S:4272 E:4277 ||| NNS
.  ||| S:4277 E:4279 ||| .
We  ||| S:4279 E:4282 ||| PRP
found  ||| S:4282 E:4288 ||| VBD
that  ||| S:4288 E:4293 ||| DT
inhibition  ||| S:4293 E:4304 ||| NN
of  ||| S:4304 E:4307 ||| IN
MEK1  ||| S:4307 E:4312 ||| CD
by  ||| S:4312 E:4315 ||| IN
U0126  ||| S:4315 E:4329 ||| NNP
significantly  ||| S:4329 E:4343 ||| RB
inhibited  ||| S:4343 E:4353 ||| JJ
AA  ||| S:4353 E:4356 ||| NN
release  ||| S:4356 E:4364 ||| NN
and  ||| S:4364 E:4368 ||| CC
this  ||| S:4368 E:4373 ||| DT
was  ||| S:4373 E:4377 ||| VBD
correlated  ||| S:4377 E:4396 ||| VBN
with  ||| S:4396 E:4401 ||| IN
inhibition  ||| S:4401 E:4412 ||| NN
of  ||| S:4412 E:4415 ||| IN
ERK  ||| S:4415 E:4419 ||| NNP
activation ||| S:4419 E:4429 ||| NN
.  ||| S:4429 E:4431 ||| .
However ||| S:4431 E:4438 ||| RB
,  ||| S:4438 E:4440 ||| ,
MEK  ||| S:4440 E:4444 ||| NNP
inhibition  ||| S:4444 E:4463 ||| VBD
only  ||| S:4463 E:4468 ||| RB
partially  ||| S:4468 E:4478 ||| RB
affected  ||| S:4478 E:4487 ||| VBN
cPLA  ||| S:4487 E:4501 ||| JJ
2  ||| S:4501 E:4503 ||| CD
phosphorylation  ||| S:4503 E:4519 ||| NNS
and  ||| S:4519 E:4523 ||| CC
had  ||| S:4523 E:4527 ||| VBD
no  ||| S:4527 E:4530 ||| DT
effect  ||| S:4530 E:4537 ||| NN
on  ||| S:4537 E:4548 ||| IN
the  ||| S:4548 E:4552 ||| DT
kinetics  ||| S:4552 E:4561 ||| NN
of  ||| S:4561 E:4564 ||| IN
Ca  ||| S:4564 E:4567 ||| NNP
2+-mediated  ||| S:4567 E:4579 ||| NNP
cPLA  ||| S:4579 E:4593 ||| NNP
2  ||| S:4593 E:4595 ||| CD
translocation  ||| S:4595 E:4609 ||| NN
to  ||| S:4609 E:4612 ||| TO
membrane ||| S:4612 E:4620 ||| VB
.  ||| S:4620 E:4622 ||| .
In  ||| S:4622 E:4633 ||| IN
addition ||| S:4633 E:4641 ||| NN
,  ||| S:4641 E:4643 ||| ,
using  ||| S:4643 E:4649 ||| VBG
cells  ||| S:4649 E:4655 ||| NNS
expressing  ||| S:4655 E:4666 ||| VBG
wild-type  ||| S:4666 E:4676 ||| JJ
cPLA  ||| S:4676 E:4690 ||| JJ
2  ||| S:4690 E:4692 ||| CD
and  ||| S:4692 E:4696 ||| CC
cPLA  ||| S:4696 E:4710 ||| JJ
2  ||| S:4710 E:4712 ||| CD
with  ||| S:4712 E:4717 ||| IN
S505A  ||| S:4717 E:4723 ||| NNP
or  ||| S:4723 E:4726 ||| CC
S727A  ||| S:4726 E:4732 ||| CD
mutations ||| S:4732 E:4741 ||| NNS
,  ||| S:4741 E:4743 ||| ,
it  ||| S:4743 E:4746 ||| PRP
was  ||| S:4746 E:4758 ||| VBD
found  ||| S:4758 E:4764 ||| VBN
that  ||| S:4764 E:4769 ||| IN
translocation  ||| S:4769 E:4783 ||| JJ
kinetics  ||| S:4783 E:4792 ||| NN
and  ||| S:4792 E:4796 ||| CC
membrane  ||| S:4796 E:4805 ||| VBP
targeting  ||| S:4805 E:4815 ||| VBG
in  ||| S:4815 E:4826 ||| IN
response  ||| S:4826 E:4835 ||| NN
to  ||| S:4835 E:4838 ||| TO
ATP  ||| S:4838 E:4842 ||| NNP
or  ||| S:4842 E:4845 ||| CC
ionomycin  ||| S:4845 E:4855 ||| NNS
was  ||| S:4855 E:4859 ||| VBD
similar  ||| S:4859 E:4867 ||| JJ
to  ||| S:4867 E:4870 ||| TO
wild-type  ||| S:4870 E:4880 ||| JJ
cPLA  ||| S:4880 E:4894 ||| JJ
2  ||| S:4894 E:4896 ||| CD
.  ||| S:4896 E:4898 ||| .
These  ||| S:4898 E:4904 ||| DT
data  ||| S:4904 E:4909 ||| NNS
suggest  ||| S:4909 E:4917 ||| VBP
that  ||| S:4917 E:4922 ||| IN
MEK1  ||| S:4922 E:4935 ||| CD
inhibition  ||| S:4935 E:4946 ||| NN
reduces  ||| S:4946 E:4954 ||| VBZ
cPLA  ||| S:4954 E:4968 ||| JJ
2  ||| S:4968 E:4970 ||| CD
catalytic  ||| S:4970 E:4980 ||| JJ
activity  ||| S:4980 E:4989 ||| NN
and  ||| S:4989 E:4993 ||| CC
AA  ||| S:4993 E:4996 ||| NN
release  ||| S:4996 E:5012 ||| NN
independently  ||| S:5012 E:5026 ||| RB
of  ||| S:5026 E:5029 ||| IN
phosphorylation  ||| S:5029 E:5045 ||| NN
and  ||| S:5045 E:5049 ||| CC
translocation ||| S:5049 E:5062 ||| NN
.  ||| S:5062 E:5086 ||| .
Results  ||| S:5086 E:5113 ||| NNS
Effect  ||| S:5113 E:5120 ||| NN
of  ||| S:5120 E:5123 ||| IN
MEK  ||| S:5123 E:5127 ||| NNP
inhibition  ||| S:5127 E:5138 ||| NN
on  ||| S:5138 E:5141 ||| IN
AA  ||| S:5141 E:5144 ||| NN
release ||| S:5144 E:5151 ||| NN
,  ||| S:5151 E:5153 ||| ,
ERK  ||| S:5153 E:5167 ||| NNP
activation ||| S:5167 E:5177 ||| NN
,  ||| S:5177 E:5179 ||| ,
and  ||| S:5179 E:5183 ||| CC
cPLA  ||| S:5183 E:5188 ||| JJ
2Ser  ||| S:5188 E:5193 ||| CD
505phosphorylation  ||| S:5193 E:5222 ||| CD
To  ||| S:5222 E:5225 ||| TO
study  ||| S:5225 E:5231 ||| VB
the  ||| S:5231 E:5235 ||| DT
role  ||| S:5235 E:5240 ||| NN
of  ||| S:5240 E:5243 ||| IN
the  ||| S:5243 E:5247 ||| DT
MEK1 ||| S:5247 E:5251 ||| NNP
/ ||| S:5251 E:5252 ||| NNP
ERK  ||| S:5252 E:5256 ||| NNP
pathway  ||| S:5256 E:5264 ||| NN
in  ||| S:5264 E:5267 ||| IN
cPLA  ||| S:5267 E:5283 ||| JJ
2  ||| S:5283 E:5285 ||| CD
activation ||| S:5285 E:5295 ||| NN
,  ||| S:5295 E:5297 ||| ,
quiesced  ||| S:5297 E:5306 ||| JJ
MDCK  ||| S:5306 E:5311 ||| NN
cells  ||| S:5311 E:5317 ||| NNS
were  ||| S:5317 E:5332 ||| VBD
treated  ||| S:5332 E:5340 ||| VBN
with  ||| S:5340 E:5345 ||| IN
the  ||| S:5345 E:5349 ||| DT
MEK1  ||| S:5349 E:5354 ||| CD
inhibitor  ||| S:5354 E:5364 ||| CD
U0126 ||| S:5364 E:5369 ||| CD
,  ||| S:5369 E:5371 ||| ,
and  ||| S:5371 E:5375 ||| CC
the  ||| S:5375 E:5379 ||| DT
effect  ||| S:5379 E:5386 ||| NN
on  ||| S:5386 E:5399 ||| IN
AA  ||| S:5399 E:5402 ||| NN
release ||| S:5402 E:5409 ||| NN
,  ||| S:5409 E:5411 ||| ,
ERK  ||| S:5411 E:5415 ||| NNP
activation ||| S:5415 E:5425 ||| NN
,  ||| S:5425 E:5427 ||| ,
and  ||| S:5427 E:5431 ||| CC
cPLA  ||| S:5431 E:5447 ||| JJ
2  ||| S:5447 E:5449 ||| CD
gel  ||| S:5449 E:5453 ||| NNS
shift  ||| S:5453 E:5459 ||| VBP
determined  ||| S:5459 E:5470 ||| VBN
( ||| S:5470 E:5471 ||| -LRB-
Fig.  ||| S:5471 E:5476 ||| CD
1 ||| S:5476 E:5477 ||| CD
) ||| S:5477 E:5478 ||| -RRB-
.  ||| S:5478 E:5480 ||| .
For  ||| S:5480 E:5494 ||| IN
equivalence  ||| S:5494 E:5506 ||| NN
with  ||| S:5506 E:5511 ||| IN
the  ||| S:5511 E:5515 ||| DT
imaging  ||| S:5515 E:5523 ||| JJ
studies ||| S:5523 E:5530 ||| NNS
,  ||| S:5530 E:5532 ||| ,
cells  ||| S:5532 E:5538 ||| NNS
expressing  ||| S:5538 E:5559 ||| VBG
EGFP-cPLA  ||| S:5559 E:5580 ||| JJ
2  ||| S:5580 E:5582 ||| CD
were  ||| S:5582 E:5587 ||| VBD
used  ||| S:5587 E:5592 ||| VBN
in  ||| S:5592 E:5595 ||| IN
all  ||| S:5595 E:5599 ||| DT
experiments ||| S:5599 E:5610 ||| NNS
.  ||| S:5610 E:5622 ||| .
EGFP-cPLA  ||| S:5622 E:5643 ||| JJ
2  ||| S:5643 E:5645 ||| CD
was  ||| S:5645 E:5649 ||| VBD
expressed  ||| S:5649 E:5659 ||| VBN
to  ||| S:5659 E:5662 ||| TO
similar  ||| S:5662 E:5670 ||| JJ
levels  ||| S:5670 E:5677 ||| NNS
as  ||| S:5677 E:5690 ||| IN
endogenous  ||| S:5690 E:5701 ||| JJ
enzyme  ||| S:5701 E:5708 ||| NN
but  ||| S:5708 E:5712 ||| CC
did  ||| S:5712 E:5716 ||| VBD
not  ||| S:5716 E:5720 ||| RB
contribute  ||| S:5720 E:5731 ||| VB
significantly  ||| S:5731 E:5745 ||| RB
to  ||| S:5745 E:5758 ||| TO
AA  ||| S:5758 E:5761 ||| NN
release  ||| S:5761 E:5769 ||| NN
in  ||| S:5769 E:5772 ||| IN
stably  ||| S:5772 E:5779 ||| JJ
transfected  ||| S:5779 E:5791 ||| JJ
cells ||| S:5791 E:5796 ||| NNS
.  ||| S:5796 E:5798 ||| .
However ||| S:5798 E:5805 ||| RB
,  ||| S:5805 E:5817 ||| ,
EGFP-cPLA  ||| S:5817 E:5838 ||| JJ
2  ||| S:5838 E:5840 ||| CD
is  ||| S:5840 E:5843 ||| VBZ
functional  ||| S:5843 E:5854 ||| VBN
since  ||| S:5854 E:5860 ||| IN
it  ||| S:5860 E:5873 ||| PRP
dose-dependently  ||| S:5873 E:5890 ||| JJ
catalyzes  ||| S:5890 E:5900 ||| JJ
release  ||| S:5900 E:5908 ||| NN
of  ||| S:5908 E:5911 ||| IN
AA  ||| S:5911 E:5914 ||| NN
when  ||| S:5914 E:5919 ||| WRB
expressed  ||| S:5919 E:5939 ||| VBN
in  ||| S:5939 E:5942 ||| IN
cells  ||| S:5942 E:5948 ||| NNS
that  ||| S:5948 E:5953 ||| WDT
lack  ||| S:5953 E:5958 ||| VBP
endogenous  ||| S:5958 E:5969 ||| JJ
cPLA  ||| S:5969 E:5985 ||| JJ
2  ||| S:5985 E:5987 ||| CD
,  ||| S:5987 E:5989 ||| ,
such  ||| S:5989 E:5994 ||| JJ
as  ||| S:5994 E:5997 ||| IN
Sf9  ||| S:5997 E:6001 ||| CD
cells  ||| S:6001 E:6007 ||| NNS
[  ||| S:6007 E:6009 ||| -LRB-
13  ||| S:6009 E:6012 ||| CD
]  ||| S:6012 E:6014 ||| -RRB-
and  ||| S:6014 E:6028 ||| CC
immortalized  ||| S:6028 E:6041 ||| JJ
mouse  ||| S:6041 E:6047 ||| NN
lung  ||| S:6047 E:6052 ||| NN
fibroblasts  ||| S:6052 E:6064 ||| NN
from  ||| S:6064 E:6069 ||| IN
cPLA  ||| S:6069 E:6085 ||| JJ
2  ||| S:6085 E:6087 ||| CD
α  ||| S:6087 E:6089 ||| CD
knock-out  ||| S:6089 E:6099 ||| JJ
mice  ||| S:6099 E:6104 ||| NNS
[  ||| S:6104 E:6106 ||| -LRB-
26  ||| S:6106 E:6109 ||| CD
]  ||| S:6109 E:6111 ||| -RRB-
.  ||| S:6111 E:6113 ||| .
In  ||| S:6113 E:6116 ||| IN
order  ||| S:6116 E:6132 ||| NN
to  ||| S:6132 E:6135 ||| TO
enhance  ||| S:6135 E:6143 ||| VB
AA  ||| S:6143 E:6146 ||| NN
release  ||| S:6146 E:6154 ||| NN
in  ||| S:6154 E:6157 ||| IN
cells  ||| S:6157 E:6163 ||| NNS
containing  ||| S:6163 E:6174 ||| VBG
endogenous  ||| S:6174 E:6185 ||| JJ
cPLA  ||| S:6185 E:6211 ||| JJ
2  ||| S:6211 E:6213 ||| CD
,  ||| S:6213 E:6215 ||| ,
it  ||| S:6215 E:6218 ||| PRP
is  ||| S:6218 E:6221 ||| VBZ
necessary  ||| S:6221 E:6231 ||| JJ
to  ||| S:6231 E:6234 ||| TO
over-express  ||| S:6234 E:6257 ||| VB
the  ||| S:6257 E:6261 ||| DT
enzyme  ||| S:6261 E:6268 ||| JJ
several  ||| S:6268 E:6276 ||| JJ
fold  ||| S:6276 E:6281 ||| NN
as  ||| S:6281 E:6284 ||| IN
previously  ||| S:6284 E:6295 ||| RB
reported  ||| S:6295 E:6304 ||| VBD
[  ||| S:6304 E:6306 ||| -LRB-
16  ||| S:6306 E:6309 ||| CD
]  ||| S:6309 E:6311 ||| -RRB-
.  ||| S:6311 E:6323 ||| .
Cytosolic  ||| S:6323 E:6333 ||| NNP
PLA  ||| S:6333 E:6348 ||| NNP
2  ||| S:6348 E:6350 ||| CD
has  ||| S:6350 E:6354 ||| VBZ
been  ||| S:6354 E:6359 ||| VBN
shown  ||| S:6359 E:6365 ||| VBN
to  ||| S:6365 E:6368 ||| TO
mediate  ||| S:6368 E:6376 ||| VB
Ca  ||| S:6376 E:6389 ||| NNP
2+-induced  ||| S:6389 E:6400 ||| NNP
AA  ||| S:6400 E:6403 ||| NN
release  ||| S:6403 E:6411 ||| NN
in  ||| S:6411 E:6414 ||| IN
MDCK  ||| S:6414 E:6419 ||| NNP
cells  ||| S:6419 E:6425 ||| NNS
treated  ||| S:6425 E:6433 ||| VBN
with  ||| S:6433 E:6438 ||| IN
ATP  ||| S:6438 E:6442 ||| NNP
and  ||| S:6442 E:6456 ||| CC
IONO  ||| S:6456 E:6461 ||| NNP
in  ||| S:6461 E:6464 ||| IN
experiments  ||| S:6464 E:6476 ||| NNS
using  ||| S:6476 E:6482 ||| VBG
the  ||| S:6482 E:6486 ||| DT
group  ||| S:6486 E:6492 ||| NN
IV  ||| S:6492 E:6495 ||| NNP
cPLA  ||| S:6495 E:6511 ||| NNP
2  ||| S:6511 E:6513 ||| CD
α-specific  ||| S:6513 E:6524 ||| JJ
inhibitor  ||| S:6524 E:6534 ||| JJ
pyrrolidine-1  ||| S:6534 E:6548 ||| NNP
[  ||| S:6548 E:6560 ||| -LRB-
27  ||| S:6560 E:6563 ||| CD
]  ||| S:6563 E:6565 ||| -RRB-
.  ||| S:6565 E:6567 ||| .
To  ||| S:6567 E:6570 ||| TO
measure  ||| S:6570 E:6578 ||| VB
cPLA  ||| S:6578 E:6594 ||| JJ
2  ||| S:6594 E:6596 ||| CD
mediated  ||| S:6596 E:6605 ||| JJ
AA  ||| S:6605 E:6608 ||| NN
release ||| S:6608 E:6615 ||| NN
,  ||| S:6615 E:6617 ||| ,
EGFP-cPLA  ||| S:6617 E:6638 ||| JJ
2  ||| S:6638 E:6640 ||| CD
-transfected  ||| S:6640 E:6653 ||| JJ
MDCK  ||| S:6653 E:6658 ||| NN
cells  ||| S:6658 E:6664 ||| NNS
labeled  ||| S:6664 E:6672 ||| VBN
with  ||| S:6672 E:6687 ||| IN
[  ||| S:6687 E:6689 ||| -LRB-
3H ||| S:6689 E:6691 ||| NNP
] ||| S:6691 E:6692 ||| -RRB-
-AA  ||| S:6692 E:6696 ||| NNP
were  ||| S:6696 E:6701 ||| VBD
incubated  ||| S:6701 E:6711 ||| VBN
with  ||| S:6711 E:6716 ||| IN
0.3 ||| S:6716 E:6719 ||| CD
,  ||| S:6719 E:6721 ||| ,
1  ||| S:6721 E:6723 ||| CD
or  ||| S:6723 E:6726 ||| CC
10  ||| S:6726 E:6729 ||| CD
μM  ||| S:6729 E:6732 ||| JJ
U0126  ||| S:6732 E:6738 ||| NN
for  ||| S:6738 E:6742 ||| IN
15  ||| S:6742 E:6755 ||| CD
min  ||| S:6755 E:6759 ||| NNS
prior  ||| S:6759 E:6765 ||| RB
to  ||| S:6765 E:6768 ||| TO
stimulation  ||| S:6768 E:6780 ||| VB
with  ||| S:6780 E:6785 ||| IN
100  ||| S:6785 E:6789 ||| CD
μM  ||| S:6789 E:6792 ||| JJ
ATP ||| S:6792 E:6795 ||| NNP
,  ||| S:6795 E:6797 ||| ,
1  ||| S:6797 E:6799 ||| CD
μM  ||| S:6799 E:6802 ||| JJ
IONO ||| S:6802 E:6806 ||| NNP
,  ||| S:6806 E:6808 ||| ,
or  ||| S:6808 E:6821 ||| CC
10  ||| S:6821 E:6824 ||| CD
μM  ||| S:6824 E:6827 ||| JJ
IONO ||| S:6827 E:6831 ||| NNP
.  ||| S:6831 E:6833 ||| .
AA  ||| S:6833 E:6836 ||| NN
release  ||| S:6836 E:6844 ||| NN
was  ||| S:6844 E:6848 ||| VBD
measured  ||| S:6848 E:6857 ||| VBN
at  ||| S:6857 E:6860 ||| IN
3  ||| S:6860 E:6862 ||| CD
min  ||| S:6862 E:6866 ||| NN
because  ||| S:6866 E:6874 ||| IN
we  ||| S:6874 E:6887 ||| PRP
have  ||| S:6887 E:6892 ||| VBP
shown  ||| S:6892 E:6898 ||| VBN
that  ||| S:6898 E:6903 ||| IN
ATP-  ||| S:6903 E:6908 ||| JJ
and  ||| S:6908 E:6912 ||| CC
IONO-stimulated  ||| S:6912 E:6928 ||| JJ
AA  ||| S:6928 E:6931 ||| NN
release  ||| S:6931 E:6939 ||| NN
peaks  ||| S:6939 E:6955 ||| NNS
between  ||| S:6955 E:6963 ||| IN
3  ||| S:6963 E:6965 ||| CD
to  ||| S:6965 E:6968 ||| TO
5  ||| S:6968 E:6970 ||| CD
min  ||| S:6970 E:6974 ||| CD
post-stimulation  ||| S:6974 E:6991 ||| NNS
[  ||| S:6991 E:6993 ||| -LRB-
15  ||| S:6993 E:6996 ||| CD
]  ||| S:6996 E:6998 ||| -RRB-
.  ||| S:6998 E:7010 ||| .
Agonist-induced  ||| S:7010 E:7026 ||| JJ
AA  ||| S:7026 E:7029 ||| NN
release  ||| S:7029 E:7037 ||| NN
was  ||| S:7037 E:7041 ||| VBD
inhibited  ||| S:7041 E:7051 ||| JJ
dose-dependently  ||| S:7051 E:7078 ||| NN
by  ||| S:7078 E:7081 ||| IN
U0126  ||| S:7081 E:7087 ||| NNP
( ||| S:7087 E:7088 ||| -LRB-
Fig.  ||| S:7088 E:7093 ||| NNP
1A ||| S:7093 E:7095 ||| NNP
)  ||| S:7095 E:7097 ||| -RRB-
with  ||| S:7097 E:7102 ||| IN
the  ||| S:7102 E:7106 ||| DT
highest  ||| S:7106 E:7114 ||| JJS
U0126  ||| S:7114 E:7120 ||| CD
concentration  ||| S:7120 E:7144 ||| NN
used  ||| S:7144 E:7149 ||| VBN
( ||| S:7149 E:7150 ||| -LRB-
10  ||| S:7150 E:7153 ||| CD
μM ||| S:7153 E:7155 ||| NN
)  ||| S:7155 E:7157 ||| -RRB-
reducing  ||| S:7157 E:7166 ||| VBG
AA  ||| S:7166 E:7169 ||| NN
release  ||| S:7169 E:7177 ||| NN
by  ||| S:7177 E:7180 ||| IN
72-80 ||| S:7180 E:7185 ||| CD
%  ||| S:7185 E:7187 ||| NN
with  ||| S:7187 E:7192 ||| IN
all  ||| S:7192 E:7206 ||| DT
agonists  ||| S:7206 E:7215 ||| NN
( ||| S:7215 E:7216 ||| -LRB-
Table  ||| S:7216 E:7222 ||| NNP
I ||| S:7222 E:7223 ||| NNP
) ||| S:7223 E:7224 ||| -RRB-
.  ||| S:7224 E:7226 ||| .
This  ||| S:7226 E:7231 ||| DT
inhibition  ||| S:7231 E:7242 ||| NN
was  ||| S:7242 E:7246 ||| VBD
independent  ||| S:7246 E:7258 ||| JJ
of  ||| S:7258 E:7271 ||| IN
the  ||| S:7271 E:7275 ||| DT
total  ||| S:7275 E:7281 ||| JJ
amount  ||| S:7281 E:7288 ||| NN
of  ||| S:7288 E:7291 ||| IN
AA  ||| S:7291 E:7294 ||| NN
released ||| S:7294 E:7302 ||| VBN
,  ||| S:7302 E:7304 ||| ,
since  ||| S:7304 E:7310 ||| IN
AA  ||| S:7310 E:7313 ||| NN
release  ||| S:7313 E:7331 ||| NN
stimulated  ||| S:7331 E:7342 ||| VBN
by  ||| S:7342 E:7345 ||| IN
10  ||| S:7345 E:7348 ||| CD
μM  ||| S:7348 E:7351 ||| JJ
IONO  ||| S:7351 E:7356 ||| NNP
was  ||| S:7356 E:7360 ||| VBD
3-fold  ||| S:7360 E:7367 ||| CD
greater  ||| S:7367 E:7375 ||| JJR
than  ||| S:7375 E:7380 ||| IN
release  ||| S:7380 E:7398 ||| NN
stimulated  ||| S:7398 E:7409 ||| VBN
with  ||| S:7409 E:7414 ||| IN
1  ||| S:7414 E:7416 ||| CD
μM  ||| S:7416 E:7419 ||| JJ
IONO  ||| S:7419 E:7424 ||| NNP
or  ||| S:7424 E:7427 ||| CC
100  ||| S:7427 E:7431 ||| CD
μM  ||| S:7431 E:7434 ||| JJ
ATP ||| S:7434 E:7437 ||| NNP
,  ||| S:7437 E:7439 ||| ,
but  ||| S:7439 E:7443 ||| CC
the  ||| S:7443 E:7447 ||| DT
percent  ||| S:7447 E:7465 ||| NN
inhibition  ||| S:7465 E:7476 ||| NN
by  ||| S:7476 E:7479 ||| IN
U0126  ||| S:7479 E:7485 ||| NNP
was  ||| S:7485 E:7489 ||| VBD
similar ||| S:7489 E:7496 ||| JJ
.  ||| S:7496 E:7498 ||| .
Treatment  ||| S:7498 E:7508 ||| NN
of  ||| S:7508 E:7511 ||| IN
MDCK  ||| S:7511 E:7516 ||| NNP
cells  ||| S:7516 E:7532 ||| NNS
with  ||| S:7532 E:7537 ||| IN
30  ||| S:7537 E:7540 ||| CD
μM  ||| S:7540 E:7543 ||| JJ
PD098059 ||| S:7543 E:7551 ||| NN
,  ||| S:7551 E:7553 ||| ,
a  ||| S:7553 E:7555 ||| DT
less  ||| S:7555 E:7560 ||| RBR
potent  ||| S:7560 E:7567 ||| JJ
inhibitor  ||| S:7567 E:7577 ||| NN
of  ||| S:7577 E:7580 ||| IN
MEK  ||| S:7580 E:7584 ||| NNP
[  ||| S:7584 E:7586 ||| -LRB-
28  ||| S:7586 E:7599 ||| CD
29  ||| S:7599 E:7602 ||| CD
]  ||| S:7602 E:7604 ||| -RRB-
,  ||| S:7604 E:7606 ||| ,
resulted  ||| S:7606 E:7615 ||| VBD
in  ||| S:7615 E:7618 ||| IN
a  ||| S:7618 E:7620 ||| DT
~50 ||| S:7620 E:7623 ||| JJ
%  ||| S:7623 E:7625 ||| NN
reduction  ||| S:7625 E:7635 ||| NN
in  ||| S:7635 E:7638 ||| IN
AA  ||| S:7638 E:7641 ||| NN
release  ||| S:7641 E:7649 ||| NN
in  ||| S:7649 E:7662 ||| IN
response  ||| S:7662 E:7671 ||| NN
to  ||| S:7671 E:7674 ||| TO
100  ||| S:7674 E:7678 ||| CD
μM  ||| S:7678 E:7681 ||| JJ
ATP ||| S:7681 E:7684 ||| NNP
,  ||| S:7684 E:7686 ||| ,
1  ||| S:7686 E:7688 ||| CD
μM  ||| S:7688 E:7691 ||| JJ
IONO ||| S:7691 E:7695 ||| NNP
,  ||| S:7695 E:7697 ||| ,
and  ||| S:7697 E:7701 ||| CC
10  ||| S:7701 E:7704 ||| CD
μM  ||| S:7704 E:7707 ||| JJ
IONO  ||| S:7707 E:7712 ||| NNP
( ||| S:7712 E:7713 ||| -LRB-
data  ||| S:7713 E:7728 ||| NNS
not  ||| S:7728 E:7732 ||| RB
shown ||| S:7732 E:7737 ||| VBN
) ||| S:7737 E:7738 ||| -RRB-
.  ||| S:7738 E:7740 ||| .
Thus ||| S:7740 E:7744 ||| RB
,  ||| S:7744 E:7746 ||| ,
in  ||| S:7746 E:7749 ||| IN
MDCK  ||| S:7749 E:7754 ||| NNP
cells ||| S:7754 E:7759 ||| NNS
,  ||| S:7759 E:7761 ||| ,
MEK1  ||| S:7761 E:7766 ||| NNP
inhibition  ||| S:7766 E:7787 ||| VBD
significantly  ||| S:7787 E:7801 ||| RB
reduces  ||| S:7801 E:7809 ||| VBZ
the  ||| S:7809 E:7813 ||| DT
ability  ||| S:7813 E:7821 ||| NN
of  ||| S:7821 E:7824 ||| IN
cPLA  ||| S:7824 E:7840 ||| JJ
2  ||| S:7840 E:7842 ||| CD
to  ||| S:7842 E:7845 ||| TO
hydrolyze  ||| S:7845 E:7855 ||| VB
AA  ||| S:7855 E:7858 ||| NN
from  ||| S:7858 E:7863 ||| IN
membrane  ||| S:7863 E:7882 ||| JJ
phospholipids ||| S:7882 E:7895 ||| NN
.  ||| S:7895 E:7907 ||| .
The  ||| S:7907 E:7911 ||| DT
effect  ||| S:7911 E:7918 ||| NN
of  ||| S:7918 E:7921 ||| IN
MEK1  ||| S:7921 E:7926 ||| CD
inhibition  ||| S:7926 E:7937 ||| NN
on  ||| S:7937 E:7940 ||| IN
activation  ||| S:7940 E:7951 ||| NN
of  ||| S:7951 E:7954 ||| IN
p42 ||| S:7954 E:7957 ||| NNP
/ ||| S:7957 E:7958 ||| NNP
p44  ||| S:7958 E:7972 ||| NNP
ERK  ||| S:7972 E:7976 ||| NNP
measured  ||| S:7976 E:7985 ||| VBD
by  ||| S:7985 E:7988 ||| IN
immunoblot  ||| S:7988 E:7999 ||| JJ
analysis  ||| S:7999 E:8008 ||| NN
using  ||| S:8008 E:8024 ||| VBG
phospho-specific  ||| S:8024 E:8041 ||| JJ
antibodies  ||| S:8041 E:8052 ||| NNS
in  ||| S:8052 E:8055 ||| IN
cells  ||| S:8055 E:8061 ||| NNS
treated  ||| S:8061 E:8069 ||| VBN
with  ||| S:8069 E:8074 ||| IN
U0126  ||| S:8074 E:8090 ||| NNP
and  ||| S:8090 E:8094 ||| CC
stimulated  ||| S:8094 E:8105 ||| VBN
as  ||| S:8105 E:8108 ||| IN
above  ||| S:8108 E:8114 ||| RB
was  ||| S:8114 E:8118 ||| VBD
determined  ||| S:8118 E:8129 ||| VBN
( ||| S:8129 E:8130 ||| -LRB-
Fig.  ||| S:8130 E:8135 ||| NNP
1B ||| S:8135 E:8137 ||| NNP
) ||| S:8137 E:8138 ||| -RRB-
.  ||| S:8138 E:8140 ||| .
Work  ||| S:8140 E:8145 ||| NN
in  ||| S:8145 E:8158 ||| IN
our  ||| S:8158 E:8162 ||| PRP$
laboratory  ||| S:8162 E:8173 ||| NN
has  ||| S:8173 E:8177 ||| VBZ
shown  ||| S:8177 E:8183 ||| VBN
that  ||| S:8183 E:8188 ||| IN
recognition  ||| S:8188 E:8200 ||| NN
of  ||| S:8200 E:8203 ||| IN
ERK  ||| S:8203 E:8207 ||| NNP
by  ||| S:8207 E:8220 ||| IN
anti-phospho-ERK  ||| S:8220 E:8237 ||| JJ
antibodies  ||| S:8237 E:8248 ||| NNS
correlates  ||| S:8248 E:8259 ||| VBN
with  ||| S:8259 E:8264 ||| IN
an  ||| S:8264 E:8267 ||| DT
increase  ||| S:8267 E:8286 ||| NN
in  ||| S:8286 E:8289 ||| IN
ERK  ||| S:8289 E:8293 ||| NNP
activity  ||| S:8293 E:8302 ||| NN
[  ||| S:8302 E:8304 ||| -LRB-
21  ||| S:8304 E:8307 ||| CD
30  ||| S:8307 E:8310 ||| CD
31  ||| S:8310 E:8313 ||| CD
]  ||| S:8313 E:8315 ||| -RRB-
.  ||| S:8315 E:8317 ||| .
Interestingly ||| S:8317 E:8330 ||| RB
,  ||| S:8330 E:8332 ||| ,
the  ||| S:8332 E:8346 ||| DT
anti-phospho-ERK  ||| S:8346 E:8363 ||| JJ
immunoblots  ||| S:8363 E:8375 ||| NN
revealed  ||| S:8375 E:8384 ||| VBD
that  ||| S:8384 E:8389 ||| IN
ERKs  ||| S:8389 E:8394 ||| NNP
were  ||| S:8394 E:8409 ||| VBD
constitutively  ||| S:8409 E:8424 ||| VBN
activated  ||| S:8424 E:8434 ||| VBN
in  ||| S:8434 E:8437 ||| IN
untreated ||| S:8437 E:8446 ||| NN
,  ||| S:8446 E:8448 ||| ,
quiesced  ||| S:8448 E:8457 ||| JJ
MDCK  ||| S:8457 E:8472 ||| NN
cells  ||| S:8472 E:8478 ||| NNS
and  ||| S:8478 E:8482 ||| CC
activation  ||| S:8482 E:8493 ||| NNS
was  ||| S:8493 E:8497 ||| VBD
not  ||| S:8497 E:8501 ||| RB
enhanced  ||| S:8501 E:8510 ||| VBN
further  ||| S:8510 E:8518 ||| RBR
by  ||| S:8518 E:8521 ||| IN
ATP  ||| S:8521 E:8525 ||| NNP
or  ||| S:8525 E:8538 ||| CC
IONO  ||| S:8538 E:8543 ||| NNP
( ||| S:8543 E:8544 ||| -LRB-
Fig.  ||| S:8544 E:8549 ||| NNP
1B ||| S:8549 E:8551 ||| NNP
,  ||| S:8551 E:8553 ||| ,
left  ||| S:8553 E:8558 ||| VBN
panel ||| S:8558 E:8563 ||| NN
) ||| S:8563 E:8564 ||| -RRB-
.  ||| S:8564 E:8566 ||| .
ERK  ||| S:8566 E:8570 ||| NNP
activation  ||| S:8570 E:8581 ||| NN
was  ||| S:8581 E:8585 ||| VBD
diminished  ||| S:8585 E:8606 ||| VBN
by  ||| S:8606 E:8609 ||| IN
increasing  ||| S:8609 E:8620 ||| VBG
concentrations  ||| S:8620 E:8635 ||| NNS
of  ||| S:8635 E:8638 ||| IN
U0126  ||| S:8638 E:8644 ||| NNP
and  ||| S:8644 E:8648 ||| CC
was  ||| S:8648 E:8662 ||| VBD
quantitatively  ||| S:8662 E:8677 ||| JJ
inhibited  ||| S:8677 E:8687 ||| NN
after  ||| S:8687 E:8693 ||| IN
15  ||| S:8693 E:8696 ||| CD
min  ||| S:8696 E:8700 ||| JJ
incubation  ||| S:8700 E:8711 ||| NN
in  ||| S:8711 E:8714 ||| IN
10  ||| S:8714 E:8717 ||| CD
μM  ||| S:8717 E:8730 ||| JJ
U0126 ||| S:8730 E:8735 ||| NN
.  ||| S:8735 E:8737 ||| .
U0126  ||| S:8737 E:8743 ||| NNP
decreased  ||| S:8743 E:8753 ||| VBD
ERK  ||| S:8753 E:8757 ||| NNP
activation  ||| S:8757 E:8768 ||| VBZ
following  ||| S:8768 E:8778 ||| VBG
ATP  ||| S:8778 E:8782 ||| NNP
or  ||| S:8782 E:8795 ||| CC
IONO  ||| S:8795 E:8800 ||| NNP
stimulation  ||| S:8800 E:8812 ||| NN
in  ||| S:8812 E:8815 ||| IN
the  ||| S:8815 E:8819 ||| DT
same  ||| S:8819 E:8824 ||| JJ
fashion  ||| S:8824 E:8832 ||| NN
as  ||| S:8832 E:8835 ||| IN
in  ||| S:8835 E:8838 ||| IN
unstimulated  ||| S:8838 E:8861 ||| JJ
cells ||| S:8861 E:8866 ||| NNS
.  ||| S:8866 E:8868 ||| .
Consequently ||| S:8868 E:8880 ||| RB
,  ||| S:8880 E:8882 ||| ,
there  ||| S:8882 E:8888 ||| EX
was  ||| S:8888 E:8892 ||| VBD
a  ||| S:8892 E:8894 ||| DT
direct  ||| S:8894 E:8901 ||| JJ
correlation  ||| S:8901 E:8923 ||| NN
between  ||| S:8923 E:8931 ||| IN
the  ||| S:8931 E:8935 ||| DT
reduction  ||| S:8935 E:8945 ||| NN
of  ||| S:8945 E:8948 ||| IN
AA  ||| S:8948 E:8951 ||| NN
release  ||| S:8951 E:8959 ||| NN
( ||| S:8959 E:8960 ||| -LRB-
Fig.  ||| S:8960 E:8965 ||| NNP
1A ||| S:8965 E:8967 ||| NNP
)  ||| S:8967 E:8969 ||| -RRB-
and  ||| S:8969 E:8983 ||| CC
inhibition  ||| S:8983 E:8994 ||| NN
of  ||| S:8994 E:8997 ||| IN
ERK  ||| S:8997 E:9001 ||| NNP
activation  ||| S:9001 E:9012 ||| NNS
( ||| S:9012 E:9013 ||| -LRB-
Fig.  ||| S:9013 E:9018 ||| NNP
1B ||| S:9018 E:9020 ||| NNP
)  ||| S:9020 E:9022 ||| -RRB-
in  ||| S:9022 E:9025 ||| IN
MDCK  ||| S:9025 E:9030 ||| NNP
cells  ||| S:9030 E:9046 ||| NNS
treated  ||| S:9046 E:9054 ||| VBN
with  ||| S:9054 E:9059 ||| IN
U0126 ||| S:9059 E:9064 ||| CD
.  ||| S:9064 E:9076 ||| .
Because  ||| S:9076 E:9084 ||| IN
cPLA  ||| S:9084 E:9100 ||| JJ
2  ||| S:9100 E:9102 ||| CD
is  ||| S:9102 E:9105 ||| VBZ
a  ||| S:9105 E:9107 ||| DT
target  ||| S:9107 E:9114 ||| NN
of  ||| S:9114 E:9117 ||| IN
the  ||| S:9117 E:9121 ||| DT
MEK1 ||| S:9121 E:9125 ||| FW
/ ||| S:9125 E:9126 ||| FW
ERK  ||| S:9126 E:9140 ||| FW
signaling  ||| S:9140 E:9150 ||| FW
cascade ||| S:9150 E:9157 ||| FW
,  ||| S:9157 E:9159 ||| ,
we  ||| S:9159 E:9162 ||| PRP
assayed  ||| S:9162 E:9170 ||| VBD
the  ||| S:9170 E:9174 ||| DT
effect  ||| S:9174 E:9181 ||| NN
of  ||| S:9181 E:9184 ||| IN
MEK1  ||| S:9184 E:9199 ||| CD
inhibition  ||| S:9199 E:9210 ||| NN
by  ||| S:9210 E:9213 ||| IN
U0126  ||| S:9213 E:9219 ||| CD
on  ||| S:9219 E:9222 ||| IN
cPLA  ||| S:9222 E:9238 ||| JJ
2  ||| S:9238 E:9240 ||| CD
phosphorylation  ||| S:9240 E:9256 ||| NN
by  ||| S:9256 E:9259 ||| IN
analyzing  ||| S:9259 E:9269 ||| VBG
gel  ||| S:9269 E:9283 ||| JJ
shift  ||| S:9283 E:9289 ||| NN
of  ||| S:9289 E:9292 ||| IN
cPLA  ||| S:9292 E:9308 ||| JJ
2  ||| S:9308 E:9310 ||| CD
.  ||| S:9310 E:9312 ||| .
Phosphorylation  ||| S:9312 E:9328 ||| NNP
of  ||| S:9328 E:9331 ||| IN
Ser  ||| S:9331 E:9335 ||| NNP
505results  ||| S:9335 E:9356 ||| NNP
in  ||| S:9356 E:9359 ||| IN
a  ||| S:9359 E:9361 ||| DT
retardation  ||| S:9361 E:9373 ||| NN
of  ||| S:9373 E:9376 ||| IN
its  ||| S:9376 E:9380 ||| PRP$
electrophoretic  ||| S:9380 E:9396 ||| JJ
mobility  ||| S:9396 E:9405 ||| NNS
( ||| S:9405 E:9406 ||| -LRB-
gel  ||| S:9406 E:9420 ||| JJ
shift ||| S:9420 E:9425 ||| NN
)  ||| S:9425 E:9427 ||| -RRB-
[  ||| S:9427 E:9429 ||| -LRB-
13  ||| S:9429 E:9432 ||| CD
16  ||| S:9432 E:9435 ||| CD
]  ||| S:9435 E:9437 ||| -RRB-
.  ||| S:9437 E:9439 ||| .
In  ||| S:9439 E:9442 ||| IN
unstimulated  ||| S:9442 E:9455 ||| JJ
cells ||| S:9455 E:9460 ||| NNS
,  ||| S:9460 E:9462 ||| ,
EGFP-tagged  ||| S:9462 E:9474 ||| JJ
and  ||| S:9474 E:9488 ||| CC
endogenous  ||| S:9488 E:9499 ||| JJ
cPLA  ||| S:9499 E:9515 ||| JJ
2  ||| S:9515 E:9517 ||| CD
were  ||| S:9517 E:9522 ||| VBD
nearly  ||| S:9522 E:9529 ||| RB
completely  ||| S:9529 E:9540 ||| RB
gel  ||| S:9540 E:9544 ||| JJ
shifted ||| S:9544 E:9551 ||| NN
,  ||| S:9551 E:9563 ||| ,
indicating  ||| S:9563 E:9574 ||| VBG
that  ||| S:9574 E:9579 ||| DT
most  ||| S:9579 E:9584 ||| RBS
cPLA  ||| S:9584 E:9600 ||| JJ
2  ||| S:9600 E:9602 ||| CD
was  ||| S:9602 E:9606 ||| VBD
phosphorylated  ||| S:9606 E:9621 ||| VBN
on  ||| S:9621 E:9624 ||| IN
Ser  ||| S:9624 E:9628 ||| NNP
505 ||| S:9628 E:9631 ||| CD
( ||| S:9631 E:9632 ||| -LRB-
Fig.  ||| S:9632 E:9647 ||| NNP
1C ||| S:9647 E:9649 ||| NNP
) ||| S:9649 E:9650 ||| -RRB-
,  ||| S:9650 E:9652 ||| ,
which  ||| S:9652 E:9658 ||| WDT
is  ||| S:9658 E:9661 ||| VBZ
consistent  ||| S:9661 E:9672 ||| JJ
with  ||| S:9672 E:9677 ||| IN
the  ||| S:9677 E:9681 ||| DT
observation  ||| S:9681 E:9693 ||| NN
that  ||| S:9693 E:9698 ||| IN
ERKs  ||| S:9698 E:9713 ||| NNS
are  ||| S:9713 E:9717 ||| VBP
constitutively  ||| S:9717 E:9732 ||| JJ
activated ||| S:9732 E:9741 ||| NN
.  ||| S:9741 E:9743 ||| .
Incubation  ||| S:9743 E:9754 ||| NNP
with  ||| S:9754 E:9759 ||| IN
U0126  ||| S:9759 E:9775 ||| NNP
resulted  ||| S:9775 E:9784 ||| VBD
in  ||| S:9784 E:9787 ||| IN
a  ||| S:9787 E:9789 ||| DT
partial  ||| S:9789 E:9797 ||| JJ
reversal  ||| S:9797 E:9806 ||| NN
of  ||| S:9806 E:9809 ||| IN
the  ||| S:9809 E:9813 ||| DT
gel  ||| S:9813 E:9817 ||| JJ
shift  ||| S:9817 E:9823 ||| NN
although ||| S:9823 E:9831 ||| IN
,  ||| S:9831 E:9843 ||| ,
at  ||| S:9843 E:9846 ||| IN
10  ||| S:9846 E:9849 ||| CD
μM  ||| S:9849 E:9852 ||| JJ
U0126 ||| S:9852 E:9857 ||| NN
,  ||| S:9857 E:9859 ||| ,
approximately  ||| S:9859 E:9873 ||| RB
half  ||| S:9873 E:9878 ||| NN
of  ||| S:9878 E:9881 ||| IN
cPLA  ||| S:9881 E:9897 ||| JJ
2  ||| S:9897 E:9899 ||| CD
remained  ||| S:9899 E:9908 ||| VBD
phosphorylated  ||| S:9908 E:9923 ||| VBN
on  ||| S:9923 E:9926 ||| IN
Ser  ||| S:9926 E:9930 ||| NNP
505 ||| S:9930 E:9933 ||| CD
.  ||| S:9933 E:9945 ||| .
Thus ||| S:9945 E:9949 ||| RB
,  ||| S:9949 E:9951 ||| ,
unlike  ||| S:9951 E:9958 ||| IN
the  ||| S:9958 E:9962 ||| DT
quantitative  ||| S:9962 E:9975 ||| JJ
effect  ||| S:9975 E:9982 ||| NN
of  ||| S:9982 E:9985 ||| IN
U0126  ||| S:9985 E:9991 ||| CD
on  ||| S:9991 E:9994 ||| IN
ERK  ||| S:9994 E:10008 ||| NNP
activation ||| S:10008 E:10018 ||| NN
,  ||| S:10018 E:10020 ||| ,
inhibition  ||| S:10020 E:10031 ||| VBG
of  ||| S:10031 E:10034 ||| IN
MEK1  ||| S:10034 E:10039 ||| CD
with  ||| S:10039 E:10044 ||| IN
U0126  ||| S:10044 E:10050 ||| NNP
only  ||| S:10050 E:10055 ||| RB
partially  ||| S:10055 E:10075 ||| RB
reversed  ||| S:10075 E:10084 ||| VBD
the  ||| S:10084 E:10088 ||| DT
gel  ||| S:10088 E:10092 ||| JJ
shift  ||| S:10092 E:10098 ||| NN
of  ||| S:10098 E:10101 ||| IN
cPLA  ||| S:10101 E:10117 ||| JJ
2  ||| S:10117 E:10119 ||| CD
.  ||| S:10119 E:10121 ||| .
The  ||| S:10121 E:10125 ||| DT
reversal  ||| S:10125 E:10134 ||| NN
of  ||| S:10134 E:10137 ||| IN
the  ||| S:10137 E:10141 ||| DT
gel  ||| S:10141 E:10145 ||| JJ
shift  ||| S:10145 E:10151 ||| NN
was  ||| S:10151 E:10165 ||| VBD
similar  ||| S:10165 E:10173 ||| JJ
in  ||| S:10173 E:10176 ||| IN
cells  ||| S:10176 E:10182 ||| NNS
treated  ||| S:10182 E:10190 ||| VBN
with  ||| S:10190 E:10195 ||| IN
ATP  ||| S:10195 E:10199 ||| NNP
and  ||| S:10199 E:10203 ||| CC
1  ||| S:10203 E:10205 ||| CD
and  ||| S:10205 E:10209 ||| CC
10  ||| S:10209 E:10212 ||| CD
μM  ||| S:10212 E:10215 ||| JJ
IONO ||| S:10215 E:10219 ||| NNP
.  ||| S:10219 E:10231 ||| .
Due  ||| S:10231 E:10235 ||| JJ
to  ||| S:10235 E:10238 ||| TO
the  ||| S:10238 E:10242 ||| DT
increased  ||| S:10242 E:10252 ||| JJ
molecular  ||| S:10252 E:10262 ||| JJ
weight  ||| S:10262 E:10269 ||| NN
of  ||| S:10269 E:10272 ||| IN
the  ||| S:10272 E:10276 ||| DT
EGFP-tagged  ||| S:10276 E:10298 ||| JJ
cPLA  ||| S:10298 E:10314 ||| JJ
2  ||| S:10314 E:10316 ||| CD
,  ||| S:10316 E:10318 ||| ,
the  ||| S:10318 E:10322 ||| DT
two  ||| S:10322 E:10326 ||| CD
forms  ||| S:10326 E:10332 ||| NNS
of  ||| S:10332 E:10335 ||| IN
cPLA  ||| S:10335 E:10351 ||| JJ
2  ||| S:10351 E:10353 ||| CD
did  ||| S:10353 E:10357 ||| VBD
not  ||| S:10357 E:10361 ||| RB
separate  ||| S:10361 E:10370 ||| JJ
as  ||| S:10370 E:10373 ||| IN
well ||| S:10373 E:10377 ||| RB
,  ||| S:10377 E:10379 ||| ,
making  ||| S:10379 E:10386 ||| VBG
the  ||| S:10386 E:10400 ||| DT
gel  ||| S:10400 E:10404 ||| JJ
shift  ||| S:10404 E:10410 ||| NN
more  ||| S:10410 E:10415 ||| RBR
difficult  ||| S:10415 E:10425 ||| JJ
to  ||| S:10425 E:10428 ||| TO
visualize ||| S:10428 E:10437 ||| VB
,  ||| S:10437 E:10439 ||| ,
but  ||| S:10439 E:10443 ||| CC
generally  ||| S:10443 E:10463 ||| RB
mirrored  ||| S:10463 E:10472 ||| VBD
the  ||| S:10472 E:10476 ||| DT
gel  ||| S:10476 E:10480 ||| JJ
shift  ||| S:10480 E:10486 ||| NN
characteristics  ||| S:10486 E:10502 ||| NNS
of  ||| S:10502 E:10505 ||| IN
the  ||| S:10505 E:10509 ||| DT
endogenous  ||| S:10509 E:10530 ||| JJ
cPLA  ||| S:10530 E:10546 ||| JJ
2  ||| S:10546 E:10548 ||| CD
.  ||| S:10548 E:10550 ||| .
These  ||| S:10550 E:10556 ||| DT
results  ||| S:10556 E:10564 ||| NNS
suggest  ||| S:10564 E:10572 ||| VBP
that ||| S:10572 E:10576 ||| RB
,  ||| S:10576 E:10578 ||| ,
in  ||| S:10578 E:10591 ||| IN
response  ||| S:10591 E:10600 ||| NN
to  ||| S:10600 E:10603 ||| TO
MEK1  ||| S:10603 E:10608 ||| CD
inhibition ||| S:10608 E:10618 ||| NN
,  ||| S:10618 E:10620 ||| ,
there  ||| S:10620 E:10626 ||| EX
is  ||| S:10626 E:10629 ||| VBZ
a  ||| S:10629 E:10631 ||| DT
quantitative ||| S:10631 E:10643 ||| JJ
,  ||| S:10643 E:10655 ||| ,
dose-dependent  ||| S:10655 E:10670 ||| JJ
decrease  ||| S:10670 E:10679 ||| NN
in  ||| S:10679 E:10682 ||| IN
AA  ||| S:10682 E:10685 ||| NN
release  ||| S:10685 E:10693 ||| NN
that  ||| S:10693 E:10698 ||| WDT
correlates  ||| S:10698 E:10719 ||| VBP
well  ||| S:10719 E:10724 ||| RB
with  ||| S:10724 E:10729 ||| IN
the  ||| S:10729 E:10733 ||| DT
loss  ||| S:10733 E:10738 ||| NN
of  ||| S:10738 E:10741 ||| IN
ERK  ||| S:10741 E:10745 ||| NNP
activation ||| S:10745 E:10755 ||| NN
,  ||| S:10755 E:10757 ||| ,
but  ||| S:10757 E:10761 ||| CC
not  ||| S:10761 E:10765 ||| RB
with  ||| S:10765 E:10770 ||| IN
the  ||| S:10770 E:10784 ||| DT
extent  ||| S:10784 E:10791 ||| NN
of  ||| S:10791 E:10794 ||| IN
cPLA  ||| S:10794 E:10810 ||| JJ
2  ||| S:10810 E:10812 ||| CD
Ser  ||| S:10812 E:10816 ||| NNP
505phosphorylation ||| S:10816 E:10834 ||| NNP
.  ||| S:10834 E:10846 ||| .
To  ||| S:10846 E:10849 ||| TO
further  ||| S:10849 E:10857 ||| RB
investigate  ||| S:10857 E:10869 ||| VB
whether  ||| S:10869 E:10877 ||| IN
the  ||| S:10877 E:10881 ||| DT
MEK1 ||| S:10881 E:10885 ||| NNP
/ ||| S:10885 E:10886 ||| NNP
ERK  ||| S:10886 E:10890 ||| NNP
pathway  ||| S:10890 E:10908 ||| NN
played  ||| S:10908 E:10915 ||| VBD
a  ||| S:10915 E:10917 ||| DT
role  ||| S:10917 E:10922 ||| NN
in  ||| S:10922 E:10925 ||| IN
regulating  ||| S:10925 E:10936 ||| VBG
AA  ||| S:10936 E:10939 ||| NN
release  ||| S:10939 E:10947 ||| NN
independent  ||| S:10947 E:10959 ||| JJ
of  ||| S:10959 E:10962 ||| IN
Ser  ||| S:10962 E:10976 ||| NNP
505phosphorylation ||| S:10976 E:10994 ||| NNP
,  ||| S:10994 E:10996 ||| ,
we  ||| S:10996 E:10999 ||| PRP
treated  ||| S:10999 E:11007 ||| VBD
cells  ||| S:11007 E:11013 ||| NNS
with  ||| S:11013 E:11018 ||| IN
anisomycin ||| S:11018 E:11028 ||| NN
,  ||| S:11028 E:11040 ||| ,
which  ||| S:11040 E:11046 ||| WDT
activates  ||| S:11046 E:11056 ||| VBZ
the  ||| S:11056 E:11060 ||| DT
MAPK  ||| S:11060 E:11065 ||| NNP
homolog  ||| S:11065 E:11073 ||| VBD
p38 ||| S:11073 E:11076 ||| CD
,  ||| S:11076 E:11078 ||| ,
but  ||| S:11078 E:11082 ||| CC
not  ||| S:11082 E:11086 ||| RB
the  ||| S:11086 E:11100 ||| DT
MEK1 ||| S:11100 E:11104 ||| FW
/ ||| S:11104 E:11105 ||| FW
ERK  ||| S:11105 E:11109 ||| FW
pathway  ||| S:11109 E:11117 ||| FW
[  ||| S:11117 E:11119 ||| -LRB-
32  ||| S:11119 E:11122 ||| CD
]  ||| S:11122 E:11124 ||| -RRB-
.  ||| S:11124 E:11126 ||| .
Activation  ||| S:11126 E:11137 ||| NNP
of  ||| S:11137 E:11140 ||| IN
p38  ||| S:11140 E:11144 ||| CD
in  ||| S:11144 E:11147 ||| IN
response  ||| S:11147 E:11166 ||| NN
to  ||| S:11166 E:11169 ||| TO
anisomycin  ||| S:11169 E:11180 ||| VB
treatment  ||| S:11180 E:11190 ||| NN
was  ||| S:11190 E:11194 ||| VBD
analyzed  ||| S:11194 E:11203 ||| VBN
by  ||| S:11203 E:11206 ||| IN
immunoblotting  ||| S:11206 E:11231 ||| NNS
using  ||| S:11231 E:11237 ||| VBG
an  ||| S:11237 E:11240 ||| DT
anti-phospho-p38  ||| S:11240 E:11257 ||| JJ
antibody  ||| S:11257 E:11266 ||| NN
( ||| S:11266 E:11267 ||| -LRB-
Fig.  ||| S:11267 E:11272 ||| NNP
2A ||| S:11272 E:11274 ||| NNP
) ||| S:11274 E:11275 ||| -RRB-
.  ||| S:11275 E:11277 ||| .
The  ||| S:11277 E:11291 ||| DT
immunoblots  ||| S:11291 E:11303 ||| JJ
demonstrate  ||| S:11303 E:11315 ||| NN
that  ||| S:11315 E:11320 ||| IN
30  ||| S:11320 E:11323 ||| CD
min  ||| S:11323 E:11327 ||| JJ
treatment  ||| S:11327 E:11337 ||| NN
in  ||| S:11337 E:11340 ||| IN
25  ||| S:11340 E:11343 ||| CD
ng ||| S:11343 E:11345 ||| CD
/ ||| S:11345 E:11346 ||| CD
ml  ||| S:11346 E:11359 ||| NNS
anisomycin  ||| S:11359 E:11370 ||| VBP
resulted  ||| S:11370 E:11379 ||| VBN
in  ||| S:11379 E:11382 ||| IN
phosphorylation  ||| S:11382 E:11398 ||| NN
of  ||| S:11398 E:11401 ||| IN
p38  ||| S:11401 E:11405 ||| CD
in  ||| S:11405 E:11418 ||| IN
unstimulated  ||| S:11418 E:11431 ||| JJ
MDCK  ||| S:11431 E:11436 ||| NN
cells  ||| S:11436 E:11442 ||| NNS
and  ||| S:11442 E:11446 ||| CC
in  ||| S:11446 E:11449 ||| IN
cells  ||| S:11449 E:11455 ||| NNS
treated  ||| S:11455 E:11463 ||| VBN
with  ||| S:11463 E:11468 ||| IN
ATP  ||| S:11468 E:11472 ||| NNP
or  ||| S:11472 E:11485 ||| CC
IONO ||| S:11485 E:11489 ||| NNP
.  ||| S:11489 E:11491 ||| .
ATP  ||| S:11491 E:11495 ||| NNP
and  ||| S:11495 E:11499 ||| CC
ionomycin  ||| S:11499 E:11509 ||| JJ
treatment  ||| S:11509 E:11519 ||| NN
in  ||| S:11519 E:11522 ||| IN
the  ||| S:11522 E:11526 ||| DT
absence  ||| S:11526 E:11534 ||| NN
of  ||| S:11534 E:11547 ||| IN
anisomycin  ||| S:11547 E:11558 ||| JJ
only  ||| S:11558 E:11563 ||| JJ
weakly  ||| S:11563 E:11570 ||| NN
increased  ||| S:11570 E:11580 ||| VBD
p38  ||| S:11580 E:11584 ||| CD
phosphorylation ||| S:11584 E:11599 ||| NNS
.  ||| S:11599 E:11601 ||| .
As  ||| S:11601 E:11614 ||| RB
expected ||| S:11614 E:11622 ||| VBN
,  ||| S:11622 E:11624 ||| ,
the  ||| S:11624 E:11628 ||| DT
MEK  ||| S:11628 E:11632 ||| NNP
inhibitor  ||| S:11632 E:11642 ||| VBD
U0126  ||| S:11642 E:11648 ||| NNP
did  ||| S:11648 E:11652 ||| VBD
not  ||| S:11652 E:11656 ||| RB
significantly  ||| S:11656 E:11680 ||| RB
affect  ||| S:11680 E:11687 ||| VB
anisomycin-stimulated  ||| S:11687 E:11709 ||| JJ
p38  ||| S:11709 E:11713 ||| CD
phosphorylation ||| S:11713 E:11728 ||| NNS
.  ||| S:11728 E:11730 ||| .
In  ||| S:11730 E:11743 ||| IN
control  ||| S:11743 E:11751 ||| NN
experiments ||| S:11751 E:11762 ||| NNS
,  ||| S:11762 E:11764 ||| ,
anisomycin  ||| S:11764 E:11775 ||| JJ
treatment  ||| S:11775 E:11785 ||| NN
did  ||| S:11785 E:11789 ||| VBD
not  ||| S:11789 E:11793 ||| RB
induce  ||| S:11793 E:11810 ||| VB
ERK  ||| S:11810 E:11814 ||| JJ
activation  ||| S:11814 E:11825 ||| NN
nor  ||| S:11825 E:11829 ||| CC
interfere  ||| S:11829 E:11839 ||| VB
with  ||| S:11839 E:11844 ||| IN
inhibition  ||| S:11844 E:11855 ||| NN
of  ||| S:11855 E:11858 ||| IN
ERK  ||| S:11858 E:11872 ||| NNP
activation  ||| S:11872 E:11883 ||| NN
by  ||| S:11883 E:11886 ||| IN
10  ||| S:11886 E:11889 ||| CD
μM  ||| S:11889 E:11892 ||| JJ
U0126  ||| S:11892 E:11898 ||| CD
treatment  ||| S:11898 E:11908 ||| NN
( ||| S:11908 E:11909 ||| -LRB-
Fig.  ||| S:11909 E:11914 ||| NNP
2B ||| S:11914 E:11916 ||| NNP
) ||| S:11916 E:11917 ||| -RRB-
.  ||| S:11917 E:11919 ||| .
We  ||| S:11919 E:11922 ||| PRP
have  ||| S:11922 E:11937 ||| VBP
previously  ||| S:11937 E:11948 ||| RB
reported  ||| S:11948 E:11957 ||| VBN
that  ||| S:11957 E:11962 ||| IN
p38  ||| S:11962 E:11966 ||| NNP
is  ||| S:11966 E:11969 ||| VBZ
also  ||| S:11969 E:11974 ||| RB
selectively  ||| S:11974 E:11996 ||| RB
activated  ||| S:11996 E:12006 ||| VBN
in  ||| S:12006 E:12009 ||| IN
anisomycin-treated  ||| S:12009 E:12028 ||| JJ
macrophages  ||| S:12028 E:12040 ||| NNS
[  ||| S:12040 E:12042 ||| -LRB-
21  ||| S:12042 E:12045 ||| CD
]  ||| S:12045 E:12047 ||| -RRB-
.  ||| S:12047 E:12059 ||| .
Importantly ||| S:12059 E:12070 ||| RB
,  ||| S:12070 E:12072 ||| ,
pretreatment  ||| S:12072 E:12085 ||| VBG
of  ||| S:12085 E:12088 ||| IN
cells  ||| S:12088 E:12094 ||| NNS
for  ||| S:12094 E:12098 ||| IN
30  ||| S:12098 E:12101 ||| CD
min  ||| S:12101 E:12105 ||| NN
with  ||| S:12105 E:12120 ||| IN
anisomycin  ||| S:12120 E:12131 ||| NN
resulted  ||| S:12131 E:12140 ||| VBD
in  ||| S:12140 E:12143 ||| IN
maintenance  ||| S:12143 E:12155 ||| NN
of  ||| S:12155 E:12158 ||| IN
the  ||| S:12158 E:12162 ||| DT
cPLA  ||| S:12162 E:12178 ||| JJ
2  ||| S:12178 E:12180 ||| CD
gel  ||| S:12180 E:12184 ||| JJ
shift  ||| S:12184 E:12190 ||| NN
in  ||| S:12190 E:12193 ||| IN
the  ||| S:12193 E:12197 ||| DT
presence  ||| S:12197 E:12206 ||| NN
of  ||| S:12206 E:12209 ||| IN
U0126  ||| S:12209 E:12225 ||| CD
in  ||| S:12225 E:12228 ||| IN
unstimulated  ||| S:12228 E:12241 ||| JJ
cells  ||| S:12241 E:12247 ||| NNS
and  ||| S:12247 E:12251 ||| CC
in  ||| S:12251 E:12254 ||| IN
cells  ||| S:12254 E:12260 ||| NNS
stimulated  ||| S:12260 E:12271 ||| VBN
with  ||| S:12271 E:12276 ||| IN
ATP  ||| S:12276 E:12290 ||| NNP
and  ||| S:12290 E:12294 ||| CC
1  ||| S:12294 E:12296 ||| CD
and  ||| S:12296 E:12300 ||| CC
10  ||| S:12300 E:12303 ||| CD
μM  ||| S:12303 E:12306 ||| JJ
IONO  ||| S:12306 E:12311 ||| NNP
( ||| S:12311 E:12312 ||| -LRB-
Fig.  ||| S:12312 E:12317 ||| NNP
2C ||| S:12317 E:12319 ||| NNP
) ||| S:12319 E:12320 ||| -RRB-
.  ||| S:12320 E:12322 ||| .
AA  ||| S:12322 E:12325 ||| NN
release  ||| S:12325 E:12333 ||| NN
assays  ||| S:12333 E:12340 ||| NNS
show  ||| S:12340 E:12355 ||| VBP
that ||| S:12355 E:12359 ||| RB
,  ||| S:12359 E:12361 ||| ,
in  ||| S:12361 E:12364 ||| IN
MDCK  ||| S:12364 E:12369 ||| NNP
cells  ||| S:12369 E:12375 ||| NNS
treated  ||| S:12375 E:12383 ||| VBN
with  ||| S:12383 E:12388 ||| IN
anisomycin ||| S:12388 E:12398 ||| NN
,  ||| S:12398 E:12400 ||| ,
U0126  ||| S:12400 E:12416 ||| NNP
resulted  ||| S:12416 E:12425 ||| VBD
in  ||| S:12425 E:12428 ||| IN
an  ||| S:12428 E:12431 ||| DT
AA  ||| S:12431 E:12434 ||| NN
release  ||| S:12434 E:12442 ||| NN
reduction  ||| S:12442 E:12452 ||| NN
of  ||| S:12452 E:12455 ||| IN
~67-76 ||| S:12455 E:12461 ||| CD
%  ||| S:12461 E:12463 ||| NN
( ||| S:12463 E:12464 ||| -LRB-
Fig.  ||| S:12464 E:12469 ||| NNP
2D ||| S:12469 E:12471 ||| NNP
)  ||| S:12471 E:12483 ||| -RRB-
similar  ||| S:12483 E:12491 ||| JJ
to  ||| S:12491 E:12494 ||| TO
the  ||| S:12494 E:12498 ||| DT
inhibition  ||| S:12498 E:12509 ||| NN
observed  ||| S:12509 E:12518 ||| VBD
without  ||| S:12518 E:12526 ||| IN
anisomycin ||| S:12526 E:12536 ||| NN
.  ||| S:12536 E:12548 ||| .
These  ||| S:12548 E:12554 ||| DT
results  ||| S:12554 E:12562 ||| NNS
demonstrate  ||| S:12562 E:12574 ||| VBP
that  ||| S:12574 E:12579 ||| DT
activation  ||| S:12579 E:12590 ||| NN
of  ||| S:12590 E:12593 ||| IN
the  ||| S:12593 E:12597 ||| DT
MEK1 ||| S:12597 E:12601 ||| NNP
/ ||| S:12601 E:12602 ||| NNP
ERK  ||| S:12602 E:12616 ||| NNP
pathway  ||| S:12616 E:12624 ||| NN
is  ||| S:12624 E:12627 ||| VBZ
required  ||| S:12627 E:12636 ||| VBN
for  ||| S:12636 E:12640 ||| IN
AA  ||| S:12640 E:12643 ||| NN
release  ||| S:12643 E:12651 ||| NN
even  ||| S:12651 E:12656 ||| RB
under  ||| S:12656 E:12662 ||| IN
conditions  ||| S:12662 E:12683 ||| NNS
where  ||| S:12683 E:12689 ||| WRB
cPLA  ||| S:12689 E:12705 ||| JJ
2  ||| S:12705 E:12707 ||| CD
Ser  ||| S:12707 E:12711 ||| NNP
505phosphorylation  ||| S:12711 E:12730 ||| NNP
is  ||| S:12730 E:12743 ||| VBZ
maintained ||| S:12743 E:12753 ||| VBN
,  ||| S:12753 E:12755 ||| ,
suggesting  ||| S:12755 E:12766 ||| VBG
an  ||| S:12766 E:12769 ||| DT
alternative  ||| S:12769 E:12781 ||| JJ
role  ||| S:12781 E:12786 ||| NN
for  ||| S:12786 E:12790 ||| IN
the  ||| S:12790 E:12804 ||| DT
MEK1 ||| S:12804 E:12808 ||| NNP
/ ||| S:12808 E:12809 ||| NNP
ERK  ||| S:12809 E:12813 ||| NNP
pathway  ||| S:12813 E:12821 ||| NN
in  ||| S:12821 E:12824 ||| IN
regulating  ||| S:12824 E:12835 ||| VBG
cPLA  ||| S:12835 E:12851 ||| JJ
2  ||| S:12851 E:12853 ||| CD
.  ||| S:12853 E:12883 ||| .
[ ||| S:12883 E:12884 ||| -LRB-
Ca  ||| S:12884 E:12887 ||| NNP
2+ ||| S:12887 E:12889 ||| NNP
]  ||| S:12889 E:12891 ||| -RRB-
iincrease  ||| S:12891 E:12901 ||| NN
is  ||| S:12901 E:12904 ||| VBZ
independent  ||| S:12904 E:12916 ||| JJ
of  ||| S:12916 E:12919 ||| IN
MEK1 ||| S:12919 E:12923 ||| NNP
/ ||| S:12923 E:12924 ||| NNP
ERK  ||| S:12924 E:12938 ||| NNP
pathway  ||| S:12938 E:12956 ||| VBD
One  ||| S:12956 E:12960 ||| CD
explanation  ||| S:12960 E:12972 ||| NN
for  ||| S:12972 E:12976 ||| IN
the  ||| S:12976 E:12980 ||| DT
decrease  ||| S:12980 E:12989 ||| NN
in  ||| S:12989 E:12992 ||| IN
AA  ||| S:12992 E:12995 ||| NN
is  ||| S:12995 E:12998 ||| VBZ
that  ||| S:12998 E:13003 ||| IN
U0126  ||| S:13003 E:13019 ||| CD
inhibits  ||| S:13019 E:13028 ||| NNS
[ ||| S:13028 E:13029 ||| -LRB-
Ca  ||| S:13029 E:13032 ||| NNP
2+ ||| S:13032 E:13034 ||| NNP
]  ||| S:13034 E:13047 ||| -RRB-
i  ||| S:13047 E:13049 ||| FW
mobilization  ||| S:13049 E:13062 ||| FW
in  ||| S:13062 E:13065 ||| IN
response  ||| S:13065 E:13074 ||| NN
to  ||| S:13074 E:13077 ||| TO
ATP  ||| S:13077 E:13081 ||| NNP
or  ||| S:13081 E:13094 ||| CC
IONO ||| S:13094 E:13098 ||| NNP
,  ||| S:13098 E:13100 ||| ,
thereby  ||| S:13100 E:13108 ||| RB
preventing  ||| S:13108 E:13119 ||| VBG
translocation  ||| S:13119 E:13133 ||| NN
of  ||| S:13133 E:13136 ||| IN
cPLA  ||| S:13136 E:13152 ||| JJ
2  ||| S:13152 E:13154 ||| CD
.  ||| S:13154 E:13156 ||| .
In  ||| S:13156 E:13159 ||| IN
chick  ||| S:13159 E:13165 ||| JJ
ventricular  ||| S:13165 E:13177 ||| JJ
myocytes ||| S:13177 E:13185 ||| NN
,  ||| S:13185 E:13197 ||| ,
inhibition  ||| S:13197 E:13208 ||| VBG
of  ||| S:13208 E:13211 ||| IN
MEK1 ||| S:13211 E:13215 ||| NNP
/ ||| S:13215 E:13216 ||| NNP
ERK  ||| S:13216 E:13220 ||| NNP
by  ||| S:13220 E:13223 ||| IN
PD98059  ||| S:13223 E:13231 ||| CD
inhibits  ||| S:13231 E:13250 ||| CD
zinterol-mediated  ||| S:13250 E:13268 ||| JJ
AA  ||| S:13268 E:13271 ||| NN
release ||| S:13271 E:13278 ||| NN
,  ||| S:13278 E:13280 ||| ,
but  ||| S:13280 E:13284 ||| CC
also  ||| S:13284 E:13289 ||| RB
inhibits  ||| S:13289 E:13308 ||| JJ
zinterol-induced  ||| S:13308 E:13325 ||| JJ
stimulation  ||| S:13325 E:13337 ||| NN
of  ||| S:13337 E:13340 ||| IN
[ ||| S:13340 E:13341 ||| -LRB-
Ca  ||| S:13341 E:13344 ||| NNP
2+ ||| S:13344 E:13346 ||| NNP
]  ||| S:13346 E:13359 ||| -RRB-
i  ||| S:13359 E:13361 ||| FW
cycling  ||| S:13361 E:13369 ||| FW
in  ||| S:13369 E:13372 ||| FW
electrically  ||| S:13372 E:13385 ||| FW
stimulated  ||| S:13385 E:13406 ||| FW
cells  ||| S:13406 E:13412 ||| FW
[  ||| S:13412 E:13414 ||| -LRB-
33  ||| S:13414 E:13417 ||| CD
]  ||| S:13417 E:13419 ||| -RRB-
.  ||| S:13419 E:13421 ||| .
In  ||| S:13421 E:13424 ||| IN
MDCK  ||| S:13424 E:13429 ||| NNP
cells ||| S:13429 E:13434 ||| NNS
,  ||| S:13434 E:13436 ||| ,
extracellular  ||| S:13436 E:13450 ||| VBG
ATP  ||| S:13450 E:13454 ||| NNP
acts  ||| S:13454 E:13459 ||| VBZ
via  ||| S:13459 E:13473 ||| IN
P  ||| S:13473 E:13486 ||| NN
2Y2  ||| S:13486 E:13490 ||| CD
receptors  ||| S:13490 E:13500 ||| NNS
to  ||| S:13500 E:13503 ||| TO
elicit  ||| S:13503 E:13510 ||| VB
an  ||| S:13510 E:13513 ||| DT
IP  ||| S:13513 E:13527 ||| NNP
3  ||| S:13527 E:13529 ||| CD
-mediated  ||| S:13529 E:13539 ||| NNS
[ ||| S:13539 E:13540 ||| -LRB-
Ca  ||| S:13540 E:13543 ||| NNP
2+ ||| S:13543 E:13545 ||| NNP
]  ||| S:13545 E:13558 ||| -RRB-
i  ||| S:13558 E:13560 ||| FW
increase  ||| S:13560 E:13569 ||| NN
[  ||| S:13569 E:13571 ||| -LRB-
34  ||| S:13571 E:13574 ||| CD
]  ||| S:13574 E:13576 ||| -RRB-
and  ||| S:13576 E:13580 ||| CC
IONO  ||| S:13580 E:13585 ||| NNP
acts  ||| S:13585 E:13590 ||| VBZ
to  ||| S:13590 E:13603 ||| TO
increase  ||| S:13603 E:13612 ||| VB
[ ||| S:13612 E:13613 ||| -LRB-
Ca  ||| S:13613 E:13616 ||| NNP
2+ ||| S:13616 E:13618 ||| NNP
]  ||| S:13618 E:13631 ||| -RRB-
i  ||| S:13631 E:13633 ||| NN
by  ||| S:13633 E:13636 ||| IN
permeabilizing  ||| S:13636 E:13651 ||| JJ
cell  ||| S:13651 E:13656 ||| NN
membranes  ||| S:13656 E:13666 ||| NN
to  ||| S:13666 E:13679 ||| TO
Ca  ||| S:13679 E:13682 ||| NNP
2+ ||| S:13682 E:13684 ||| NNP
.  ||| S:13684 E:13686 ||| .
To  ||| S:13686 E:13689 ||| TO
determine  ||| S:13689 E:13699 ||| VB
the  ||| S:13699 E:13703 ||| DT
effect  ||| S:13703 E:13710 ||| NN
of  ||| S:13710 E:13713 ||| IN
U0126  ||| S:13713 E:13719 ||| CD
on  ||| S:13719 E:13722 ||| IN
intracellular  ||| S:13722 E:13746 ||| JJ
Ca  ||| S:13746 E:13749 ||| JJ
2+mobilization  ||| S:13749 E:13764 ||| NN
by  ||| S:13764 E:13767 ||| IN
100  ||| S:13767 E:13771 ||| CD
μM  ||| S:13771 E:13774 ||| JJ
ATP  ||| S:13774 E:13778 ||| NNP
or  ||| S:13778 E:13781 ||| CC
10  ||| S:13781 E:13784 ||| CD
μM  ||| S:13784 E:13787 ||| JJ
IONO ||| S:13787 E:13791 ||| NNP
,  ||| S:13791 E:13793 ||| ,
we  ||| S:13793 E:13806 ||| PRP
utilized  ||| S:13806 E:13815 ||| VBP
single-cell  ||| S:13815 E:13827 ||| JJ
fluorescence  ||| S:13827 E:13840 ||| JJ
microscopy  ||| S:13840 E:13851 ||| NN
on  ||| S:13851 E:13854 ||| IN
cells  ||| S:13854 E:13870 ||| NNS
loaded  ||| S:13870 E:13877 ||| VBN
with  ||| S:13877 E:13882 ||| IN
the  ||| S:13882 E:13886 ||| DT
calcium  ||| S:13886 E:13894 ||| JJ
indicator  ||| S:13894 E:13904 ||| NN
Fura2 ||| S:13904 E:13909 ||| NN
.  ||| S:13909 E:13911 ||| .
Analysis  ||| S:13911 E:13920 ||| NN
of  ||| S:13920 E:13923 ||| IN
the  ||| S:13923 E:13937 ||| DT
[ ||| S:13937 E:13938 ||| -LRB-
Ca  ||| S:13938 E:13941 ||| NNP
2+ ||| S:13941 E:13943 ||| NNP
]  ||| S:13943 E:13956 ||| -RRB-
i  ||| S:13956 E:13958 ||| FW
increase  ||| S:13958 E:13967 ||| NN
in  ||| S:13967 E:13970 ||| IN
individual  ||| S:13970 E:13981 ||| JJ
cells  ||| S:13981 E:13987 ||| NNS
reveals  ||| S:13987 E:14005 ||| VBZ
the  ||| S:14005 E:14009 ||| DT
heterogeneity  ||| S:14009 E:14023 ||| NN
in  ||| S:14023 E:14026 ||| IN
the  ||| S:14026 E:14030 ||| DT
response  ||| S:14030 E:14039 ||| NN
to  ||| S:14039 E:14042 ||| TO
ATP ||| S:14042 E:14045 ||| NNP
,  ||| S:14045 E:14047 ||| ,
although  ||| S:14047 E:14056 ||| IN
most  ||| S:14056 E:14071 ||| JJS
cells  ||| S:14071 E:14077 ||| NNS
exhibited  ||| S:14077 E:14087 ||| VBP
[ ||| S:14087 E:14088 ||| -LRB-
Ca  ||| S:14088 E:14091 ||| NNP
2+ ||| S:14091 E:14093 ||| NNP
]  ||| S:14093 E:14106 ||| -RRB-
i  ||| S:14106 E:14108 ||| FW
spikes  ||| S:14108 E:14115 ||| FW
of  ||| S:14115 E:14118 ||| IN
similar  ||| S:14118 E:14126 ||| JJ
magnitude  ||| S:14126 E:14136 ||| NN
and  ||| S:14136 E:14150 ||| CC
duration  ||| S:14150 E:14159 ||| NN
( ||| S:14159 E:14160 ||| -LRB-
Fig.  ||| S:14160 E:14165 ||| NNP
3Aand  ||| S:14165 E:14171 ||| NNP
3B ||| S:14171 E:14173 ||| NNP
,  ||| S:14173 E:14175 ||| ,
thin  ||| S:14175 E:14180 ||| JJ
lines ||| S:14180 E:14185 ||| NNS
) ||| S:14185 E:14186 ||| -RRB-
.  ||| S:14186 E:14188 ||| .
Analysis  ||| S:14188 E:14197 ||| NN
of  ||| S:14197 E:14200 ||| IN
the  ||| S:14200 E:14204 ||| DT
[ ||| S:14204 E:14205 ||| -LRB-
Ca  ||| S:14205 E:14218 ||| NNP
2+ ||| S:14218 E:14220 ||| NNP
]  ||| S:14220 E:14233 ||| -RRB-
i  ||| S:14233 E:14235 ||| FW
increase  ||| S:14235 E:14244 ||| NN
in  ||| S:14244 E:14247 ||| IN
several  ||| S:14247 E:14255 ||| JJ
cells  ||| S:14255 E:14261 ||| NNS
( ||| S:14261 E:14262 ||| -LRB-
Fig.  ||| S:14262 E:14277 ||| NNP
3Aand  ||| S:14277 E:14283 ||| NNP
3B ||| S:14283 E:14285 ||| NNP
,  ||| S:14285 E:14287 ||| ,
thick  ||| S:14287 E:14293 ||| JJ
line ||| S:14293 E:14297 ||| NN
)  ||| S:14297 E:14299 ||| -RRB-
revealed  ||| S:14299 E:14308 ||| VBD
that  ||| S:14308 E:14313 ||| IN
although  ||| S:14313 E:14322 ||| IN
the  ||| S:14322 E:14326 ||| DT
duration  ||| S:14326 E:14345 ||| NN
of  ||| S:14345 E:14348 ||| IN
the  ||| S:14348 E:14352 ||| DT
[ ||| S:14352 E:14353 ||| -LRB-
Ca  ||| S:14353 E:14356 ||| NNP
2+ ||| S:14356 E:14358 ||| NNP
]  ||| S:14358 E:14371 ||| -RRB-
i  ||| S:14371 E:14373 ||| FW
increase  ||| S:14373 E:14382 ||| NN
elicited  ||| S:14382 E:14391 ||| NN
by  ||| S:14391 E:14394 ||| IN
ATP  ||| S:14394 E:14398 ||| NNP
in  ||| S:14398 E:14401 ||| IN
control  ||| S:14401 E:14419 ||| NN
cells  ||| S:14419 E:14425 ||| NNS
was  ||| S:14425 E:14429 ||| VBD
the  ||| S:14429 E:14433 ||| DT
same  ||| S:14433 E:14438 ||| JJ
as  ||| S:14438 E:14441 ||| IN
in  ||| S:14441 E:14444 ||| IN
the  ||| S:14444 E:14448 ||| DT
U0126-treated  ||| S:14448 E:14462 ||| CD
cells ||| S:14462 E:14467 ||| NNS
,  ||| S:14467 E:14479 ||| ,
approximately  ||| S:14479 E:14493 ||| RB
3-4  ||| S:14493 E:14497 ||| CD
min ||| S:14497 E:14500 ||| NN
,  ||| S:14500 E:14502 ||| ,
the  ||| S:14502 E:14506 ||| DT
amplitude  ||| S:14506 E:14516 ||| NN
of  ||| S:14516 E:14519 ||| IN
the  ||| S:14519 E:14523 ||| DT
[ ||| S:14523 E:14524 ||| -LRB-
Ca  ||| S:14524 E:14527 ||| NNP
2+ ||| S:14527 E:14529 ||| NNP
]  ||| S:14529 E:14542 ||| -RRB-
i  ||| S:14542 E:14544 ||| FW
increase  ||| S:14544 E:14553 ||| NN
was  ||| S:14553 E:14557 ||| VBD
slightly  ||| S:14557 E:14566 ||| RB
higher  ||| S:14566 E:14573 ||| JJR
( ||| S:14573 E:14574 ||| -LRB-
~20 ||| S:14574 E:14577 ||| NNP
% ||| S:14577 E:14578 ||| NN
)  ||| S:14578 E:14590 ||| -RRB-
in  ||| S:14590 E:14593 ||| IN
the  ||| S:14593 E:14597 ||| DT
U0126-treated  ||| S:14597 E:14611 ||| CD
cells ||| S:14611 E:14616 ||| NNS
.  ||| S:14616 E:14618 ||| .
IONO  ||| S:14618 E:14623 ||| NNP
elicited  ||| S:14623 E:14632 ||| VBD
a  ||| S:14632 E:14634 ||| DT
sustained ||| S:14634 E:14643 ||| JJ
,  ||| S:14643 E:14655 ||| ,
supraphysiological  ||| S:14655 E:14674 ||| NNS
[ ||| S:14674 E:14675 ||| -LRB-
Ca  ||| S:14675 E:14678 ||| NNP
2+ ||| S:14678 E:14680 ||| NNP
]  ||| S:14680 E:14693 ||| -RRB-
i  ||| S:14693 E:14695 ||| FW
increase  ||| S:14695 E:14704 ||| NN
in  ||| S:14704 E:14707 ||| IN
cells  ||| S:14707 E:14713 ||| NNS
that  ||| S:14713 E:14718 ||| WDT
was  ||| S:14718 E:14722 ||| VBD
also  ||| S:14722 E:14737 ||| RB
slightly  ||| S:14737 E:14746 ||| RB
enhanced  ||| S:14746 E:14755 ||| VBN
by  ||| S:14755 E:14758 ||| IN
U0126  ||| S:14758 E:14764 ||| NNP
( ||| S:14764 E:14765 ||| -LRB-
Fig.  ||| S:14765 E:14770 ||| CD
3Cand  ||| S:14770 E:14776 ||| CD
3D ||| S:14776 E:14778 ||| CD
) ||| S:14778 E:14779 ||| -RRB-
.  ||| S:14779 E:14781 ||| .
These  ||| S:14781 E:14797 ||| DT
experiments  ||| S:14797 E:14809 ||| NNS
demonstrate  ||| S:14809 E:14821 ||| VBP
that  ||| S:14821 E:14826 ||| IN
U0126  ||| S:14826 E:14832 ||| NNP
does  ||| S:14832 E:14837 ||| VBZ
not  ||| S:14837 E:14841 ||| RB
decrease  ||| S:14841 E:14850 ||| VB
[ ||| S:14850 E:14851 ||| -LRB-
Ca  ||| S:14851 E:14864 ||| NNP
2+ ||| S:14864 E:14866 ||| NNP
]  ||| S:14866 E:14879 ||| -RRB-
i  ||| S:14879 E:14881 ||| FW
mobilization ||| S:14881 E:14893 ||| FW
,  ||| S:14893 E:14895 ||| ,
and  ||| S:14895 E:14899 ||| CC
the  ||| S:14899 E:14903 ||| DT
inhibition  ||| S:14903 E:14914 ||| NN
of  ||| S:14914 E:14927 ||| IN
AA  ||| S:14927 E:14930 ||| NN
release  ||| S:14930 E:14938 ||| NN
by  ||| S:14938 E:14941 ||| IN
U0126  ||| S:14941 E:14947 ||| CD
cannot  ||| S:14947 E:14954 ||| NNS
be  ||| S:14954 E:14957 ||| VB
ascribed  ||| S:14957 E:14966 ||| VBN
to  ||| S:14966 E:14969 ||| TO
a  ||| S:14969 E:14971 ||| DT
failure  ||| S:14971 E:14979 ||| NN
in  ||| S:14979 E:14992 ||| IN
[ ||| S:14992 E:14993 ||| -LRB-
Ca  ||| S:14993 E:14996 ||| NNP
2+ ||| S:14996 E:14998 ||| NNP
]  ||| S:14998 E:15011 ||| -RRB-
i  ||| S:15011 E:15013 ||| FW
mobilization.  ||| S:15013 E:15055 ||| FW
cPLA  ||| S:15055 E:15060 ||| FW
2translocation  ||| S:15060 E:15075 ||| FW
is  ||| S:15075 E:15078 ||| VBZ
independent  ||| S:15078 E:15090 ||| JJ
of  ||| S:15090 E:15093 ||| IN
MEK1 ||| S:15093 E:15097 ||| NNP
/ ||| S:15097 E:15098 ||| NNP
ERK  ||| S:15098 E:15112 ||| NNP
pathway  ||| S:15112 E:15130 ||| VBD
The  ||| S:15130 E:15134 ||| DT
effect  ||| S:15134 E:15141 ||| NN
of  ||| S:15141 E:15144 ||| IN
inhibition  ||| S:15144 E:15155 ||| NN
of  ||| S:15155 E:15158 ||| IN
the  ||| S:15158 E:15162 ||| DT
MEK1 ||| S:15162 E:15166 ||| NNP
/ ||| S:15166 E:15167 ||| NNP
ERK  ||| S:15167 E:15171 ||| NNP
pathway  ||| S:15171 E:15179 ||| NN
by  ||| S:15179 E:15192 ||| IN
U0126  ||| S:15192 E:15198 ||| CD
on  ||| S:15198 E:15201 ||| IN
translocation  ||| S:15201 E:15215 ||| NN
of  ||| S:15215 E:15218 ||| IN
cPLA  ||| S:15218 E:15234 ||| JJ
2  ||| S:15234 E:15236 ||| CD
was  ||| S:15236 E:15240 ||| VBD
investigated ||| S:15240 E:15252 ||| VBN
.  ||| S:15252 E:15254 ||| .
Although  ||| S:15254 E:15263 ||| IN
there  ||| S:15263 E:15269 ||| EX
is  ||| S:15269 E:15282 ||| VBZ
no  ||| S:15282 E:15285 ||| DT
inhibition  ||| S:15285 E:15296 ||| NN
of  ||| S:15296 E:15299 ||| IN
[ ||| S:15299 E:15300 ||| -LRB-
Ca  ||| S:15300 E:15303 ||| NNP
2+ ||| S:15303 E:15305 ||| NNP
]  ||| S:15305 E:15318 ||| -RRB-
i  ||| S:15318 E:15320 ||| FW
release  ||| S:15320 E:15328 ||| NN
by  ||| S:15328 E:15331 ||| IN
U0126  ||| S:15331 E:15337 ||| NNP
and  ||| S:15337 E:15341 ||| CC
little  ||| S:15341 E:15348 ||| JJ
effect  ||| S:15348 E:15365 ||| NN
on  ||| S:15365 E:15368 ||| IN
Ser  ||| S:15368 E:15372 ||| NNP
505phosphorylation ||| S:15372 E:15390 ||| NNP
,  ||| S:15390 E:15392 ||| ,
it  ||| S:15392 E:15395 ||| PRP
is  ||| S:15395 E:15398 ||| VBZ
possible  ||| S:15398 E:15407 ||| JJ
that  ||| S:15407 E:15412 ||| IN
MEK1  ||| S:15412 E:15427 ||| CD
inhibition  ||| S:15427 E:15438 ||| NN
by  ||| S:15438 E:15441 ||| IN
U0126  ||| S:15441 E:15447 ||| NNP
prevents  ||| S:15447 E:15456 ||| VBZ
cPLA  ||| S:15456 E:15472 ||| JJ
2  ||| S:15472 E:15474 ||| CD
translocation  ||| S:15474 E:15488 ||| NN
by  ||| S:15488 E:15491 ||| IN
another  ||| S:15491 E:15499 ||| DT
mechanism ||| S:15499 E:15508 ||| NN
.  ||| S:15508 E:15520 ||| .
To  ||| S:15520 E:15523 ||| TO
investigate  ||| S:15523 E:15535 ||| VB
this  ||| S:15535 E:15540 ||| DT
possibility ||| S:15540 E:15551 ||| NN
,  ||| S:15551 E:15553 ||| ,
cells  ||| S:15553 E:15559 ||| NNS
were  ||| S:15559 E:15564 ||| VBD
transfected  ||| S:15564 E:15586 ||| VBN
with  ||| S:15586 E:15591 ||| IN
a  ||| S:15591 E:15593 ||| DT
wild-type  ||| S:15593 E:15603 ||| JJ
cPLA  ||| S:15603 E:15619 ||| JJ
2  ||| S:15619 E:15621 ||| CD
fused  ||| S:15621 E:15627 ||| NN
to  ||| S:15627 E:15630 ||| TO
EYFP  ||| S:15630 E:15635 ||| NNP
( ||| S:15635 E:15636 ||| -LRB-
EYFP-cPLA  ||| S:15636 E:15657 ||| NNP
2  ||| S:15657 E:15659 ||| CD
)  ||| S:15659 E:15661 ||| -RRB-
and  ||| S:15661 E:15665 ||| CC
the  ||| S:15665 E:15669 ||| DT
distribution  ||| S:15669 E:15682 ||| NN
of  ||| S:15682 E:15685 ||| IN
EYFP-cPLA  ||| S:15685 E:15706 ||| JJ
2  ||| S:15706 E:15708 ||| CD
was  ||| S:15708 E:15712 ||| VBD
imaged  ||| S:15712 E:15719 ||| VBN
in  ||| S:15719 E:15722 ||| IN
response  ||| S:15722 E:15731 ||| NN
to  ||| S:15731 E:15734 ||| TO
[ ||| S:15734 E:15735 ||| -LRB-
Ca  ||| S:15735 E:15738 ||| NNP
2+ ||| S:15738 E:15740 ||| NNP
]  ||| S:15740 E:15753 ||| -RRB-
i  ||| S:15753 E:15755 ||| FW
transients  ||| S:15755 E:15766 ||| FW
elicited  ||| S:15766 E:15775 ||| FW
by  ||| S:15775 E:15778 ||| IN
ATP  ||| S:15778 E:15782 ||| NNP
and  ||| S:15782 E:15796 ||| CC
sustained  ||| S:15796 E:15806 ||| VBD
[ ||| S:15806 E:15807 ||| -LRB-
Ca  ||| S:15807 E:15810 ||| NNP
2+ ||| S:15810 E:15812 ||| NNP
]  ||| S:15812 E:15825 ||| -RRB-
i  ||| S:15825 E:15827 ||| FW
elevations  ||| S:15827 E:15838 ||| FW
elicited  ||| S:15838 E:15847 ||| FW
by  ||| S:15847 E:15850 ||| IN
IONO ||| S:15850 E:15854 ||| NNP
,  ||| S:15854 E:15856 ||| ,
in  ||| S:15856 E:15859 ||| IN
the  ||| S:15859 E:15873 ||| DT
presence  ||| S:15873 E:15882 ||| NN
and  ||| S:15882 E:15886 ||| CC
absence  ||| S:15886 E:15894 ||| NN
of  ||| S:15894 E:15897 ||| IN
U0126 ||| S:15897 E:15902 ||| CD
.  ||| S:15902 E:15904 ||| .
Following  ||| S:15904 E:15914 ||| VBG
stimulation  ||| S:15914 E:15926 ||| NN
with  ||| S:15926 E:15941 ||| IN
100  ||| S:15941 E:15945 ||| CD
μM  ||| S:15945 E:15948 ||| JJ
ATP ||| S:15948 E:15951 ||| NNP
,  ||| S:15951 E:15953 ||| ,
there  ||| S:15953 E:15959 ||| EX
was  ||| S:15959 E:15963 ||| VBD
a  ||| S:15963 E:15965 ||| DT
rapid  ||| S:15965 E:15971 ||| JJ
translocation  ||| S:15971 E:15985 ||| NN
of  ||| S:15985 E:15988 ||| IN
EYFP-cPLA  ||| S:15988 E:16009 ||| JJ
2  ||| S:16009 E:16011 ||| CD
to  ||| S:16011 E:16014 ||| TO
Golgi  ||| S:16014 E:16020 ||| NNP
that  ||| S:16020 E:16025 ||| WDT
was  ||| S:16025 E:16029 ||| VBD
unaffected  ||| S:16029 E:16040 ||| VBN
by  ||| S:16040 E:16053 ||| IN
U0126  ||| S:16053 E:16059 ||| NNP
( ||| S:16059 E:16060 ||| -LRB-
Fig.  ||| S:16060 E:16065 ||| NNP
4A ||| S:16065 E:16067 ||| NNP
, ||| S:16067 E:16068 ||| ,
4B ||| S:16068 E:16070 ||| CD
) ||| S:16070 E:16071 ||| -RRB-
.  ||| S:16071 E:16073 ||| .
In  ||| S:16073 E:16076 ||| IN
response  ||| S:16076 E:16085 ||| NN
to  ||| S:16085 E:16088 ||| TO
physiological  ||| S:16088 E:16102 ||| VB
agonists  ||| S:16102 E:16121 ||| VBN
that  ||| S:16121 E:16126 ||| IN
elicit  ||| S:16126 E:16133 ||| JJ
transient  ||| S:16133 E:16143 ||| NNS
[ ||| S:16143 E:16144 ||| -LRB-
Ca  ||| S:16144 E:16147 ||| NNP
2+ ||| S:16147 E:16149 ||| NNP
]  ||| S:16149 E:16162 ||| -RRB-
i  ||| S:16162 E:16164 ||| FW
changes ||| S:16164 E:16171 ||| NNS
,  ||| S:16171 E:16173 ||| ,
only  ||| S:16173 E:16178 ||| RB
a  ||| S:16178 E:16180 ||| DT
small  ||| S:16180 E:16186 ||| JJ
fraction  ||| S:16186 E:16195 ||| NN
of  ||| S:16195 E:16208 ||| IN
the  ||| S:16208 E:16212 ||| DT
cPLA  ||| S:16212 E:16228 ||| JJ
2  ||| S:16228 E:16230 ||| CD
translocates ||| S:16230 E:16242 ||| NNS
.  ||| S:16242 E:16244 ||| .
This  ||| S:16244 E:16249 ||| DT
observation  ||| S:16249 E:16261 ||| NN
is  ||| S:16261 E:16274 ||| VBZ
consistent  ||| S:16274 E:16285 ||| JJ
with  ||| S:16285 E:16290 ||| IN
our  ||| S:16290 E:16294 ||| PRP$
previous  ||| S:16294 E:16303 ||| JJ
results  ||| S:16303 E:16311 ||| NNS
[  ||| S:16311 E:16313 ||| -LRB-
15  ||| S:16313 E:16316 ||| CD
]  ||| S:16316 E:16318 ||| -RRB-
and  ||| S:16318 E:16322 ||| CC
has  ||| S:16322 E:16326 ||| VBZ
been  ||| S:16326 E:16341 ||| VBN
demonstrated  ||| S:16341 E:16354 ||| VBN
by  ||| S:16354 E:16357 ||| IN
Hirabayashi  ||| S:16357 E:16369 ||| NNP
et  ||| S:16369 E:16372 ||| FW
al.  ||| S:16372 E:16376 ||| FW
[  ||| S:16376 E:16378 ||| -LRB-
35  ||| S:16378 E:16381 ||| CD
]  ||| S:16381 E:16383 ||| -RRB-
.  ||| S:16383 E:16385 ||| .
Most  ||| S:16385 E:16390 ||| JJS
studies  ||| S:16390 E:16408 ||| NNS
of  ||| S:16408 E:16411 ||| IN
cPLA  ||| S:16411 E:16427 ||| JJ
2  ||| S:16427 E:16429 ||| CD
translocation  ||| S:16429 E:16443 ||| NNS
have  ||| S:16443 E:16448 ||| VBP
utilized  ||| S:16448 E:16467 ||| JJ
ionophore ||| S:16467 E:16476 ||| NN
,  ||| S:16476 E:16478 ||| ,
which  ||| S:16478 E:16484 ||| WDT
elicits  ||| S:16484 E:16492 ||| VBZ
a  ||| S:16492 E:16494 ||| DT
large ||| S:16494 E:16499 ||| JJ
,  ||| S:16499 E:16501 ||| ,
supraphysiological  ||| S:16501 E:16530 ||| VBD
sustained  ||| S:16530 E:16540 ||| VBN
increase  ||| S:16540 E:16549 ||| NN
in  ||| S:16549 E:16552 ||| IN
[ ||| S:16552 E:16553 ||| -LRB-
Ca  ||| S:16553 E:16556 ||| NNP
2+ ||| S:16556 E:16558 ||| NNP
]  ||| S:16558 E:16571 ||| -RRB-
i  ||| S:16571 E:16573 ||| FW
[  ||| S:16573 E:16575 ||| -LRB-
14  ||| S:16575 E:16578 ||| CD
15  ||| S:16578 E:16581 ||| CD
25  ||| S:16581 E:16584 ||| CD
35  ||| S:16584 E:16587 ||| CD
36  ||| S:16587 E:16590 ||| CD
37  ||| S:16590 E:16593 ||| CD
38  ||| S:16593 E:16596 ||| CD
]  ||| S:16596 E:16598 ||| -RRB-
,  ||| S:16598 E:16600 ||| ,
or  ||| S:16600 E:16613 ||| CC
agonists  ||| S:16613 E:16622 ||| NNS
that  ||| S:16622 E:16627 ||| WDT
produce  ||| S:16627 E:16635 ||| VBP
a  ||| S:16635 E:16637 ||| DT
sustained  ||| S:16637 E:16647 ||| JJ
[ ||| S:16647 E:16648 ||| -LRB-
Ca  ||| S:16648 E:16651 ||| NNP
2+ ||| S:16651 E:16653 ||| NNP
]  ||| S:16653 E:16666 ||| -RRB-
i  ||| S:16666 E:16668 ||| FW
increase  ||| S:16668 E:16677 ||| NN
[  ||| S:16677 E:16679 ||| -LRB-
35  ||| S:16679 E:16682 ||| CD
]  ||| S:16682 E:16684 ||| -RRB-
.  ||| S:16684 E:16686 ||| .
Under  ||| S:16686 E:16692 ||| IN
these  ||| S:16692 E:16708 ||| DT
conditions ||| S:16708 E:16718 ||| NNS
,  ||| S:16718 E:16720 ||| ,
a  ||| S:16720 E:16722 ||| DT
large  ||| S:16722 E:16728 ||| JJ
proportion  ||| S:16728 E:16739 ||| NN
of  ||| S:16739 E:16742 ||| IN
cPLA  ||| S:16742 E:16758 ||| JJ
2  ||| S:16758 E:16760 ||| CD
binds  ||| S:16760 E:16766 ||| NN
to  ||| S:16766 E:16769 ||| TO
membrane ||| S:16769 E:16777 ||| VB
.  ||| S:16777 E:16779 ||| .
These  ||| S:16779 E:16785 ||| DT
studies  ||| S:16785 E:16803 ||| NNS
show  ||| S:16803 E:16808 ||| VBP
extensive  ||| S:16808 E:16818 ||| JJ
translocation  ||| S:16818 E:16832 ||| NN
to  ||| S:16832 E:16835 ||| TO
the  ||| S:16835 E:16839 ||| DT
endoplasmic  ||| S:16839 E:16851 ||| JJ
reticulum  ||| S:16851 E:16871 ||| NNS
( ||| S:16871 E:16872 ||| -LRB-
ER ||| S:16872 E:16874 ||| NNP
) ||| S:16874 E:16875 ||| -RRB-
,  ||| S:16875 E:16877 ||| ,
nuclear  ||| S:16877 E:16885 ||| JJ
envelope  ||| S:16885 E:16894 ||| NN
and  ||| S:16894 E:16898 ||| CC
Golgi  ||| S:16898 E:16904 ||| NNP
[  ||| S:16904 E:16906 ||| -LRB-
14  ||| S:16906 E:16909 ||| CD
15  ||| S:16909 E:16912 ||| CD
35  ||| S:16912 E:16915 ||| CD
36  ||| S:16915 E:16918 ||| CD
38  ||| S:16918 E:16921 ||| CD
]  ||| S:16921 E:16923 ||| -RRB-
.  ||| S:16923 E:16925 ||| .
We  ||| S:16925 E:16938 ||| PRP
found  ||| S:16938 E:16944 ||| VBD
that  ||| S:16944 E:16949 ||| IN
U0126  ||| S:16949 E:16955 ||| NNP
also  ||| S:16955 E:16960 ||| RB
failed  ||| S:16960 E:16967 ||| VBN
to  ||| S:16967 E:16970 ||| TO
alter  ||| S:16970 E:16976 ||| VB
extensive  ||| S:16976 E:16986 ||| JJ
EYFP-cPLA  ||| S:16986 E:17017 ||| JJ
2  ||| S:17017 E:17019 ||| CD
translocation  ||| S:17019 E:17033 ||| NN
to  ||| S:17033 E:17036 ||| TO
Golgi  ||| S:17036 E:17042 ||| NNP
and  ||| S:17042 E:17046 ||| CC
ER  ||| S:17046 E:17049 ||| NNP
in  ||| S:17049 E:17062 ||| IN
response  ||| S:17062 E:17071 ||| NN
10  ||| S:17071 E:17074 ||| CD
μM  ||| S:17074 E:17077 ||| JJ
IONO  ||| S:17077 E:17082 ||| NNP
( ||| S:17082 E:17083 ||| -LRB-
Fig.  ||| S:17083 E:17088 ||| NNP
4C ||| S:17088 E:17090 ||| NNP
, ||| S:17090 E:17091 ||| ,
4D ||| S:17091 E:17093 ||| CD
) ||| S:17093 E:17094 ||| -RRB-
.  ||| S:17094 E:17096 ||| .
These  ||| S:17096 E:17102 ||| DT
results  ||| S:17102 E:17120 ||| NNS
demonstrate  ||| S:17120 E:17132 ||| VBP
that  ||| S:17132 E:17137 ||| IN
MEK  ||| S:17137 E:17141 ||| NNP
inhibition  ||| S:17141 E:17152 ||| NN
has  ||| S:17152 E:17156 ||| VBZ
no  ||| S:17156 E:17159 ||| DT
effect  ||| S:17159 E:17166 ||| NN
on  ||| S:17166 E:17169 ||| IN
cPLA  ||| S:17169 E:17185 ||| JJ
2  ||| S:17185 E:17187 ||| CD
translocation ||| S:17187 E:17200 ||| NNS
.  ||| S:17200 E:17230 ||| .
Translocation  ||| S:17230 E:17244 ||| NNP
of  ||| S:17244 E:17247 ||| IN
phosphorylation  ||| S:17247 E:17263 ||| JJ
site  ||| S:17263 E:17268 ||| NN
mutants  ||| S:17268 E:17276 ||| VBD
S505A  ||| S:17276 E:17292 ||| CD
or  ||| S:17292 E:17295 ||| CC
S727A  ||| S:17295 E:17301 ||| NNP
is  ||| S:17301 E:17304 ||| VBZ
similar  ||| S:17304 E:17312 ||| JJ
as  ||| S:17312 E:17315 ||| IN
wild-type  ||| S:17315 E:17325 ||| JJ
cPLA  ||| S:17325 E:17330 ||| JJ
2  ||| S:17330 E:17342 ||| CD
Phosphorylation  ||| S:17342 E:17358 ||| NNS
of  ||| S:17358 E:17361 ||| IN
cPLA  ||| S:17361 E:17377 ||| JJ
2  ||| S:17377 E:17379 ||| CD
on  ||| S:17379 E:17382 ||| IN
Ser  ||| S:17382 E:17386 ||| NNP
505has  ||| S:17386 E:17393 ||| VBZ
been  ||| S:17393 E:17398 ||| VBN
hypothesized  ||| S:17398 E:17411 ||| VBN
to  ||| S:17411 E:17424 ||| TO
play  ||| S:17424 E:17429 ||| VB
a  ||| S:17429 E:17431 ||| DT
role  ||| S:17431 E:17436 ||| NN
in  ||| S:17436 E:17439 ||| IN
Ca  ||| S:17439 E:17442 ||| NNP
2+-mediated  ||| S:17442 E:17454 ||| NNP
translocation  ||| S:17454 E:17468 ||| NN
since  ||| S:17468 E:17474 ||| IN
Ser  ||| S:17474 E:17488 ||| NNP
505phosphorylation  ||| S:17488 E:17507 ||| NNP
is  ||| S:17507 E:17510 ||| VBZ
required  ||| S:17510 E:17519 ||| VBN
for  ||| S:17519 E:17523 ||| IN
cPLA  ||| S:17523 E:17539 ||| JJ
2  ||| S:17539 E:17541 ||| CD
-mediated  ||| S:17541 E:17551 ||| JJ
AA  ||| S:17551 E:17554 ||| NN
release  ||| S:17554 E:17562 ||| NN
in  ||| S:17562 E:17565 ||| IN
response  ||| S:17565 E:17574 ||| NN
to  ||| S:17574 E:17587 ||| TO
low-dose ||| S:17587 E:17595 ||| JJ
,  ||| S:17595 E:17597 ||| ,
but  ||| S:17597 E:17601 ||| CC
not  ||| S:17601 E:17605 ||| RB
high-dose ||| S:17605 E:17614 ||| JJ
,  ||| S:17614 E:17616 ||| ,
ionophore  ||| S:17616 E:17626 ||| NNS
[  ||| S:17626 E:17628 ||| -LRB-
22  ||| S:17628 E:17631 ||| CD
]  ||| S:17631 E:17633 ||| -RRB-
.  ||| S:17633 E:17645 ||| .
Translocation  ||| S:17645 E:17659 ||| NNP
of  ||| S:17659 E:17662 ||| IN
cPLA  ||| S:17662 E:17678 ||| JJ
2  ||| S:17678 E:17680 ||| CD
S505A  ||| S:17680 E:17686 ||| CD
in  ||| S:17686 E:17689 ||| IN
CHO  ||| S:17689 E:17693 ||| NNP
cells  ||| S:17693 E:17699 ||| NNS
has  ||| S:17699 E:17703 ||| VBZ
been  ||| S:17703 E:17708 ||| VBN
reported  ||| S:17708 E:17727 ||| VBN
in  ||| S:17727 E:17730 ||| IN
response  ||| S:17730 E:17739 ||| NN
to  ||| S:17739 E:17742 ||| TO
ionophore  ||| S:17742 E:17752 ||| VB
stimulation  ||| S:17752 E:17764 ||| NNS
[  ||| S:17764 E:17766 ||| -LRB-
25  ||| S:17766 E:17769 ||| CD
]  ||| S:17769 E:17771 ||| -RRB-
,  ||| S:17771 E:17773 ||| ,
but  ||| S:17773 E:17777 ||| CC
the  ||| S:17777 E:17791 ||| DT
effect  ||| S:17791 E:17798 ||| NN
of  ||| S:17798 E:17801 ||| IN
Ser  ||| S:17801 E:17805 ||| NNP
505phosphorylation  ||| S:17805 E:17824 ||| NNP
on  ||| S:17824 E:17827 ||| IN
the  ||| S:17827 E:17831 ||| DT
kinetics  ||| S:17831 E:17840 ||| NN
of  ||| S:17840 E:17853 ||| IN
translocation ||| S:17853 E:17866 ||| NN
,  ||| S:17866 E:17868 ||| ,
targeting ||| S:17868 E:17877 ||| VBG
,  ||| S:17877 E:17879 ||| ,
and  ||| S:17879 E:17883 ||| CC
in  ||| S:17883 E:17886 ||| IN
response  ||| S:17886 E:17895 ||| NN
to  ||| S:17895 E:17898 ||| TO
a  ||| S:17898 E:17910 ||| DT
physiological  ||| S:17910 E:17924 ||| JJ
agonist  ||| S:17924 E:17932 ||| NN
was  ||| S:17932 E:17936 ||| VBD
not  ||| S:17936 E:17940 ||| RB
investigated ||| S:17940 E:17952 ||| VBN
.  ||| S:17952 E:17954 ||| .
MDCK  ||| S:17954 E:17959 ||| NNP
cells  ||| S:17959 E:17975 ||| NNS
were  ||| S:17975 E:17980 ||| VBD
co-transfected  ||| S:17980 E:17995 ||| JJ
with  ||| S:17995 E:18000 ||| IN
EYFP-cPLA  ||| S:18000 E:18021 ||| JJ
2  ||| S:18021 E:18023 ||| CD
and  ||| S:18023 E:18027 ||| CC
a  ||| S:18027 E:18029 ||| DT
cPLA  ||| S:18029 E:18045 ||| JJ
2  ||| S:18045 E:18047 ||| CD
with  ||| S:18047 E:18052 ||| IN
a  ||| S:18052 E:18054 ||| DT
S505A  ||| S:18054 E:18060 ||| JJ
mutation  ||| S:18060 E:18069 ||| NN
fused  ||| S:18069 E:18075 ||| NN
to  ||| S:18075 E:18078 ||| TO
ECFP  ||| S:18078 E:18093 ||| NNP
( ||| S:18093 E:18094 ||| -LRB-
ECFP-cPLA  ||| S:18094 E:18115 ||| NNP
2  ||| S:18115 E:18117 ||| CD
S505A ||| S:18117 E:18122 ||| CD
) ||| S:18122 E:18123 ||| -RRB-
.  ||| S:18123 E:18125 ||| .
Using  ||| S:18125 E:18131 ||| VBG
dual  ||| S:18131 E:18136 ||| JJ
EYFP ||| S:18136 E:18140 ||| NNP
/ ||| S:18140 E:18141 ||| NNP
ECFP  ||| S:18141 E:18156 ||| NNP
imaging ||| S:18156 E:18163 ||| NN
,  ||| S:18163 E:18165 ||| ,
we  ||| S:18165 E:18168 ||| PRP
were  ||| S:18168 E:18173 ||| VBD
able  ||| S:18173 E:18178 ||| JJ
to  ||| S:18178 E:18181 ||| TO
directly  ||| S:18181 E:18190 ||| RB
compare  ||| S:18190 E:18198 ||| VB
translocation  ||| S:18198 E:18222 ||| VBN
of  ||| S:18222 E:18225 ||| IN
both  ||| S:18225 E:18230 ||| DT
constructs  ||| S:18230 E:18241 ||| NN
in  ||| S:18241 E:18244 ||| IN
the  ||| S:18244 E:18248 ||| DT
same  ||| S:18248 E:18253 ||| JJ
cell ||| S:18253 E:18257 ||| NN
.  ||| S:18257 E:18259 ||| .
The  ||| S:18259 E:18263 ||| DT
resting  ||| S:18263 E:18281 ||| JJ
distribution  ||| S:18281 E:18294 ||| NN
of  ||| S:18294 E:18297 ||| IN
EYFP-cPLA  ||| S:18297 E:18318 ||| JJ
2  ||| S:18318 E:18320 ||| CD
was  ||| S:18320 E:18324 ||| VBD
similar  ||| S:18324 E:18332 ||| JJ
to  ||| S:18332 E:18335 ||| TO
that  ||| S:18335 E:18340 ||| DT
of  ||| S:18340 E:18343 ||| IN
ECFP-cPLA  ||| S:18343 E:18364 ||| JJ
2  ||| S:18364 E:18366 ||| CD
S505A  ||| S:18366 E:18372 ||| CD
and ||| S:18372 E:18375 ||| CC
,  ||| S:18375 E:18377 ||| ,
in  ||| S:18377 E:18380 ||| IN
response  ||| S:18380 E:18389 ||| NN
to  ||| S:18389 E:18392 ||| TO
ATP  ||| S:18392 E:18406 ||| NNP
followed  ||| S:18406 E:18415 ||| VBD
by  ||| S:18415 E:18418 ||| IN
IONO ||| S:18418 E:18422 ||| NNP
,  ||| S:18422 E:18424 ||| ,
the  ||| S:18424 E:18428 ||| DT
pattern  ||| S:18428 E:18436 ||| NN
of  ||| S:18436 E:18439 ||| IN
translocation  ||| S:18439 E:18453 ||| NN
of  ||| S:18453 E:18466 ||| IN
EYFP-cPLA  ||| S:18466 E:18487 ||| JJ
2  ||| S:18487 E:18489 ||| CD
was  ||| S:18489 E:18493 ||| VBD
similar  ||| S:18493 E:18501 ||| JJ
to  ||| S:18501 E:18504 ||| TO
ECFP-cPLA  ||| S:18504 E:18525 ||| JJ
2  ||| S:18525 E:18527 ||| CD
S505A  ||| S:18527 E:18533 ||| CD
( ||| S:18533 E:18534 ||| -LRB-
Fig.  ||| S:18534 E:18539 ||| NNP
5panels  ||| S:18539 E:18547 ||| NNP
A  ||| S:18547 E:18549 ||| NNP
and  ||| S:18549 E:18553 ||| CC
B ||| S:18553 E:18554 ||| NNP
,  ||| S:18554 E:18556 ||| ,
D ||| S:18556 E:18557 ||| NNP
) ||| S:18557 E:18558 ||| -RRB-
.  ||| S:18558 E:18570 ||| .
Analysis  ||| S:18570 E:18579 ||| NN
of  ||| S:18579 E:18582 ||| IN
the  ||| S:18582 E:18586 ||| DT
increase  ||| S:18586 E:18595 ||| NN
in  ||| S:18595 E:18598 ||| IN
fluorescence  ||| S:18598 E:18611 ||| NN
at  ||| S:18611 E:18614 ||| IN
the  ||| S:18614 E:18618 ||| DT
Golgi  ||| S:18618 E:18634 ||| NNP
with  ||| S:18634 E:18639 ||| IN
respect  ||| S:18639 E:18647 ||| NN
to  ||| S:18647 E:18650 ||| TO
time  ||| S:18650 E:18655 ||| NN
demonstrates  ||| S:18655 E:18668 ||| VBZ
that  ||| S:18668 E:18673 ||| IN
the  ||| S:18673 E:18677 ||| DT
rates  ||| S:18677 E:18683 ||| NNS
of  ||| S:18683 E:18696 ||| IN
translocation  ||| S:18696 E:18710 ||| NN
of  ||| S:18710 E:18713 ||| IN
cPLA  ||| S:18713 E:18729 ||| JJ
2  ||| S:18729 E:18731 ||| CD
and  ||| S:18731 E:18735 ||| CC
cPLA  ||| S:18735 E:18751 ||| JJ
2  ||| S:18751 E:18753 ||| CD
S505A  ||| S:18753 E:18759 ||| CD
elicited  ||| S:18759 E:18768 ||| NN
by  ||| S:18768 E:18771 ||| IN
ATP  ||| S:18771 E:18775 ||| NNP
followed  ||| S:18775 E:18784 ||| VBD
by  ||| S:18784 E:18797 ||| IN
IONO  ||| S:18797 E:18802 ||| NNP
are  ||| S:18802 E:18806 ||| VBP
very  ||| S:18806 E:18811 ||| RB
similar  ||| S:18811 E:18819 ||| JJ
( ||| S:18819 E:18820 ||| -LRB-
Fig.  ||| S:18820 E:18825 ||| NNP
5C ||| S:18825 E:18827 ||| NNP
) ||| S:18827 E:18828 ||| -RRB-
.  ||| S:18828 E:18830 ||| .
As  ||| S:18830 E:18833 ||| RB
previously  ||| S:18833 E:18844 ||| RB
reported  ||| S:18844 E:18853 ||| VBD
[  ||| S:18853 E:18865 ||| -LRB-
22  ||| S:18865 E:18868 ||| CD
]  ||| S:18868 E:18870 ||| -RRB-
,  ||| S:18870 E:18872 ||| ,
the  ||| S:18872 E:18876 ||| DT
cPLA  ||| S:18876 E:18892 ||| JJ
2  ||| S:18892 E:18894 ||| CD
S727A  ||| S:18894 E:18900 ||| CD
mutation  ||| S:18900 E:18909 ||| NN
has  ||| S:18909 E:18913 ||| VBZ
a  ||| S:18913 E:18915 ||| DT
similar  ||| S:18915 E:18933 ||| JJ
phenotype  ||| S:18933 E:18943 ||| NN
on  ||| S:18943 E:18946 ||| IN
AA  ||| S:18946 E:18949 ||| NN
release  ||| S:18949 E:18957 ||| NN
as  ||| S:18957 E:18960 ||| IN
the  ||| S:18960 E:18964 ||| DT
S505A  ||| S:18964 E:18970 ||| JJ
mutation  ||| S:18970 E:18979 ||| NN
and  ||| S:18979 E:18983 ||| CC
Ser  ||| S:18983 E:18997 ||| NNP
727was  ||| S:18997 E:19004 ||| NNP
found  ||| S:19004 E:19010 ||| VBD
to  ||| S:19010 E:19013 ||| TO
be  ||| S:19013 E:19016 ||| VB
phosphorylated  ||| S:19016 E:19031 ||| VBN
in  ||| S:19031 E:19034 ||| IN
tandem  ||| S:19034 E:19041 ||| NN
with  ||| S:19041 E:19046 ||| IN
Ser  ||| S:19046 E:19050 ||| NNP
505 ||| S:19050 E:19053 ||| CD
.  ||| S:19053 E:19065 ||| .
Imaging  ||| S:19065 E:19073 ||| JJ
experiments  ||| S:19073 E:19085 ||| NNS
were  ||| S:19085 E:19090 ||| VBD
performed  ||| S:19090 E:19100 ||| VBN
using  ||| S:19100 E:19106 ||| VBG
EYFP-cPLA  ||| S:19106 E:19127 ||| JJ
2  ||| S:19127 E:19129 ||| CD
and  ||| S:19129 E:19133 ||| CC
ECFP-cPLA  ||| S:19133 E:19154 ||| JJ
2  ||| S:19154 E:19156 ||| CD
S727A  ||| S:19156 E:19162 ||| CD
and  ||| S:19162 E:19166 ||| CC
we  ||| S:19166 E:19169 ||| PRP
found  ||| S:19169 E:19175 ||| VBD
that  ||| S:19175 E:19180 ||| IN
the  ||| S:19180 E:19194 ||| DT
distribution  ||| S:19194 E:19207 ||| NN
of  ||| S:19207 E:19210 ||| IN
EYFP-cPLA  ||| S:19210 E:19231 ||| JJ
2  ||| S:19231 E:19233 ||| CD
was  ||| S:19233 E:19237 ||| VBD
identical  ||| S:19237 E:19247 ||| JJ
to  ||| S:19247 E:19250 ||| TO
that  ||| S:19250 E:19255 ||| DT
of  ||| S:19255 E:19258 ||| IN
ECFP-cPLA  ||| S:19258 E:19279 ||| JJ
2  ||| S:19279 E:19281 ||| CD
S727A  ||| S:19281 E:19287 ||| CD
before  ||| S:19287 E:19294 ||| IN
and  ||| S:19294 E:19298 ||| CC
after  ||| S:19298 E:19304 ||| IN
stimulation  ||| S:19304 E:19326 ||| NN
with  ||| S:19326 E:19331 ||| IN
10  ||| S:19331 E:19334 ||| CD
μM  ||| S:19334 E:19337 ||| JJ
IONO  ||| S:19337 E:19342 ||| NNP
( ||| S:19342 E:19343 ||| -LRB-
Fig.  ||| S:19343 E:19348 ||| CD
7  ||| S:19348 E:19350 ||| CD
panels  ||| S:19350 E:19357 ||| NNS
A  ||| S:19357 E:19359 ||| DT
and  ||| S:19359 E:19363 ||| CC
B ||| S:19363 E:19364 ||| NNP
,  ||| S:19364 E:19366 ||| ,
D ||| S:19366 E:19367 ||| NNP
) ||| S:19367 E:19368 ||| -RRB-
.  ||| S:19368 E:19370 ||| .
Analysis  ||| S:19370 E:19379 ||| NN
of  ||| S:19379 E:19392 ||| IN
the  ||| S:19392 E:19396 ||| DT
increase  ||| S:19396 E:19405 ||| NN
in  ||| S:19405 E:19408 ||| IN
fluorescence  ||| S:19408 E:19421 ||| NN
at  ||| S:19421 E:19424 ||| IN
the  ||| S:19424 E:19428 ||| DT
Golgi  ||| S:19428 E:19434 ||| NNP
with  ||| S:19434 E:19439 ||| IN
respect  ||| S:19439 E:19447 ||| NN
to  ||| S:19447 E:19460 ||| TO
time  ||| S:19460 E:19465 ||| NN
demonstrates  ||| S:19465 E:19478 ||| VBZ
that  ||| S:19478 E:19483 ||| IN
the  ||| S:19483 E:19487 ||| DT
rates  ||| S:19487 E:19493 ||| NNS
of  ||| S:19493 E:19496 ||| IN
translocation  ||| S:19496 E:19510 ||| NN
of  ||| S:19510 E:19513 ||| IN
cPLA  ||| S:19513 E:19539 ||| JJ
2  ||| S:19539 E:19541 ||| CD
and  ||| S:19541 E:19545 ||| CC
the  ||| S:19545 E:19549 ||| DT
cPLA  ||| S:19549 E:19565 ||| JJ
2  ||| S:19565 E:19567 ||| CD
S727A  ||| S:19567 E:19573 ||| CD
elicited  ||| S:19573 E:19582 ||| NN
by  ||| S:19582 E:19585 ||| IN
IONO  ||| S:19585 E:19590 ||| NNP
are  ||| S:19590 E:19594 ||| VBP
very  ||| S:19594 E:19609 ||| RB
similar  ||| S:19609 E:19617 ||| JJ
( ||| S:19617 E:19618 ||| -LRB-
Fig.  ||| S:19618 E:19623 ||| NNP
6C ||| S:19623 E:19625 ||| NNP
) ||| S:19625 E:19626 ||| -RRB-
.  ||| S:19626 E:19659 ||| .
Discussion  ||| S:19659 E:19678 ||| NN
The  ||| S:19678 E:19682 ||| DT
MEK1 ||| S:19682 E:19686 ||| NNP
/ ||| S:19686 E:19687 ||| NNP
ERK  ||| S:19687 E:19691 ||| NNP
pathway  ||| S:19691 E:19699 ||| NN
regulates  ||| S:19699 E:19709 ||| VBZ
cPLA  ||| S:19709 E:19723 ||| JJ
2  ||| S:19723 E:19725 ||| CD
and  ||| S:19725 E:19729 ||| CC
ERKs  ||| S:19729 E:19734 ||| JJ
phosphorylate  ||| S:19734 E:19748 ||| JJ
cPLA  ||| S:19748 E:19762 ||| JJ
2  ||| S:19762 E:19764 ||| CD
on  ||| S:19764 E:19767 ||| IN
Ser  ||| S:19767 E:19771 ||| NNP
505 ||| S:19771 E:19774 ||| CD
.  ||| S:19774 E:19776 ||| .
The  ||| S:19776 E:19780 ||| DT
results  ||| S:19780 E:19788 ||| NNS
of  ||| S:19788 E:19791 ||| IN
this  ||| S:19791 E:19796 ||| DT
study  ||| S:19796 E:19810 ||| NN
demonstrate  ||| S:19810 E:19822 ||| NN
that  ||| S:19822 E:19827 ||| IN
this  ||| S:19827 E:19832 ||| DT
pathway  ||| S:19832 E:19840 ||| NN
is  ||| S:19840 E:19843 ||| VBZ
required  ||| S:19843 E:19852 ||| VBN
for  ||| S:19852 E:19856 ||| IN
cPLA  ||| S:19856 E:19870 ||| JJ
2  ||| S:19870 E:19872 ||| CD
-mediated  ||| S:19872 E:19882 ||| JJ
AA  ||| S:19882 E:19885 ||| NN
release  ||| S:19885 E:19893 ||| NN
independent  ||| S:19893 E:19905 ||| JJ
of  ||| S:19905 E:19916 ||| IN
Ser  ||| S:19916 E:19920 ||| NNP
505phosphorylation  ||| S:19920 E:19939 ||| NNP
and  ||| S:19939 E:19943 ||| CC
extend  ||| S:19943 E:19950 ||| VB
our  ||| S:19950 E:19954 ||| PRP$
previous  ||| S:19954 E:19963 ||| JJ
work  ||| S:19963 E:19968 ||| NN
in  ||| S:19968 E:19979 ||| IN
macrophages  ||| S:19979 E:19991 ||| NNS
[  ||| S:19991 E:19993 ||| -LRB-
13  ||| S:19993 E:19996 ||| CD
]  ||| S:19996 E:19998 ||| -RRB-
by  ||| S:19998 E:20001 ||| IN
demonstrating  ||| S:20001 E:20015 ||| VBG
that  ||| S:20015 E:20020 ||| IN
this  ||| S:20020 E:20025 ||| DT
alternative  ||| S:20025 E:20045 ||| JJ
role  ||| S:20045 E:20050 ||| NN
of  ||| S:20050 E:20053 ||| IN
the  ||| S:20053 E:20057 ||| DT
MEK1 ||| S:20057 E:20061 ||| NNP
/ ||| S:20061 E:20062 ||| NNP
ERK  ||| S:20062 E:20066 ||| NNP
pathway  ||| S:20066 E:20074 ||| NN
is  ||| S:20074 E:20077 ||| VBZ
not  ||| S:20077 E:20081 ||| RB
involved  ||| S:20081 E:20090 ||| VBN
in  ||| S:20090 E:20093 ||| IN
regulating  ||| S:20093 E:20112 ||| VBG
[ ||| S:20112 E:20113 ||| -LRB-
Ca  ||| S:20113 E:20116 ||| NNP
2+ ||| S:20116 E:20118 ||| NNP
]  ||| S:20118 E:20129 ||| -RRB-
i  ||| S:20129 E:20131 ||| FW
change  ||| S:20131 E:20138 ||| NN
or  ||| S:20138 E:20141 ||| CC
cPLA  ||| S:20141 E:20155 ||| JJ
2  ||| S:20155 E:20157 ||| CD
translocation  ||| S:20157 E:20171 ||| CD
kinetics  ||| S:20171 E:20180 ||| NNS
or  ||| S:20180 E:20183 ||| CC
targeting ||| S:20183 E:20192 ||| VBG
,  ||| S:20192 E:20202 ||| ,
but  ||| S:20202 E:20206 ||| CC
is  ||| S:20206 E:20209 ||| VBZ
required  ||| S:20209 E:20218 ||| VBN
for  ||| S:20218 E:20222 ||| IN
optimal  ||| S:20222 E:20230 ||| JJ
hydrolytic  ||| S:20230 E:20241 ||| JJ
activity  ||| S:20241 E:20250 ||| NN
and  ||| S:20250 E:20254 ||| CC
AA  ||| S:20254 E:20265 ||| NN
release ||| S:20265 E:20272 ||| NN
.  ||| S:20272 E:20282 ||| .
The  ||| S:20282 E:20286 ||| DT
results  ||| S:20286 E:20294 ||| NNS
shown  ||| S:20294 E:20300 ||| VBN
here  ||| S:20300 E:20305 ||| RB
demonstrate  ||| S:20305 E:20317 ||| VB
that  ||| S:20317 E:20322 ||| DT
inhibition  ||| S:20322 E:20333 ||| NN
of  ||| S:20333 E:20344 ||| IN
MEK  ||| S:20344 E:20348 ||| NNP
with  ||| S:20348 E:20353 ||| IN
U0126  ||| S:20353 E:20359 ||| CD
quantitatively  ||| S:20359 E:20374 ||| NNS
inhibits  ||| S:20374 E:20383 ||| VBP
both  ||| S:20383 E:20388 ||| DT
ERK  ||| S:20388 E:20400 ||| NNP
phosphorylation  ||| S:20400 E:20416 ||| NN
and  ||| S:20416 E:20420 ||| CC
AA  ||| S:20420 E:20423 ||| NN
release  ||| S:20423 E:20431 ||| NN
in  ||| S:20431 E:20434 ||| IN
MDCK  ||| S:20434 E:20439 ||| NNP
cells  ||| S:20439 E:20445 ||| NNS
in  ||| S:20445 E:20448 ||| IN
response  ||| S:20448 E:20457 ||| NN
to  ||| S:20457 E:20468 ||| TO
[ ||| S:20468 E:20469 ||| -LRB-
Ca  ||| S:20469 E:20472 ||| NNP
2+ ||| S:20472 E:20474 ||| NNP
]  ||| S:20474 E:20485 ||| -RRB-
i  ||| S:20485 E:20487 ||| FW
mobilization ||| S:20487 E:20499 ||| FW
.  ||| S:20499 E:20501 ||| .
The  ||| S:20501 E:20505 ||| DT
MEK  ||| S:20505 E:20509 ||| NNP
inhibitor  ||| S:20509 E:20527 ||| VBD
PD098059 ||| S:20527 E:20535 ||| CD
,  ||| S:20535 E:20537 ||| ,
a  ||| S:20537 E:20539 ||| DT
less  ||| S:20539 E:20544 ||| RBR
potent  ||| S:20544 E:20551 ||| JJ
inhibitor  ||| S:20551 E:20561 ||| NNS
[  ||| S:20561 E:20563 ||| -LRB-
28  ||| S:20563 E:20566 ||| CD
29  ||| S:20566 E:20569 ||| CD
]  ||| S:20569 E:20571 ||| -RRB-
,  ||| S:20571 E:20573 ||| ,
also  ||| S:20573 E:20586 ||| RB
inhibited  ||| S:20586 E:20596 ||| VBD
ATP-  ||| S:20596 E:20601 ||| JJ
and  ||| S:20601 E:20605 ||| CC
IONO-induced  ||| S:20605 E:20618 ||| JJ
AA  ||| S:20618 E:20621 ||| NN
release  ||| S:20621 E:20629 ||| NN
( ||| S:20629 E:20630 ||| -LRB-
data  ||| S:20630 E:20635 ||| NNS
not  ||| S:20635 E:20647 ||| RB
shown ||| S:20647 E:20652 ||| VBN
) ||| S:20652 E:20653 ||| -RRB-
.  ||| S:20653 E:20655 ||| .
ERK  ||| S:20655 E:20659 ||| NNP
was  ||| S:20659 E:20663 ||| VBD
found  ||| S:20663 E:20669 ||| VBN
to  ||| S:20669 E:20672 ||| TO
be  ||| S:20672 E:20675 ||| VB
constitutively  ||| S:20675 E:20690 ||| JJ
phosphorylated  ||| S:20690 E:20713 ||| NN
in  ||| S:20713 E:20716 ||| IN
our  ||| S:20716 E:20720 ||| PRP$
study  ||| S:20720 E:20726 ||| NN
using  ||| S:20726 E:20732 ||| VBG
MDCK  ||| S:20732 E:20737 ||| NNP
cells  ||| S:20737 E:20743 ||| NNS
from  ||| S:20743 E:20748 ||| IN
ATCC ||| S:20748 E:20752 ||| NNP
,  ||| S:20752 E:20754 ||| ,
in  ||| S:20754 E:20757 ||| IN
contrast  ||| S:20757 E:20766 ||| NN
to  ||| S:20766 E:20777 ||| TO
what  ||| S:20777 E:20782 ||| WP
has  ||| S:20782 E:20786 ||| VBZ
been  ||| S:20786 E:20791 ||| VBN
reported  ||| S:20791 E:20800 ||| VBN
previously  ||| S:20800 E:20811 ||| RB
for  ||| S:20811 E:20815 ||| IN
MDCK-D  ||| S:20815 E:20831 ||| JJ
1  ||| S:20831 E:20833 ||| CD
,  ||| S:20833 E:20835 ||| ,
a  ||| S:20835 E:20837 ||| DT
subclone  ||| S:20837 E:20846 ||| NN
of  ||| S:20846 E:20849 ||| IN
MDCK  ||| S:20849 E:20854 ||| NNP
selected  ||| S:20854 E:20863 ||| VBD
for  ||| S:20863 E:20875 ||| IN
adrenergic  ||| S:20875 E:20886 ||| JJ
receptor  ||| S:20886 E:20895 ||| NN
expression  ||| S:20895 E:20906 ||| NN
[  ||| S:20906 E:20908 ||| -LRB-
39  ||| S:20908 E:20911 ||| CD
40  ||| S:20911 E:20914 ||| CD
]  ||| S:20914 E:20916 ||| -RRB-
.  ||| S:20916 E:20918 ||| .
However ||| S:20918 E:20925 ||| RB
,  ||| S:20925 E:20927 ||| ,
a  ||| S:20927 E:20937 ||| DT
side-by-side  ||| S:20937 E:20950 ||| JJ
comparison  ||| S:20950 E:20961 ||| NN
of  ||| S:20961 E:20964 ||| IN
MDCK  ||| S:20964 E:20969 ||| NNP
cells  ||| S:20969 E:20975 ||| NNS
from  ||| S:20975 E:20980 ||| IN
ATCC  ||| S:20980 E:20985 ||| NNP
and  ||| S:20985 E:20989 ||| CC
the  ||| S:20989 E:21001 ||| DT
MDCK-D  ||| S:21001 E:21017 ||| JJ
1  ||| S:21017 E:21019 ||| CD
subclone  ||| S:21019 E:21028 ||| NNS
( ||| S:21028 E:21029 ||| -LRB-
kindly  ||| S:21029 E:21036 ||| RB
provided  ||| S:21036 E:21045 ||| VBN
by  ||| S:21045 E:21048 ||| IN
Dr.  ||| S:21048 E:21052 ||| NNP
Paul  ||| S:21052 E:21065 ||| NNP
Insel ||| S:21065 E:21070 ||| NNP
,  ||| S:21070 E:21072 ||| ,
UCSD ||| S:21072 E:21076 ||| NNP
)  ||| S:21076 E:21078 ||| -RRB-
demonstrated  ||| S:21078 E:21091 ||| VBD
constitutive  ||| S:21091 E:21104 ||| JJ
activation  ||| S:21104 E:21115 ||| NN
of  ||| S:21115 E:21118 ||| IN
ERKs  ||| S:21118 E:21131 ||| JJ
when  ||| S:21131 E:21136 ||| WRB
both  ||| S:21136 E:21141 ||| DT
are  ||| S:21141 E:21145 ||| VBP
grown  ||| S:21145 E:21151 ||| VBN
at  ||| S:21151 E:21154 ||| IN
low  ||| S:21154 E:21158 ||| JJ
density  ||| S:21158 E:21166 ||| NNS
( ||| S:21166 E:21167 ||| -LRB-
not  ||| S:21167 E:21171 ||| RB
shown ||| S:21171 E:21176 ||| VBN
) ||| S:21176 E:21177 ||| -RRB-
.  ||| S:21177 E:21179 ||| .
However ||| S:21179 E:21186 ||| RB
,  ||| S:21186 E:21188 ||| ,
at  ||| S:21188 E:21199 ||| IN
high  ||| S:21199 E:21204 ||| JJ
density  ||| S:21204 E:21212 ||| NN
ERKs  ||| S:21212 E:21217 ||| NNS
are  ||| S:21217 E:21221 ||| VBP
less  ||| S:21221 E:21226 ||| RBR
active  ||| S:21226 E:21233 ||| JJ
and  ||| S:21233 E:21237 ||| CC
can  ||| S:21237 E:21241 ||| MD
be  ||| S:21241 E:21244 ||| VB
further  ||| S:21244 E:21260 ||| RB
activated  ||| S:21260 E:21270 ||| VBN
by  ||| S:21270 E:21273 ||| IN
phorbol  ||| S:21273 E:21281 ||| JJ
ester  ||| S:21281 E:21287 ||| NNS
( ||| S:21287 E:21288 ||| -LRB-
not  ||| S:21288 E:21292 ||| RB
shown ||| S:21292 E:21297 ||| VBN
) ||| S:21297 E:21298 ||| -RRB-
.  ||| S:21298 E:21308 ||| .
In  ||| S:21308 E:21311 ||| IN
MDCK-D  ||| S:21311 E:21328 ||| JJ
1  ||| S:21328 E:21330 ||| CD
cells ||| S:21330 E:21335 ||| NNS
,  ||| S:21335 E:21337 ||| ,
without  ||| S:21337 E:21345 ||| IN
constitutively  ||| S:21345 E:21360 ||| JJ
active  ||| S:21360 E:21375 ||| JJ
ERKs ||| S:21375 E:21379 ||| NN
,  ||| S:21379 E:21381 ||| ,
AA  ||| S:21381 E:21384 ||| NN
release  ||| S:21384 E:21392 ||| NN
is  ||| S:21392 E:21395 ||| VBZ
delayed  ||| S:21395 E:21403 ||| VBN
after  ||| S:21403 E:21409 ||| IN
[ ||| S:21409 E:21410 ||| -LRB-
Ca  ||| S:21410 E:21413 ||| NNP
2+ ||| S:21413 E:21415 ||| NNP
]  ||| S:21415 E:21426 ||| -RRB-
i  ||| S:21426 E:21428 ||| FW
mobilization ||| S:21428 E:21440 ||| FW
,  ||| S:21440 E:21442 ||| ,
and  ||| S:21442 E:21446 ||| CC
is  ||| S:21446 E:21449 ||| VBZ
temporally  ||| S:21449 E:21468 ||| JJ
correlated  ||| S:21468 E:21479 ||| NN
with  ||| S:21479 E:21484 ||| IN
ERK  ||| S:21484 E:21488 ||| NNP
activation  ||| S:21488 E:21499 ||| NNS
[  ||| S:21499 E:21501 ||| -LRB-
40  ||| S:21501 E:21504 ||| CD
]  ||| S:21504 E:21506 ||| -RRB-
,  ||| S:21506 E:21508 ||| ,
whereas  ||| S:21508 E:21516 ||| VBG
in  ||| S:21516 E:21519 ||| IN
MDCK  ||| S:21519 E:21532 ||| NNP
cells  ||| S:21532 E:21538 ||| NNS
with  ||| S:21538 E:21543 ||| IN
constitutively  ||| S:21543 E:21558 ||| JJ
active  ||| S:21558 E:21565 ||| JJ
ERKs ||| S:21565 E:21569 ||| NN
,  ||| S:21569 E:21571 ||| ,
AA  ||| S:21571 E:21574 ||| NN
release  ||| S:21574 E:21582 ||| NN
is  ||| S:21582 E:21585 ||| VBZ
rapid ||| S:21585 E:21590 ||| JJ
,  ||| S:21590 E:21600 ||| ,
with  ||| S:21600 E:21605 ||| IN
significant  ||| S:21605 E:21617 ||| JJ
AA  ||| S:21617 E:21620 ||| NN
release  ||| S:21620 E:21628 ||| NN
measured  ||| S:21628 E:21637 ||| VBD
30  ||| S:21637 E:21640 ||| CD
s  ||| S:21640 E:21642 ||| NN
after  ||| S:21642 E:21648 ||| IN
[ ||| S:21648 E:21649 ||| -LRB-
Ca  ||| S:21649 E:21652 ||| NNP
2+ ||| S:21652 E:21654 ||| NNP
]  ||| S:21654 E:21665 ||| -RRB-
i  ||| S:21665 E:21667 ||| FW
increase  ||| S:21667 E:21676 ||| NN
[  ||| S:21676 E:21678 ||| -LRB-
15  ||| S:21678 E:21681 ||| CD
]  ||| S:21681 E:21683 ||| -RRB-
.  ||| S:21683 E:21685 ||| .
This  ||| S:21685 E:21690 ||| DT
temporal  ||| S:21690 E:21707 ||| JJ
correlation  ||| S:21707 E:21719 ||| NN
between  ||| S:21719 E:21727 ||| IN
AA  ||| S:21727 E:21730 ||| NN
release  ||| S:21730 E:21738 ||| NN
and  ||| S:21738 E:21742 ||| CC
ERK  ||| S:21742 E:21746 ||| NNP
activation  ||| S:21746 E:21757 ||| NN
has  ||| S:21757 E:21761 ||| VBZ
also  ||| S:21761 E:21774 ||| RB
been  ||| S:21774 E:21779 ||| VBN
reported  ||| S:21779 E:21788 ||| VBN
in  ||| S:21788 E:21791 ||| IN
CHO  ||| S:21791 E:21795 ||| NNP
cells  ||| S:21795 E:21801 ||| NNS
in  ||| S:21801 E:21804 ||| IN
response  ||| S:21804 E:21813 ||| NN
to  ||| S:21813 E:21816 ||| TO
PAF  ||| S:21816 E:21820 ||| NNP
stimulation  ||| S:21820 E:21832 ||| NN
[  ||| S:21832 E:21842 ||| -LRB-
35  ||| S:21842 E:21845 ||| CD
41  ||| S:21845 E:21848 ||| CD
]  ||| S:21848 E:21850 ||| -RRB-
.  ||| S:21850 E:21852 ||| .
These  ||| S:21852 E:21858 ||| DT
results  ||| S:21858 E:21866 ||| NNS
support  ||| S:21866 E:21874 ||| VBP
the  ||| S:21874 E:21878 ||| DT
observations  ||| S:21878 E:21891 ||| NNS
made  ||| S:21891 E:21896 ||| VBD
here  ||| S:21896 E:21909 ||| RB
that  ||| S:21909 E:21914 ||| IN
ERK  ||| S:21914 E:21918 ||| NNP
activity  ||| S:21918 E:21927 ||| NN
is  ||| S:21927 E:21930 ||| VBZ
required  ||| S:21930 E:21939 ||| VBN
for  ||| S:21939 E:21943 ||| IN
phospholipid  ||| S:21943 E:21956 ||| JJ
hydrolysis  ||| S:21956 E:21975 ||| NNS
independently  ||| S:21975 E:21989 ||| RB
of  ||| S:21989 E:21992 ||| IN
cPLA  ||| S:21992 E:22006 ||| JJ
2  ||| S:22006 E:22008 ||| CD
translocation.  ||| S:22008 E:22031 ||| CD
cPLA  ||| S:22031 E:22045 ||| JJ
2  ||| S:22045 E:22047 ||| CD
-mediated  ||| S:22047 E:22057 ||| JJ
AA  ||| S:22057 E:22060 ||| NN
release  ||| S:22060 E:22068 ||| NN
must  ||| S:22068 E:22073 ||| MD
be  ||| S:22073 E:22076 ||| VB
preceded  ||| S:22076 E:22093 ||| VBN
by  ||| S:22093 E:22096 ||| IN
translocation  ||| S:22096 E:22110 ||| NN
of  ||| S:22110 E:22113 ||| IN
the  ||| S:22113 E:22117 ||| DT
enzyme  ||| S:22117 E:22124 ||| NN
to  ||| S:22124 E:22127 ||| TO
its  ||| S:22127 E:22131 ||| PRP$
membrane  ||| S:22131 E:22140 ||| JJ
substrate  ||| S:22140 E:22158 ||| NN
which  ||| S:22158 E:22164 ||| WDT
is  ||| S:22164 E:22167 ||| VBZ
a  ||| S:22167 E:22169 ||| DT
Ca  ||| S:22169 E:22172 ||| NNP
2+-dependent  ||| S:22172 E:22185 ||| NNP
process  ||| S:22185 E:22193 ||| NN
and  ||| S:22193 E:22197 ||| CC
is  ||| S:22197 E:22200 ||| VBZ
a  ||| S:22200 E:22202 ||| DT
function  ||| S:22202 E:22211 ||| NN
of  ||| S:22211 E:22214 ||| IN
the  ||| S:22214 E:22226 ||| DT
calcium-dependent  ||| S:22226 E:22244 ||| JJ
lipid-binding  ||| S:22244 E:22258 ||| NN
( ||| S:22258 E:22259 ||| -LRB-
C2 ||| S:22259 E:22261 ||| NNP
)  ||| S:22261 E:22263 ||| -RRB-
domain.  ||| S:22263 E:22271 ||| NNP
cPLA  ||| S:22271 E:22285 ||| NNP
2  ||| S:22285 E:22287 ||| CD
translocates  ||| S:22287 E:22300 ||| NNS
primarily  ||| S:22300 E:22310 ||| RB
to  ||| S:22310 E:22313 ||| TO
Golgi  ||| S:22313 E:22319 ||| NNP
in  ||| S:22319 E:22330 ||| IN
response  ||| S:22330 E:22339 ||| NN
to  ||| S:22339 E:22342 ||| TO
a  ||| S:22342 E:22344 ||| DT
transient  ||| S:22344 E:22354 ||| NN
[ ||| S:22354 E:22355 ||| -LRB-
Ca  ||| S:22355 E:22358 ||| NNP
2+ ||| S:22358 E:22360 ||| NNP
]  ||| S:22360 E:22371 ||| -RRB-
i  ||| S:22371 E:22373 ||| FW
changes  ||| S:22373 E:22381 ||| NNS
and  ||| S:22381 E:22385 ||| CC
to  ||| S:22385 E:22388 ||| TO
Golgi  ||| S:22388 E:22394 ||| NNP
and  ||| S:22394 E:22398 ||| CC
ER  ||| S:22398 E:22401 ||| NNP
in  ||| S:22401 E:22412 ||| IN
response  ||| S:22412 E:22421 ||| NN
to  ||| S:22421 E:22424 ||| TO
a  ||| S:22424 E:22426 ||| DT
sustained  ||| S:22426 E:22436 ||| JJ
[ ||| S:22436 E:22437 ||| -LRB-
Ca  ||| S:22437 E:22440 ||| NNP
2+ ||| S:22440 E:22442 ||| NNP
]  ||| S:22442 E:22453 ||| -RRB-
i  ||| S:22453 E:22455 ||| FW
increase  ||| S:22455 E:22464 ||| NN
[  ||| S:22464 E:22466 ||| -LRB-
15  ||| S:22466 E:22469 ||| CD
]  ||| S:22469 E:22471 ||| -RRB-
.  ||| S:22471 E:22473 ||| .
The  ||| S:22473 E:22477 ||| DT
reduction  ||| S:22477 E:22487 ||| NN
in  ||| S:22487 E:22490 ||| IN
AA  ||| S:22490 E:22501 ||| NN
release  ||| S:22501 E:22509 ||| NN
by  ||| S:22509 E:22512 ||| IN
MEK  ||| S:22512 E:22516 ||| NNP
inhibition  ||| S:22516 E:22527 ||| NN
did  ||| S:22527 E:22531 ||| VBD
not  ||| S:22531 E:22535 ||| RB
involve  ||| S:22535 E:22543 ||| VB
a  ||| S:22543 E:22545 ||| DT
failure  ||| S:22545 E:22553 ||| NN
in  ||| S:22553 E:22556 ||| IN
[ ||| S:22556 E:22557 ||| -LRB-
Ca  ||| S:22557 E:22568 ||| NNP
2+ ||| S:22568 E:22570 ||| NNP
]  ||| S:22570 E:22581 ||| -RRB-
i  ||| S:22581 E:22583 ||| FW
release  ||| S:22583 E:22591 ||| NN
or  ||| S:22591 E:22594 ||| CC
translocation ||| S:22594 E:22607 ||| NN
.  ||| S:22607 E:22609 ||| .
These  ||| S:22609 E:22623 ||| DT
results  ||| S:22623 E:22631 ||| NNS
show  ||| S:22631 E:22636 ||| VBP
that  ||| S:22636 E:22641 ||| DT
translocation  ||| S:22641 E:22655 ||| NN
is  ||| S:22655 E:22658 ||| VBZ
necessary  ||| S:22658 E:22668 ||| JJ
but  ||| S:22668 E:22672 ||| CC
not  ||| S:22672 E:22684 ||| RB
sufficient  ||| S:22684 E:22695 ||| JJ
for  ||| S:22695 E:22699 ||| IN
optimum  ||| S:22699 E:22707 ||| JJ
hydrolytic  ||| S:22707 E:22718 ||| JJ
activity ||| S:22718 E:22726 ||| NN
.  ||| S:22726 E:22736 ||| .
Measuring  ||| S:22736 E:22746 ||| VBG
cPLA  ||| S:22746 E:22760 ||| JJ
2  ||| S:22760 E:22762 ||| CD
translocation  ||| S:22762 E:22776 ||| NN
is  ||| S:22776 E:22779 ||| VBZ
not  ||| S:22779 E:22783 ||| RB
a  ||| S:22783 E:22785 ||| DT
trivial  ||| S:22785 E:22793 ||| JJ
matter  ||| S:22793 E:22808 ||| NN
when  ||| S:22808 E:22813 ||| WRB
investigating  ||| S:22813 E:22827 ||| VBG
mechanisms  ||| S:22827 E:22838 ||| NNS
of  ||| S:22838 E:22841 ||| IN
AA  ||| S:22841 E:22844 ||| NN
release ||| S:22844 E:22851 ||| NN
.  ||| S:22851 E:22853 ||| .
For  ||| S:22853 E:22857 ||| IN
example ||| S:22857 E:22864 ||| NN
,  ||| S:22864 E:22874 ||| ,
cPLA  ||| S:22874 E:22888 ||| JJ
2  ||| S:22888 E:22890 ||| CD
constructs  ||| S:22890 E:22901 ||| NN
with  ||| S:22901 E:22906 ||| IN
a  ||| S:22906 E:22908 ||| DT
S505A  ||| S:22908 E:22914 ||| CD
mutation  ||| S:22914 E:22923 ||| NNS
have  ||| S:22923 E:22936 ||| VBP
long  ||| S:22936 E:22941 ||| RB
been  ||| S:22941 E:22946 ||| VBN
recognized  ||| S:22946 E:22957 ||| VBN
as  ||| S:22957 E:22960 ||| IN
unable  ||| S:22960 E:22967 ||| JJ
to  ||| S:22967 E:22970 ||| TO
support  ||| S:22970 E:22978 ||| VB
AA  ||| S:22978 E:22981 ||| NN
release  ||| S:22981 E:22989 ||| NN
in  ||| S:22989 E:23000 ||| IN
response  ||| S:23000 E:23009 ||| NN
to  ||| S:23009 E:23012 ||| TO
physiological  ||| S:23012 E:23026 ||| VB
agonists  ||| S:23026 E:23035 ||| NNS
or  ||| S:23035 E:23038 ||| CC
low-dose  ||| S:23038 E:23047 ||| JJ
ionophore  ||| S:23047 E:23065 ||| NN
when  ||| S:23065 E:23070 ||| WRB
transfected  ||| S:23070 E:23082 ||| NNS
in  ||| S:23082 E:23085 ||| IN
cells ||| S:23085 E:23090 ||| NNS
.  ||| S:23090 E:23092 ||| .
In  ||| S:23092 E:23095 ||| IN
contrast ||| S:23095 E:23103 ||| NN
,  ||| S:23103 E:23105 ||| ,
cPLA  ||| S:23105 E:23119 ||| JJ
2  ||| S:23119 E:23121 ||| CD
S505A  ||| S:23121 E:23127 ||| CD
is  ||| S:23127 E:23130 ||| VBZ
active  ||| S:23130 E:23137 ||| JJ
in  ||| S:23137 E:23140 ||| IN
vitro  ||| S:23140 E:23146 ||| NN
and  ||| S:23146 E:23158 ||| CC
phosphorylation  ||| S:23158 E:23174 ||| VBP
only  ||| S:23174 E:23179 ||| RB
modestly  ||| S:23179 E:23188 ||| RB
increases  ||| S:23188 E:23198 ||| VBZ
the  ||| S:23198 E:23202 ||| DT
activity  ||| S:23202 E:23211 ||| NN
of  ||| S:23211 E:23214 ||| IN
the  ||| S:23214 E:23226 ||| DT
enzyme  ||| S:23226 E:23233 ||| NN
[  ||| S:23233 E:23235 ||| -LRB-
16  ||| S:23235 E:23238 ||| CD
17  ||| S:23238 E:23241 ||| CD
24  ||| S:23241 E:23244 ||| CD
]  ||| S:23244 E:23246 ||| -RRB-
.  ||| S:23246 E:23248 ||| .
Interestingly ||| S:23248 E:23261 ||| RB
,  ||| S:23261 E:23263 ||| ,
the  ||| S:23263 E:23267 ||| DT
inhibitory  ||| S:23267 E:23278 ||| JJ
effect  ||| S:23278 E:23293 ||| NN
of  ||| S:23293 E:23296 ||| IN
the  ||| S:23296 E:23300 ||| DT
S505A  ||| S:23300 E:23306 ||| JJ
mutation  ||| S:23306 E:23315 ||| NN
on  ||| S:23315 E:23318 ||| IN
AA  ||| S:23318 E:23321 ||| NN
release  ||| S:23321 E:23329 ||| NN
is  ||| S:23329 E:23332 ||| VBZ
obviated  ||| S:23332 E:23341 ||| VBN
by  ||| S:23341 E:23344 ||| IN
a  ||| S:23344 E:23346 ||| DT
high  ||| S:23346 E:23359 ||| JJ
[ ||| S:23359 E:23360 ||| -LRB-
Ca  ||| S:23360 E:23363 ||| NNP
2+ ||| S:23363 E:23365 ||| NNP
]  ||| S:23365 E:23376 ||| -RRB-
i  ||| S:23376 E:23378 ||| FW
increase ||| S:23378 E:23386 ||| NN
.  ||| S:23386 E:23388 ||| .
In  ||| S:23388 E:23391 ||| IN
light  ||| S:23391 E:23397 ||| NN
of  ||| S:23397 E:23400 ||| IN
these  ||| S:23400 E:23414 ||| DT
observations ||| S:23414 E:23426 ||| NNS
,  ||| S:23426 E:23428 ||| ,
it  ||| S:23428 E:23431 ||| PRP
is  ||| S:23431 E:23434 ||| VBZ
possible  ||| S:23434 E:23443 ||| JJ
that  ||| S:23443 E:23448 ||| IN
Ser  ||| S:23448 E:23452 ||| NNP
505phosphorylation  ||| S:23452 E:23479 ||| NNP
may  ||| S:23479 E:23483 ||| MD
alter  ||| S:23483 E:23489 ||| VB
the  ||| S:23489 E:23493 ||| DT
[ ||| S:23493 E:23494 ||| -LRB-
Ca  ||| S:23494 E:23497 ||| NNP
2+ ||| S:23497 E:23499 ||| NNP
]  ||| S:23499 E:23510 ||| -RRB-
i  ||| S:23510 E:23512 ||| FW
sensitivity  ||| S:23512 E:23524 ||| FW
of  ||| S:23524 E:23527 ||| IN
the  ||| S:23527 E:23531 ||| DT
enzyme ||| S:23531 E:23537 ||| NN
,  ||| S:23537 E:23539 ||| ,
its  ||| S:23539 E:23543 ||| PRP$
rate  ||| S:23543 E:23548 ||| NN
of  ||| S:23548 E:23559 ||| IN
translocation ||| S:23559 E:23572 ||| NN
,  ||| S:23572 E:23574 ||| ,
its  ||| S:23574 E:23578 ||| PRP$
intracellular  ||| S:23578 E:23592 ||| JJ
targeting  ||| S:23592 E:23602 ||| NN
or ||| S:23602 E:23604 ||| CC
,  ||| S:23604 E:23606 ||| ,
as  ||| S:23606 E:23609 ||| RB
has  ||| S:23609 E:23613 ||| VBZ
been  ||| S:23613 E:23626 ||| VBN
previously  ||| S:23626 E:23637 ||| RB
suggested  ||| S:23637 E:23647 ||| VBD
[  ||| S:23647 E:23649 ||| -LRB-
22  ||| S:23649 E:23652 ||| CD
]  ||| S:23652 E:23654 ||| -RRB-
,  ||| S:23654 E:23656 ||| ,
the  ||| S:23656 E:23660 ||| DT
ability  ||| S:23660 E:23668 ||| NN
of  ||| S:23668 E:23671 ||| IN
cPLA  ||| S:23671 E:23685 ||| JJ
2  ||| S:23685 E:23687 ||| CD
to  ||| S:23687 E:23690 ||| TO
release  ||| S:23690 E:23698 ||| VB
from  ||| S:23698 E:23703 ||| IN
a  ||| S:23703 E:23705 ||| DT
non-membrane  ||| S:23705 E:23726 ||| JJ
sequestering  ||| S:23726 E:23739 ||| JJ
agent ||| S:23739 E:23744 ||| NN
.  ||| S:23744 E:23746 ||| .
Although  ||| S:23746 E:23755 ||| IN
one  ||| S:23755 E:23759 ||| CD
report  ||| S:23759 E:23766 ||| NN
has  ||| S:23766 E:23770 ||| VBZ
shown  ||| S:23770 E:23776 ||| VBN
that  ||| S:23776 E:23781 ||| IN
cPLA  ||| S:23781 E:23803 ||| JJ
2  ||| S:23803 E:23805 ||| CD
S505A  ||| S:23805 E:23811 ||| CD
translocates  ||| S:23811 E:23824 ||| NN
in  ||| S:23824 E:23827 ||| IN
CHO  ||| S:23827 E:23831 ||| NNP
cells  ||| S:23831 E:23837 ||| NNS
in  ||| S:23837 E:23848 ||| IN
response  ||| S:23848 E:23857 ||| NN
to  ||| S:23857 E:23860 ||| TO
ionophore ||| S:23860 E:23869 ||| VB
,  ||| S:23869 E:23871 ||| ,
we  ||| S:23871 E:23874 ||| PRP
were  ||| S:23874 E:23879 ||| VBD
able  ||| S:23879 E:23884 ||| JJ
to  ||| S:23884 E:23887 ||| TO
directly  ||| S:23887 E:23896 ||| RB
compare  ||| S:23896 E:23912 ||| VB
rates  ||| S:23912 E:23918 ||| NNS
of  ||| S:23918 E:23921 ||| IN
translocation  ||| S:23921 E:23935 ||| NN
between  ||| S:23935 E:23943 ||| IN
cPLA  ||| S:23943 E:23957 ||| JJ
2  ||| S:23957 E:23959 ||| CD
and  ||| S:23959 E:23963 ||| CC
cPLA  ||| S:23963 E:23977 ||| JJ
2  ||| S:23977 E:23979 ||| CD
S505A  ||| S:23979 E:23985 ||| CD
to  ||| S:23985 E:23988 ||| TO
a  ||| S:23988 E:23990 ||| DT
physiological  ||| S:23990 E:24004 ||| JJ
agonist  ||| S:24004 E:24012 ||| NN
and  ||| S:24012 E:24024 ||| CC
found  ||| S:24024 E:24030 ||| VBD
no  ||| S:24030 E:24033 ||| DT
difference  ||| S:24033 E:24044 ||| NN
between  ||| S:24044 E:24052 ||| IN
translocation  ||| S:24052 E:24066 ||| JJ
rates  ||| S:24066 E:24072 ||| NNS
or  ||| S:24072 E:24083 ||| CC
intracellular  ||| S:24083 E:24097 ||| JJ
targeting ||| S:24097 E:24106 ||| NN
.  ||| S:24106 E:24108 ||| .
We  ||| S:24108 E:24111 ||| PRP
also  ||| S:24111 E:24116 ||| RB
demonstrated  ||| S:24116 E:24129 ||| VBN
that  ||| S:24129 E:24134 ||| IN
there  ||| S:24134 E:24148 ||| EX
was  ||| S:24148 E:24152 ||| VBD
no  ||| S:24152 E:24155 ||| DT
difference  ||| S:24155 E:24166 ||| NN
in  ||| S:24166 E:24169 ||| IN
translocation  ||| S:24169 E:24183 ||| JJ
rates  ||| S:24183 E:24189 ||| NNS
or  ||| S:24189 E:24192 ||| CC
intracellular  ||| S:24192 E:24214 ||| VBP
targeting  ||| S:24214 E:24224 ||| VBG
between  ||| S:24224 E:24232 ||| IN
wild-type  ||| S:24232 E:24242 ||| JJ
cPLA  ||| S:24242 E:24256 ||| JJ
2  ||| S:24256 E:24258 ||| CD
and  ||| S:24258 E:24262 ||| CC
cPLA  ||| S:24262 E:24276 ||| JJ
2  ||| S:24276 E:24278 ||| CD
S727A ||| S:24278 E:24283 ||| CD
,  ||| S:24283 E:24285 ||| ,
which  ||| S:24285 E:24291 ||| WDT
has  ||| S:24291 E:24295 ||| VBZ
the  ||| S:24295 E:24299 ||| DT
same  ||| S:24299 E:24304 ||| JJ
phenotype  ||| S:24304 E:24314 ||| NN
as  ||| S:24314 E:24325 ||| IN
S505A  ||| S:24325 E:24331 ||| CD
with  ||| S:24331 E:24336 ||| IN
regard  ||| S:24336 E:24343 ||| NN
to  ||| S:24343 E:24346 ||| TO
AA  ||| S:24346 E:24349 ||| NN
release  ||| S:24349 E:24357 ||| NN
when  ||| S:24357 E:24362 ||| WRB
transfected  ||| S:24362 E:24374 ||| NNS
into  ||| S:24374 E:24387 ||| IN
cells ||| S:24387 E:24392 ||| NNS
.  ||| S:24392 E:24394 ||| .
Thus ||| S:24394 E:24398 ||| RB
,  ||| S:24398 E:24400 ||| ,
the  ||| S:24400 E:24404 ||| DT
role  ||| S:24404 E:24409 ||| NN
of  ||| S:24409 E:24412 ||| IN
cPLA  ||| S:24412 E:24426 ||| JJ
2  ||| S:24426 E:24428 ||| CD
phosphorylation  ||| S:24428 E:24444 ||| NN
in  ||| S:24444 E:24447 ||| IN
mediating  ||| S:24447 E:24457 ||| JJ
AA  ||| S:24457 E:24468 ||| NN
release  ||| S:24468 E:24476 ||| NN
remains  ||| S:24476 E:24484 ||| VBZ
unclear ||| S:24484 E:24491 ||| JJ
.  ||| S:24491 E:24501 ||| .
Although  ||| S:24501 E:24510 ||| IN
the  ||| S:24510 E:24514 ||| DT
alternative  ||| S:24514 E:24526 ||| JJ
mechanism  ||| S:24526 E:24536 ||| NN
whereby  ||| S:24536 E:24544 ||| WRB
the  ||| S:24544 E:24548 ||| DT
MEK1 ||| S:24548 E:24552 ||| NNP
/ ||| S:24552 E:24553 ||| NNP
ERK  ||| S:24553 E:24565 ||| NNP
pathway  ||| S:24565 E:24573 ||| NN
regulates  ||| S:24573 E:24583 ||| VBZ
cPLA  ||| S:24583 E:24597 ||| JJ
2  ||| S:24597 E:24599 ||| CD
is  ||| S:24599 E:24602 ||| VBZ
not  ||| S:24602 E:24606 ||| RB
known ||| S:24606 E:24611 ||| VBN
,  ||| S:24611 E:24613 ||| ,
it  ||| S:24613 E:24616 ||| PRP
is  ||| S:24616 E:24619 ||| VBZ
possible  ||| S:24619 E:24628 ||| JJ
that  ||| S:24628 E:24633 ||| IN
it  ||| S:24633 E:24644 ||| PRP
affects  ||| S:24644 E:24652 ||| VBZ
membrane  ||| S:24652 E:24661 ||| JJ
properties  ||| S:24661 E:24672 ||| NNS
and ||| S:24672 E:24675 ||| CC
/ ||| S:24675 E:24676 ||| NNP
or  ||| S:24676 E:24679 ||| CC
cPLA  ||| S:24679 E:24693 ||| JJ
2  ||| S:24693 E:24695 ||| CD
conformation  ||| S:24695 E:24708 ||| NNS
that  ||| S:24708 E:24713 ||| WDT
promotes  ||| S:24713 E:24722 ||| VBZ
optimal  ||| S:24722 E:24738 ||| JJ
hydrolytic  ||| S:24738 E:24749 ||| JJ
activity ||| S:24749 E:24757 ||| NN
.  ||| S:24757 E:24759 ||| .
It  ||| S:24759 E:24762 ||| PRP
is  ||| S:24762 E:24765 ||| VBZ
also  ||| S:24765 E:24770 ||| RB
possible  ||| S:24770 E:24779 ||| JJ
that  ||| S:24779 E:24784 ||| IN
the  ||| S:24784 E:24796 ||| DT
alternative  ||| S:24796 E:24808 ||| JJ
mechanism  ||| S:24808 E:24818 ||| NN
is  ||| S:24818 E:24821 ||| VBZ
due  ||| S:24821 E:24825 ||| JJ
to  ||| S:24825 E:24828 ||| TO
phosphorylation  ||| S:24828 E:24844 ||| VB
of  ||| S:24844 E:24847 ||| IN
cPLA  ||| S:24847 E:24861 ||| JJ
2  ||| S:24861 E:24863 ||| CD
on  ||| S:24863 E:24866 ||| IN
a  ||| S:24866 E:24868 ||| DT
novel  ||| S:24868 E:24874 ||| NN
site  ||| S:24874 E:24879 ||| NN
by  ||| S:24879 E:24882 ||| IN
a  ||| S:24882 E:24884 ||| DT
kinase  ||| S:24884 E:24891 ||| NN
that  ||| S:24891 E:24896 ||| WDT
is  ||| S:24896 E:24907 ||| VBZ
downstream  ||| S:24907 E:24918 ||| VBN
of  ||| S:24918 E:24921 ||| IN
the  ||| S:24921 E:24925 ||| DT
MEK1 ||| S:24925 E:24929 ||| NNP
/ ||| S:24929 E:24930 ||| NNP
ERK  ||| S:24930 E:24934 ||| NNP
pathway  ||| S:24934 E:24942 ||| NN
or  ||| S:24942 E:24945 ||| CC
phosphorylation  ||| S:24945 E:24961 ||| NN
of  ||| S:24961 E:24964 ||| IN
a  ||| S:24964 E:24974 ||| DT
regulatory  ||| S:24974 E:24985 ||| JJ
protein ||| S:24985 E:24992 ||| NN
.  ||| S:24992 E:25016 ||| .
Conclusions  ||| S:25016 E:25036 ||| NNP
Translocation  ||| S:25036 E:25050 ||| NNP
to  ||| S:25050 E:25053 ||| TO
membrane  ||| S:25053 E:25062 ||| NN
is  ||| S:25062 E:25065 ||| VBZ
a  ||| S:25065 E:25067 ||| DT
critical  ||| S:25067 E:25076 ||| JJ
regulatory  ||| S:25076 E:25087 ||| JJ
step  ||| S:25087 E:25100 ||| NN
for  ||| S:25100 E:25104 ||| IN
the  ||| S:25104 E:25108 ||| DT
action  ||| S:25108 E:25115 ||| NN
of  ||| S:25115 E:25118 ||| IN
cPLA  ||| S:25118 E:25132 ||| JJ
2  ||| S:25132 E:25134 ||| CD
because  ||| S:25134 E:25142 ||| IN
it  ||| S:25142 E:25145 ||| PRP
is  ||| S:25145 E:25148 ||| VBZ
necessary  ||| S:25148 E:25158 ||| JJ
for  ||| S:25158 E:25162 ||| IN
access  ||| S:25162 E:25169 ||| NN
to  ||| S:25169 E:25180 ||| TO
substrate ||| S:25180 E:25189 ||| VB
.  ||| S:25189 E:25191 ||| .
In  ||| S:25191 E:25194 ||| IN
this  ||| S:25194 E:25199 ||| DT
study  ||| S:25199 E:25205 ||| NN
we  ||| S:25205 E:25208 ||| PRP
demonstrate ||| S:25208 E:25219 ||| VBP
,  ||| S:25219 E:25221 ||| ,
however ||| S:25221 E:25228 ||| RB
,  ||| S:25228 E:25230 ||| ,
that  ||| S:25230 E:25243 ||| DT
association  ||| S:25243 E:25255 ||| NN
of  ||| S:25255 E:25258 ||| IN
cPLA  ||| S:25258 E:25272 ||| JJ
2  ||| S:25272 E:25274 ||| CD
with  ||| S:25274 E:25279 ||| IN
membrane  ||| S:25279 E:25288 ||| NN
when  ||| S:25288 E:25293 ||| WRB
phosphorylated  ||| S:25293 E:25308 ||| NNS
on  ||| S:25308 E:25319 ||| IN
Ser  ||| S:25319 E:25323 ||| NNP
505is  ||| S:25323 E:25329 ||| NNP
not  ||| S:25329 E:25333 ||| RB
sufficient  ||| S:25333 E:25344 ||| JJ
for  ||| S:25344 E:25348 ||| IN
its  ||| S:25348 E:25352 ||| PRP$
full  ||| S:25352 E:25357 ||| JJ
activity  ||| S:25357 E:25366 ||| NN
in  ||| S:25366 E:25369 ||| IN
vivo ||| S:25369 E:25373 ||| NN
.  ||| S:25373 E:25383 ||| .
This  ||| S:25383 E:25388 ||| DT
is  ||| S:25388 E:25391 ||| VBZ
demonstrated  ||| S:25391 E:25404 ||| VBN
by  ||| S:25404 E:25407 ||| IN
the  ||| S:25407 E:25411 ||| DT
results  ||| S:25411 E:25419 ||| NNS
showing  ||| S:25419 E:25427 ||| VBG
that  ||| S:25427 E:25432 ||| DT
inhibition  ||| S:25432 E:25451 ||| NN
of  ||| S:25451 E:25454 ||| IN
the  ||| S:25454 E:25458 ||| DT
MEK1 ||| S:25458 E:25462 ||| NNP
/ ||| S:25462 E:25463 ||| NNP
ERK  ||| S:25463 E:25467 ||| NNP
pathway  ||| S:25467 E:25475 ||| VBD
significantly  ||| S:25475 E:25489 ||| RB
blocks  ||| S:25489 E:25496 ||| JJ
AA  ||| S:25496 E:25499 ||| NN
release  ||| S:25499 E:25507 ||| NN
but  ||| S:25507 E:25519 ||| CC
has  ||| S:25519 E:25523 ||| VBZ
no  ||| S:25523 E:25526 ||| DT
effect  ||| S:25526 E:25533 ||| NN
on  ||| S:25533 E:25536 ||| IN
[ ||| S:25536 E:25537 ||| -LRB-
Ca  ||| S:25537 E:25540 ||| NNP
2+ ||| S:25540 E:25542 ||| NNP
]  ||| S:25542 E:25553 ||| -RRB-
i  ||| S:25553 E:25555 ||| FW
mobilization  ||| S:25555 E:25568 ||| FW
or  ||| S:25568 E:25571 ||| CC
cPLA  ||| S:25571 E:25585 ||| JJ
2  ||| S:25585 E:25587 ||| CD
translocation  ||| S:25587 E:25601 ||| NNS
and  ||| S:25601 E:25605 ||| CC
targeting ||| S:25605 E:25614 ||| VBG
.  ||| S:25614 E:25624 ||| .
Diminution  ||| S:25624 E:25635 ||| NNP
of  ||| S:25635 E:25638 ||| IN
AA  ||| S:25638 E:25641 ||| NN
release  ||| S:25641 E:25649 ||| NN
by  ||| S:25649 E:25652 ||| IN
MEK1 ||| S:25652 E:25656 ||| NNP
/ ||| S:25656 E:25657 ||| NNP
ERK  ||| S:25657 E:25661 ||| NNP
is  ||| S:25661 E:25664 ||| VBZ
also  ||| S:25664 E:25669 ||| RB
independent  ||| S:25669 E:25681 ||| JJ
of  ||| S:25681 E:25692 ||| IN
cPLA  ||| S:25692 E:25706 ||| JJ
2  ||| S:25706 E:25708 ||| CD
phosphorylation  ||| S:25708 E:25724 ||| NN
on  ||| S:25724 E:25727 ||| IN
Ser  ||| S:25727 E:25731 ||| NNP
505 ||| S:25731 E:25734 ||| CD
.  ||| S:25734 E:25744 ||| .
Consequently ||| S:25744 E:25756 ||| RB
,  ||| S:25756 E:25758 ||| ,
our  ||| S:25758 E:25762 ||| PRP$
results  ||| S:25762 E:25770 ||| NNS
demonstrate  ||| S:25770 E:25782 ||| VBP
in  ||| S:25782 E:25785 ||| IN
living  ||| S:25785 E:25792 ||| VBG
cells  ||| S:25792 E:25798 ||| NNS
that  ||| S:25798 E:25811 ||| IN
the  ||| S:25811 E:25815 ||| DT
translocation  ||| S:25815 E:25829 ||| JJ
process  ||| S:25829 E:25837 ||| NN
and  ||| S:25837 E:25841 ||| CC
subsequent  ||| S:25841 E:25852 ||| JJ
catalytic  ||| S:25852 E:25862 ||| JJ
activity  ||| S:25862 E:25879 ||| NN
on  ||| S:25879 E:25882 ||| IN
the  ||| S:25882 E:25886 ||| DT
membrane  ||| S:25886 E:25895 ||| NNS
are  ||| S:25895 E:25899 ||| VBP
two  ||| S:25899 E:25903 ||| CD
independently  ||| S:25903 E:25917 ||| RB
regulated  ||| S:25917 E:25927 ||| VBN
steps ||| S:25927 E:25932 ||| NNS
.  ||| S:25932 E:25956 ||| .
Materials  ||| S:25956 E:25966 ||| NNS
and  ||| S:25966 E:25970 ||| CC
Methods  ||| S:25970 E:25997 ||| NNP
Fluorescent  ||| S:25997 E:26009 ||| NNP
protein-cPLA  ||| S:26009 E:26022 ||| NNP
2fusion  ||| S:26022 E:26030 ||| NNP
constructs  ||| S:26030 E:26051 ||| VBD
DNA  ||| S:26051 E:26055 ||| NNP
encoding  ||| S:26055 E:26064 ||| VBD
the  ||| S:26064 E:26068 ||| DT
full-length  ||| S:26068 E:26080 ||| JJ
human  ||| S:26080 E:26086 ||| JJ
cPLA  ||| S:26086 E:26102 ||| JJ
2  ||| S:26102 E:26104 ||| CD
was  ||| S:26104 E:26108 ||| VBD
cloned  ||| S:26108 E:26115 ||| VBN
into  ||| S:26115 E:26120 ||| IN
the  ||| S:26120 E:26124 ||| DT
vector  ||| S:26124 E:26131 ||| JJ
pEGFP-C3  ||| S:26131 E:26150 ||| NNP
( ||| S:26150 E:26151 ||| -LRB-
Clontech ||| S:26151 E:26159 ||| NNP
)  ||| S:26159 E:26161 ||| -RRB-
to  ||| S:26161 E:26164 ||| TO
create  ||| S:26164 E:26171 ||| VB
pEGFP-cPLA  ||| S:26171 E:26193 ||| JJ
2  ||| S:26193 E:26195 ||| CD
,  ||| S:26195 E:26197 ||| ,
as  ||| S:26197 E:26200 ||| RB
previously  ||| S:26200 E:26211 ||| RB
described  ||| S:26211 E:26221 ||| VBN
[  ||| S:26221 E:26223 ||| -LRB-
15  ||| S:26223 E:26226 ||| CD
]  ||| S:26226 E:26228 ||| -RRB-
.  ||| S:26228 E:26240 ||| .
The  ||| S:26240 E:26244 ||| DT
XbaI ||| S:26244 E:26248 ||| JJ
/ ||| S:26248 E:26249 ||| CD
PstI  ||| S:26249 E:26254 ||| JJ
fragment  ||| S:26254 E:26263 ||| NN
from  ||| S:26263 E:26268 ||| IN
a  ||| S:26268 E:26270 ||| DT
cPLA  ||| S:26270 E:26286 ||| JJ
2  ||| S:26286 E:26288 ||| CD
α  ||| S:26288 E:26290 ||| NNS
clone  ||| S:26290 E:26296 ||| VBP
containing  ||| S:26296 E:26307 ||| VBG
S505A  ||| S:26307 E:26313 ||| NNP
or  ||| S:26313 E:26316 ||| CC
S727A  ||| S:26316 E:26332 ||| CD
mutations  ||| S:26332 E:26342 ||| NNS
[  ||| S:26342 E:26344 ||| -LRB-
13  ||| S:26344 E:26347 ||| CD
]  ||| S:26347 E:26349 ||| -RRB-
was  ||| S:26349 E:26353 ||| VBD
inserted  ||| S:26353 E:26362 ||| VBN
into  ||| S:26362 E:26367 ||| IN
an  ||| S:26367 E:26370 ||| DT
XbaI ||| S:26370 E:26374 ||| JJ
/ ||| S:26374 E:26375 ||| CD
PstI  ||| S:26375 E:26380 ||| JJ
site  ||| S:26380 E:26385 ||| NN
in  ||| S:26385 E:26398 ||| IN
pEGFP-cPLA  ||| S:26398 E:26420 ||| JJ
2  ||| S:26420 E:26422 ||| CD
to  ||| S:26422 E:26425 ||| TO
generate  ||| S:26425 E:26434 ||| VB
pEGFP-cPLA  ||| S:26434 E:26456 ||| JJ
2  ||| S:26456 E:26458 ||| CD
S505A  ||| S:26458 E:26464 ||| CD
and  ||| S:26464 E:26468 ||| CC
pECFP-cPLA  ||| S:26468 E:26490 ||| JJ
2  ||| S:26490 E:26492 ||| CD
S727A ||| S:26492 E:26497 ||| CD
.  ||| S:26497 E:26499 ||| .
Different  ||| S:26499 E:26509 ||| JJ
fluorescent-protein  ||| S:26509 E:26539 ||| JJ
tagged  ||| S:26539 E:26546 ||| JJ
constructs  ||| S:26546 E:26557 ||| NN
were  ||| S:26557 E:26562 ||| VBD
produced  ||| S:26562 E:26571 ||| VBN
by  ||| S:26571 E:26574 ||| IN
exchanging  ||| S:26574 E:26585 ||| VBG
the  ||| S:26585 E:26599 ||| DT
NheI ||| S:26599 E:26603 ||| JJ
/ ||| S:26603 E:26604 ||| CD
BsrGI  ||| S:26604 E:26610 ||| JJ
fragment  ||| S:26610 E:26619 ||| NN
containing  ||| S:26619 E:26630 ||| VBG
the  ||| S:26630 E:26634 ||| DT
fluorescent  ||| S:26634 E:26646 ||| JJ
protein  ||| S:26646 E:26664 ||| NN
coding  ||| S:26664 E:26671 ||| NN
sequence  ||| S:26671 E:26680 ||| NN
between  ||| S:26680 E:26688 ||| IN
EGFP ||| S:26688 E:26692 ||| NNP
,  ||| S:26692 E:26694 ||| ,
EYFP ||| S:26694 E:26698 ||| NNP
,  ||| S:26698 E:26700 ||| ,
and  ||| S:26700 E:26704 ||| CC
ECFP ||| S:26704 E:26708 ||| NNP
.  ||| S:26708 E:26710 ||| .
All  ||| S:26710 E:26724 ||| DT
constructs  ||| S:26724 E:26735 ||| NN
were  ||| S:26735 E:26740 ||| VBD
confirmed  ||| S:26740 E:26750 ||| VBN
by  ||| S:26750 E:26753 ||| IN
sequencing ||| S:26753 E:26763 ||| NN
.  ||| S:26763 E:26793 ||| .
Cell  ||| S:26793 E:26798 ||| NN
culture  ||| S:26798 E:26816 ||| NN
MDCK  ||| S:26816 E:26821 ||| NN
cells  ||| S:26821 E:26827 ||| NNS
obtained  ||| S:26827 E:26836 ||| VBN
from  ||| S:26836 E:26841 ||| IN
ATCC  ||| S:26841 E:26846 ||| NNP
were  ||| S:26846 E:26851 ||| VBD
cultured  ||| S:26851 E:26860 ||| VBN
in  ||| S:26860 E:26863 ||| IN
DMEM  ||| S:26863 E:26878 ||| NNP
containing  ||| S:26878 E:26889 ||| VBG
10 ||| S:26889 E:26891 ||| CD
%  ||| S:26891 E:26893 ||| NN
FBS ||| S:26893 E:26896 ||| NNP
,  ||| S:26896 E:26898 ||| ,
100  ||| S:26898 E:26902 ||| CD
U ||| S:26902 E:26903 ||| NNP
/ ||| S:26903 E:26904 ||| FW
ml  ||| S:26904 E:26907 ||| FW
penicillin ||| S:26907 E:26917 ||| FW
,  ||| S:26917 E:26919 ||| ,
100  ||| S:26919 E:26923 ||| CD
μg ||| S:26923 E:26925 ||| CD
/ ||| S:26925 E:26926 ||| CD
ml  ||| S:26926 E:26939 ||| JJ
streptomycin ||| S:26939 E:26951 ||| NN
,  ||| S:26951 E:26953 ||| ,
0.292  ||| S:26953 E:26959 ||| FW
mg ||| S:26959 E:26961 ||| FW
/ ||| S:26961 E:26962 ||| FW
ml  ||| S:26962 E:26965 ||| FW
glutamine  ||| S:26965 E:26975 ||| FW
( ||| S:26975 E:26976 ||| -LRB-
growth  ||| S:26976 E:26983 ||| NN
medium ||| S:26983 E:26989 ||| NN
)  ||| S:26989 E:26991 ||| -RRB-
in  ||| S:26991 E:26994 ||| IN
5 ||| S:26994 E:26995 ||| CD
%  ||| S:26995 E:27007 ||| NN
CO  ||| S:27007 E:27021 ||| NNP
2  ||| S:27021 E:27023 ||| CD
at  ||| S:27023 E:27026 ||| IN
37°C ||| S:27026 E:27030 ||| CD
.  ||| S:27030 E:27032 ||| .
Subconfluent  ||| S:27032 E:27045 ||| JJ
cells  ||| S:27045 E:27051 ||| NNS
( ||| S:27051 E:27052 ||| -LRB-
5  ||| S:27052 E:27054 ||| CD
×  ||| S:27054 E:27056 ||| CD
10  ||| S:27056 E:27069 ||| CD
3cells ||| S:27069 E:27075 ||| CD
/ ||| S:27075 E:27076 ||| CD
cm  ||| S:27076 E:27079 ||| CD
2 ||| S:27079 E:27080 ||| CD
)  ||| S:27080 E:27082 ||| -RRB-
were  ||| S:27082 E:27087 ||| VBD
transfected  ||| S:27087 E:27099 ||| VBN
with  ||| S:27099 E:27104 ||| IN
2  ||| S:27104 E:27106 ||| CD
μg  ||| S:27106 E:27109 ||| NN
of  ||| S:27109 E:27112 ||| IN
the  ||| S:27112 E:27116 ||| DT
relevant  ||| S:27116 E:27135 ||| JJ
plasmid  ||| S:27135 E:27143 ||| NNS
using  ||| S:27143 E:27149 ||| VBG
Fugene-6  ||| S:27149 E:27158 ||| NNP
( ||| S:27158 E:27159 ||| -LRB-
Boehringer  ||| S:27159 E:27170 ||| NNP
Mannheim ||| S:27170 E:27178 ||| NNP
)  ||| S:27178 E:27180 ||| -RRB-
in  ||| S:27180 E:27183 ||| IN
DMEM  ||| S:27183 E:27198 ||| NNP
containing  ||| S:27198 E:27209 ||| VBG
0.2 ||| S:27209 E:27212 ||| CD
%  ||| S:27212 E:27214 ||| NN
BSA ||| S:27214 E:27217 ||| NNP
,  ||| S:27217 E:27219 ||| ,
100  ||| S:27219 E:27223 ||| CD
U ||| S:27223 E:27224 ||| NNP
/ ||| S:27224 E:27225 ||| FW
ml  ||| S:27225 E:27228 ||| FW
penicillin ||| S:27228 E:27238 ||| FW
,  ||| S:27238 E:27240 ||| ,
100  ||| S:27240 E:27244 ||| CD
μg ||| S:27244 E:27246 ||| CD
/ ||| S:27246 E:27247 ||| CD
ml  ||| S:27247 E:27260 ||| JJ
streptomycin ||| S:27260 E:27272 ||| NN
,  ||| S:27272 E:27274 ||| ,
0.292  ||| S:27274 E:27280 ||| FW
mg ||| S:27280 E:27282 ||| FW
/ ||| S:27282 E:27283 ||| FW
ml  ||| S:27283 E:27286 ||| FW
glutamine  ||| S:27286 E:27296 ||| FW
( ||| S:27296 E:27297 ||| -LRB-
serum-free  ||| S:27297 E:27308 ||| JJ
medium ||| S:27308 E:27314 ||| NN
)  ||| S:27314 E:27326 ||| -RRB-
following  ||| S:27326 E:27336 ||| VBG
the  ||| S:27336 E:27340 ||| DT
manufacturer ||| S:27340 E:27352 ||| NN
's  ||| S:27352 E:27355 ||| POS
protocol ||| S:27355 E:27363 ||| NN
.  ||| S:27363 E:27365 ||| .
Stable  ||| S:27365 E:27372 ||| JJ
lines  ||| S:27372 E:27388 ||| NNS
expressing  ||| S:27388 E:27399 ||| VBG
EGFP-cPLA  ||| S:27399 E:27420 ||| JJ
2  ||| S:27420 E:27422 ||| CD
were  ||| S:27422 E:27427 ||| VBD
generated  ||| S:27427 E:27437 ||| VBN
by  ||| S:27437 E:27440 ||| IN
growing  ||| S:27440 E:27458 ||| VBG
transfected  ||| S:27458 E:27470 ||| JJ
cells  ||| S:27470 E:27476 ||| NNS
in  ||| S:27476 E:27479 ||| IN
growth  ||| S:27479 E:27486 ||| NN
medium  ||| S:27486 E:27493 ||| NN
for  ||| S:27493 E:27497 ||| IN
3  ||| S:27497 E:27499 ||| CD
d ||| S:27499 E:27500 ||| NN
,  ||| S:27500 E:27502 ||| ,
supplementing  ||| S:27502 E:27526 ||| VBG
the  ||| S:27526 E:27530 ||| DT
growth  ||| S:27530 E:27537 ||| NN
medium  ||| S:27537 E:27544 ||| NN
with  ||| S:27544 E:27549 ||| IN
5  ||| S:27549 E:27551 ||| CD
mg ||| S:27551 E:27553 ||| FW
/ ||| S:27553 E:27554 ||| FW
ml  ||| S:27554 E:27557 ||| FW
Geneticin  ||| S:27557 E:27567 ||| FW
( ||| S:27567 E:27568 ||| -LRB-
antibiotic  ||| S:27568 E:27589 ||| FW
G418-sulfate ||| S:27589 E:27601 ||| FW
) ||| S:27601 E:27602 ||| -RRB-
,  ||| S:27602 E:27604 ||| ,
and  ||| S:27604 E:27608 ||| CC
culturing  ||| S:27608 E:27618 ||| NN
for  ||| S:27618 E:27622 ||| IN
an  ||| S:27622 E:27625 ||| DT
additional  ||| S:27625 E:27636 ||| JJ
2  ||| S:27636 E:27638 ||| CD
wk  ||| S:27638 E:27641 ||| NN
in  ||| S:27641 E:27654 ||| IN
Geneticin ||| S:27654 E:27663 ||| NNP
.  ||| S:27663 E:27665 ||| .
Cells  ||| S:27665 E:27671 ||| NNS
expressing  ||| S:27671 E:27682 ||| VBG
EGFP  ||| S:27682 E:27687 ||| NNP
fluorescence  ||| S:27687 E:27700 ||| NN
were  ||| S:27700 E:27715 ||| VBD
selected  ||| S:27715 E:27724 ||| VBN
using  ||| S:27724 E:27730 ||| VBG
a  ||| S:27730 E:27732 ||| DT
fluorescence-activated  ||| S:27732 E:27755 ||| JJ
cell  ||| S:27755 E:27760 ||| NN
sorter ||| S:27760 E:27766 ||| NN
.  ||| S:27766 E:27768 ||| .
The  ||| S:27768 E:27782 ||| DT
EGFP-positive  ||| S:27782 E:27796 ||| JJ
cells  ||| S:27796 E:27802 ||| NNS
were  ||| S:27802 E:27807 ||| VBD
maintained  ||| S:27807 E:27818 ||| VBN
in  ||| S:27818 E:27821 ||| IN
growth  ||| S:27821 E:27828 ||| NN
medium  ||| S:27828 E:27845 ||| NN
supplemented  ||| S:27845 E:27858 ||| NN
with  ||| S:27858 E:27863 ||| IN
5  ||| S:27863 E:27865 ||| CD
mg ||| S:27865 E:27867 ||| FW
/ ||| S:27867 E:27868 ||| FW
ml  ||| S:27868 E:27871 ||| FW
Geneticin ||| S:27871 E:27880 ||| FW
.  ||| S:27880 E:27882 ||| .
For  ||| S:27882 E:27886 ||| IN
imaging  ||| S:27886 E:27894 ||| JJ
studies ||| S:27894 E:27901 ||| NNS
,  ||| S:27901 E:27913 ||| ,
MDCK  ||| S:27913 E:27918 ||| NNP
cells  ||| S:27918 E:27924 ||| NNS
were  ||| S:27924 E:27929 ||| VBD
plated  ||| S:27929 E:27936 ||| VBN
on  ||| S:27936 E:27939 ||| IN
glass-bottomed  ||| S:27939 E:27954 ||| JJ
35  ||| S:27954 E:27957 ||| CD
mm  ||| S:27957 E:27960 ||| JJ
culture  ||| S:27960 E:27978 ||| NN
dishes  ||| S:27978 E:27985 ||| NNS
( ||| S:27985 E:27986 ||| -LRB-
MatTek ||| S:27986 E:27992 ||| NNP
)  ||| S:27992 E:27994 ||| -RRB-
at  ||| S:27994 E:27997 ||| IN
5  ||| S:27997 E:27999 ||| CD
×  ||| S:27999 E:28001 ||| CD
10  ||| S:28001 E:28004 ||| CD
3cells ||| S:28004 E:28010 ||| CD
/ ||| S:28010 E:28011 ||| CD
cm  ||| S:28011 E:28014 ||| CD
2in  ||| S:28014 E:28018 ||| CD
growth  ||| S:28018 E:28025 ||| NN
medium  ||| S:28025 E:28032 ||| NN
and  ||| S:28032 E:28046 ||| CC
incubated  ||| S:28046 E:28056 ||| JJ
overnight ||| S:28056 E:28065 ||| JJ
,  ||| S:28065 E:28067 ||| ,
transfected  ||| S:28067 E:28079 ||| VBG
with  ||| S:28079 E:28084 ||| IN
the  ||| S:28084 E:28088 ||| DT
relevant  ||| S:28088 E:28107 ||| JJ
plasmid ||| S:28107 E:28114 ||| NNS
( ||| S:28114 E:28115 ||| -LRB-
s ||| S:28115 E:28116 ||| LS
) ||| S:28116 E:28117 ||| -RRB-
,  ||| S:28117 E:28119 ||| ,
changed  ||| S:28119 E:28127 ||| VBN
into  ||| S:28127 E:28132 ||| IN
serum-free  ||| S:28132 E:28143 ||| JJ
medium  ||| S:28143 E:28150 ||| NN
to  ||| S:28150 E:28153 ||| TO
quiesce  ||| S:28153 E:28161 ||| VB
the  ||| S:28161 E:28175 ||| DT
cells ||| S:28175 E:28180 ||| NNS
,  ||| S:28180 E:28182 ||| ,
incubated  ||| S:28182 E:28192 ||| JJ
overnight ||| S:28192 E:28201 ||| JJ
,  ||| S:28201 E:28203 ||| ,
and  ||| S:28203 E:28207 ||| CC
used  ||| S:28207 E:28212 ||| VBD
the  ||| S:28212 E:28216 ||| DT
next  ||| S:28216 E:28221 ||| JJ
day ||| S:28221 E:28224 ||| NN
.  ||| S:28224 E:28254 ||| .
Immunoblotting  ||| S:28254 E:28279 ||| NNP
Stable  ||| S:28279 E:28286 ||| NNP
EGFP-cPLA  ||| S:28286 E:28307 ||| NNP
2  ||| S:28307 E:28309 ||| CD
transfectants  ||| S:28309 E:28323 ||| NNS
were  ||| S:28323 E:28328 ||| VBD
grown  ||| S:28328 E:28334 ||| VBN
on  ||| S:28334 E:28337 ||| IN
100  ||| S:28337 E:28341 ||| CD
mm  ||| S:28341 E:28354 ||| CD
dishes  ||| S:28354 E:28361 ||| NNS
at  ||| S:28361 E:28364 ||| IN
5  ||| S:28364 E:28366 ||| CD
×  ||| S:28366 E:28368 ||| CD
10  ||| S:28368 E:28371 ||| CD
3cells ||| S:28371 E:28377 ||| CD
/ ||| S:28377 E:28378 ||| CD
cm  ||| S:28378 E:28381 ||| CD
2in  ||| S:28381 E:28385 ||| CD
growth  ||| S:28385 E:28392 ||| NN
medium  ||| S:28392 E:28399 ||| NN
for  ||| S:28399 E:28403 ||| IN
one  ||| S:28403 E:28407 ||| CD
day ||| S:28407 E:28410 ||| NN
,  ||| S:28410 E:28422 ||| ,
then  ||| S:28422 E:28427 ||| RB
quiesced  ||| S:28427 E:28436 ||| VBN
in  ||| S:28436 E:28439 ||| IN
serum-free  ||| S:28439 E:28450 ||| JJ
medium  ||| S:28450 E:28457 ||| NN
overnight ||| S:28457 E:28466 ||| RB
.  ||| S:28466 E:28468 ||| .
Cells  ||| S:28468 E:28474 ||| NNS
were  ||| S:28474 E:28489 ||| VBD
scraped  ||| S:28489 E:28497 ||| VBN
into  ||| S:28497 E:28502 ||| IN
ice-cold  ||| S:28502 E:28511 ||| JJ
lysis  ||| S:28511 E:28517 ||| JJ
buffer ||| S:28517 E:28523 ||| NN
:  ||| S:28523 E:28525 ||| :
50  ||| S:28525 E:28528 ||| CD
mM  ||| S:28528 E:28531 ||| JJ
HEPES ||| S:28531 E:28536 ||| NNP
,  ||| S:28536 E:28538 ||| ,
pH  ||| S:28538 E:28541 ||| JJ
7.4 ||| S:28541 E:28544 ||| CD
,  ||| S:28544 E:28556 ||| ,
150  ||| S:28556 E:28560 ||| CD
mM  ||| S:28560 E:28563 ||| JJ
sodium  ||| S:28563 E:28570 ||| JJ
chloride ||| S:28570 E:28578 ||| NN
,  ||| S:28578 E:28580 ||| ,
1.5  ||| S:28580 E:28584 ||| CD
mM  ||| S:28584 E:28587 ||| JJ
magnesium  ||| S:28587 E:28597 ||| JJ
chloride ||| S:28597 E:28605 ||| NN
,  ||| S:28605 E:28607 ||| ,
10 ||| S:28607 E:28609 ||| CD
%  ||| S:28609 E:28621 ||| NN
glycerol ||| S:28621 E:28629 ||| NN
,  ||| S:28629 E:28631 ||| ,
1 ||| S:28631 E:28632 ||| CD
%  ||| S:28632 E:28634 ||| NN
Triton  ||| S:28634 E:28641 ||| NNP
X-100 ||| S:28641 E:28646 ||| NNP
,  ||| S:28646 E:28648 ||| ,
1  ||| S:28648 E:28650 ||| CD
mM  ||| S:28650 E:28653 ||| JJ
EGTA ||| S:28653 E:28657 ||| NNP
,  ||| S:28657 E:28659 ||| ,
200  ||| S:28659 E:28663 ||| CD
μM  ||| S:28663 E:28666 ||| JJ
sodium  ||| S:28666 E:28683 ||| JJ
vanadate ||| S:28683 E:28691 ||| NN
,  ||| S:28691 E:28693 ||| ,
10  ||| S:28693 E:28696 ||| CD
mM  ||| S:28696 E:28699 ||| JJ
tetrasodium  ||| S:28699 E:28711 ||| JJ
pyrophosphate ||| S:28711 E:28724 ||| NN
,  ||| S:28724 E:28726 ||| ,
100  ||| S:28726 E:28730 ||| CD
mM  ||| S:28730 E:28733 ||| JJ
sodium  ||| S:28733 E:28750 ||| JJ
fluoride ||| S:28750 E:28758 ||| NN
,  ||| S:28758 E:28760 ||| ,
10  ||| S:28760 E:28763 ||| CD
μg ||| S:28763 E:28765 ||| CD
/ ||| S:28765 E:28766 ||| CD
ml  ||| S:28766 E:28769 ||| JJ
leupeptin ||| S:28769 E:28778 ||| NN
,  ||| S:28778 E:28780 ||| ,
and  ||| S:28780 E:28784 ||| CC
10  ||| S:28784 E:28787 ||| CD
μg ||| S:28787 E:28789 ||| CD
/ ||| S:28789 E:28790 ||| CD
ml  ||| S:28790 E:28793 ||| CD
aprotinin ||| S:28793 E:28802 ||| NNS
.  ||| S:28802 E:28814 ||| .
Lysates  ||| S:28814 E:28822 ||| NNP
were  ||| S:28822 E:28827 ||| VBD
centrifuged  ||| S:28827 E:28839 ||| VBN
at  ||| S:28839 E:28842 ||| IN
15,000  ||| S:28842 E:28849 ||| CD
×  ||| S:28849 E:28862 ||| CD
g  ||| S:28862 E:28864 ||| NN
for  ||| S:28864 E:28868 ||| IN
15  ||| S:28868 E:28871 ||| CD
min ||| S:28871 E:28874 ||| NN
,  ||| S:28874 E:28876 ||| ,
and  ||| S:28876 E:28880 ||| CC
protein  ||| S:28880 E:28898 ||| NN
concentration  ||| S:28898 E:28912 ||| NN
of  ||| S:28912 E:28915 ||| IN
the  ||| S:28915 E:28919 ||| DT
supernatant  ||| S:28919 E:28931 ||| NN
was  ||| S:28931 E:28935 ||| VBD
determined  ||| S:28935 E:28946 ||| VBN
by  ||| S:28946 E:28949 ||| IN
the  ||| S:28949 E:28963 ||| DT
bicinchoninic  ||| S:28963 E:28977 ||| JJ
acid  ||| S:28977 E:28982 ||| NN
method ||| S:28982 E:28988 ||| NN
.  ||| S:28988 E:28990 ||| .
Laemmli  ||| S:28990 E:28998 ||| FW
electrophoresis  ||| S:28998 E:29014 ||| FW
sample  ||| S:29014 E:29031 ||| FW
buffer  ||| S:29031 E:29038 ||| FW
( ||| S:29038 E:29039 ||| -LRB-
5× ||| S:29039 E:29041 ||| NNP
)  ||| S:29041 E:29043 ||| -RRB-
was  ||| S:29043 E:29047 ||| VBD
added  ||| S:29047 E:29053 ||| VBN
to  ||| S:29053 E:29056 ||| TO
the  ||| S:29056 E:29060 ||| DT
lysates ||| S:29060 E:29067 ||| NN
,  ||| S:29067 E:29069 ||| ,
and  ||| S:29069 E:29083 ||| CC
SDS-polyacrylamide  ||| S:29083 E:29102 ||| JJ
gel  ||| S:29102 E:29106 ||| JJ
electrophoresis  ||| S:29106 E:29122 ||| NN
and  ||| S:29122 E:29126 ||| CC
immunoblotting  ||| S:29126 E:29151 ||| NNS
were  ||| S:29151 E:29156 ||| VBD
performed  ||| S:29156 E:29166 ||| VBN
using  ||| S:29166 E:29172 ||| VBG
35  ||| S:29172 E:29175 ||| CD
μg  ||| S:29175 E:29178 ||| CD
lysate  ||| S:29178 E:29185 ||| JJ
protein ||| S:29185 E:29192 ||| NN
,  ||| S:29192 E:29204 ||| ,
phospho-specific  ||| S:29204 E:29221 ||| JJ
antibodies  ||| S:29221 E:29232 ||| NNS
for  ||| S:29232 E:29236 ||| IN
ERK  ||| S:29236 E:29240 ||| NNP
and  ||| S:29240 E:29244 ||| CC
p38 ||| S:29244 E:29247 ||| NNP
,  ||| S:29247 E:29249 ||| ,
and  ||| S:29249 E:29253 ||| CC
rabbit  ||| S:29253 E:29270 ||| JJ
polyclonal  ||| S:29270 E:29281 ||| JJ
antibody  ||| S:29281 E:29290 ||| NN
for  ||| S:29290 E:29294 ||| IN
cPLA  ||| S:29294 E:29310 ||| JJ
2  ||| S:29310 E:29312 ||| CD
[  ||| S:29312 E:29314 ||| -LRB-
21  ||| S:29314 E:29317 ||| CD
]  ||| S:29317 E:29319 ||| -RRB-
.  ||| S:29319 E:29349 ||| .
Dual  ||| S:29349 E:29354 ||| JJ
imaging  ||| S:29354 E:29362 ||| NN
microscopy  ||| S:29362 E:29373 ||| NN
of  ||| S:29373 E:29376 ||| IN
fluorescent  ||| S:29376 E:29388 ||| JJ
protein  ||| S:29388 E:29406 ||| NN
translocation  ||| S:29406 E:29430 ||| NN
In  ||| S:29430 E:29433 ||| IN
order  ||| S:29433 E:29439 ||| NN
to  ||| S:29439 E:29442 ||| TO
compare  ||| S:29442 E:29450 ||| VB
the  ||| S:29450 E:29454 ||| DT
characteristics  ||| S:29454 E:29470 ||| NN
of  ||| S:29470 E:29473 ||| IN
full-length  ||| S:29473 E:29495 ||| JJ
cPLA  ||| S:29495 E:29511 ||| JJ
2  ||| S:29511 E:29513 ||| CD
and  ||| S:29513 E:29517 ||| CC
cPLA  ||| S:29517 E:29533 ||| JJ
2  ||| S:29533 E:29535 ||| CD
S505A  ||| S:29535 E:29541 ||| CD
or  ||| S:29541 E:29544 ||| CC
cPLA  ||| S:29544 E:29560 ||| JJ
2  ||| S:29560 E:29562 ||| CD
S727A  ||| S:29562 E:29568 ||| CD
translocation ||| S:29568 E:29581 ||| NN
,  ||| S:29581 E:29583 ||| ,
while  ||| S:29583 E:29599 ||| IN
controlling  ||| S:29599 E:29611 ||| VBG
for  ||| S:29611 E:29615 ||| IN
cell-to-cell  ||| S:29615 E:29628 ||| JJ
heterogeneity ||| S:29628 E:29641 ||| NN
,  ||| S:29641 E:29643 ||| ,
we  ||| S:29643 E:29646 ||| PRP
used  ||| S:29646 E:29651 ||| VBD
a  ||| S:29651 E:29663 ||| DT
dual  ||| S:29663 E:29668 ||| JJ
CFP ||| S:29668 E:29671 ||| NNP
/ ||| S:29671 E:29672 ||| NNP
YFP  ||| S:29672 E:29676 ||| NNP
imaging  ||| S:29676 E:29684 ||| NN
approach ||| S:29684 E:29692 ||| NN
.  ||| S:29692 E:29694 ||| .
EYFP-cPLA  ||| S:29694 E:29715 ||| JJ
2  ||| S:29715 E:29717 ||| CD
/ ||| S:29717 E:29718 ||| CD
ECFP-cPLA  ||| S:29718 E:29739 ||| JJ
2  ||| S:29739 E:29741 ||| CD
S505A-  ||| S:29741 E:29748 ||| CD
or  ||| S:29748 E:29751 ||| CC
pECFP-cPLA  ||| S:29751 E:29773 ||| JJ
2  ||| S:29773 E:29775 ||| CD
S727A-transfected  ||| S:29775 E:29793 ||| CD
MDCK  ||| S:29793 E:29798 ||| NN
cells  ||| S:29798 E:29804 ||| NNS
grown  ||| S:29804 E:29820 ||| VBN
on  ||| S:29820 E:29823 ||| IN
MatTek  ||| S:29823 E:29830 ||| JJ
plates  ||| S:29830 E:29837 ||| NN
were  ||| S:29837 E:29842 ||| VBD
quiesced  ||| S:29842 E:29851 ||| JJ
overnight  ||| S:29851 E:29861 ||| JJ
in  ||| S:29861 E:29864 ||| IN
serum-free  ||| S:29864 E:29885 ||| JJ
medium ||| S:29885 E:29891 ||| NN
,  ||| S:29891 E:29893 ||| ,
washed  ||| S:29893 E:29900 ||| VBN
with  ||| S:29900 E:29905 ||| IN
and  ||| S:29905 E:29909 ||| CC
incubated  ||| S:29909 E:29919 ||| NN
in  ||| S:29919 E:29922 ||| IN
Hank ||| S:29922 E:29926 ||| NNP
's  ||| S:29926 E:29929 ||| POS
balanced  ||| S:29929 E:29938 ||| JJ
salt  ||| S:29938 E:29953 ||| NN
solution  ||| S:29953 E:29962 ||| NN
( ||| S:29962 E:29963 ||| -LRB-
HBSS ||| S:29963 E:29967 ||| NNP
)  ||| S:29967 E:29969 ||| -RRB-
additionally  ||| S:29969 E:29982 ||| RB
buffered  ||| S:29982 E:29991 ||| VBN
with  ||| S:29991 E:29996 ||| IN
25  ||| S:29996 E:29999 ||| CD
mM  ||| S:29999 E:30002 ||| JJ
HEPES  ||| S:30002 E:30008 ||| NNP
pH  ||| S:30008 E:30021 ||| NNP
7.4  ||| S:30021 E:30025 ||| CD
( ||| S:30025 E:30026 ||| -LRB-
HHBSS ||| S:30026 E:30031 ||| NNP
) ||| S:30031 E:30032 ||| -RRB-
.  ||| S:30032 E:30034 ||| .
Cells  ||| S:30034 E:30040 ||| NNS
were  ||| S:30040 E:30045 ||| VBD
imaged  ||| S:30045 E:30052 ||| VBN
using  ||| S:30052 E:30058 ||| VBG
an  ||| S:30058 E:30061 ||| DT
Olympus  ||| S:30061 E:30069 ||| JJ
inverted  ||| S:30069 E:30088 ||| NNS
microscope  ||| S:30088 E:30099 ||| VBP
equipped  ||| S:30099 E:30108 ||| VBN
with  ||| S:30108 E:30113 ||| IN
a  ||| S:30113 E:30115 ||| DT
60× ||| S:30115 E:30118 ||| NNP
,  ||| S:30118 E:30120 ||| ,
1.25  ||| S:30120 E:30125 ||| CD
NA  ||| S:30125 E:30128 ||| JJ
oil  ||| S:30128 E:30132 ||| NN
immersion  ||| S:30132 E:30152 ||| NN
objective ||| S:30152 E:30161 ||| NN
,  ||| S:30161 E:30163 ||| ,
CFP  ||| S:30163 E:30167 ||| NNP
and  ||| S:30167 E:30171 ||| CC
YFP  ||| S:30171 E:30175 ||| NNP
emission  ||| S:30175 E:30184 ||| NN
filters  ||| S:30184 E:30192 ||| NNS
( ||| S:30192 E:30193 ||| -LRB-
Chroma ||| S:30193 E:30199 ||| NNP
)  ||| S:30199 E:30201 ||| -RRB-
in  ||| S:30201 E:30204 ||| IN
a  ||| S:30204 E:30216 ||| DT
Sutter  ||| S:30216 E:30223 ||| JJ
filter  ||| S:30223 E:30230 ||| JJ
wheel ||| S:30230 E:30235 ||| NN
,  ||| S:30235 E:30237 ||| ,
a  ||| S:30237 E:30239 ||| DT
dual  ||| S:30239 E:30244 ||| JJ
CFP ||| S:30244 E:30247 ||| NNP
/ ||| S:30247 E:30248 ||| NNP
YFP  ||| S:30248 E:30252 ||| NNP
dichroic  ||| S:30252 E:30261 ||| JJ
mirror ||| S:30261 E:30267 ||| NN
,  ||| S:30267 E:30269 ||| ,
and  ||| S:30269 E:30283 ||| CC
a  ||| S:30283 E:30285 ||| DT
TILL  ||| S:30285 E:30290 ||| NNP
Imago  ||| S:30290 E:30296 ||| NNP
CCD  ||| S:30296 E:30300 ||| NNP
camera  ||| S:30300 E:30307 ||| NN
( ||| S:30307 E:30308 ||| -LRB-
TILL  ||| S:30308 E:30313 ||| NNP
Photonics ||| S:30313 E:30322 ||| NNP
) ||| S:30322 E:30323 ||| -RRB-
.  ||| S:30323 E:30325 ||| .
Excitation  ||| S:30325 E:30346 ||| JJ
light  ||| S:30346 E:30352 ||| NN
of  ||| S:30352 E:30355 ||| IN
430  ||| S:30355 E:30359 ||| CD
and  ||| S:30359 E:30363 ||| CC
510  ||| S:30363 E:30367 ||| CD
nm  ||| S:30367 E:30370 ||| NN
for  ||| S:30370 E:30374 ||| IN
CFP  ||| S:30374 E:30378 ||| NNP
and  ||| S:30378 E:30382 ||| CC
YFP ||| S:30382 E:30385 ||| NNP
,  ||| S:30385 E:30387 ||| ,
respectively ||| S:30387 E:30399 ||| RB
,  ||| S:30399 E:30411 ||| ,
was  ||| S:30411 E:30415 ||| VBD
provided  ||| S:30415 E:30424 ||| VBN
using  ||| S:30424 E:30430 ||| VBG
a  ||| S:30430 E:30432 ||| DT
Polychrome  ||| S:30432 E:30443 ||| NNP
IV  ||| S:30443 E:30446 ||| NNP
monochromator  ||| S:30446 E:30460 ||| NNS
( ||| S:30460 E:30461 ||| -LRB-
TILL  ||| S:30461 E:30476 ||| NNP
Photonics ||| S:30476 E:30485 ||| NNP
) ||| S:30485 E:30486 ||| -RRB-
.  ||| S:30486 E:30488 ||| .
TILLvisION  ||| S:30488 E:30499 ||| JJ
software  ||| S:30499 E:30508 ||| NN
was  ||| S:30508 E:30512 ||| VBD
used  ||| S:30512 E:30517 ||| VBN
for  ||| S:30517 E:30521 ||| IN
acquisition  ||| S:30521 E:30543 ||| NN
and  ||| S:30543 E:30547 ||| CC
analysis ||| S:30547 E:30555 ||| NN
.  ||| S:30555 E:30557 ||| .
Bleach  ||| S:30557 E:30564 ||| JJ
values  ||| S:30564 E:30571 ||| NNS
for  ||| S:30571 E:30575 ||| IN
ECFP  ||| S:30575 E:30580 ||| NNP
and  ||| S:30580 E:30584 ||| CC
EYFP  ||| S:30584 E:30589 ||| NNP
were  ||| S:30589 E:30604 ||| VBD
calculated  ||| S:30604 E:30615 ||| VBN
by  ||| S:30615 E:30618 ||| IN
determining  ||| S:30618 E:30630 ||| VBG
the  ||| S:30630 E:30634 ||| DT
background-corrected  ||| S:30634 E:30665 ||| JJ
fluorescence  ||| S:30665 E:30678 ||| NN
for  ||| S:30678 E:30682 ||| IN
the  ||| S:30682 E:30686 ||| DT
entire  ||| S:30686 E:30693 ||| JJ
cell  ||| S:30693 E:30698 ||| NN
with  ||| S:30698 E:30703 ||| IN
respect  ||| S:30703 E:30711 ||| NN
to  ||| S:30711 E:30714 ||| TO
time  ||| S:30714 E:30719 ||| NN
and  ||| S:30719 E:30733 ||| CC
normalizing  ||| S:30733 E:30745 ||| VBG
each  ||| S:30745 E:30750 ||| DT
value  ||| S:30750 E:30756 ||| NN
to  ||| S:30756 E:30759 ||| TO
the  ||| S:30759 E:30763 ||| DT
initial  ||| S:30763 E:30771 ||| JJ
value ||| S:30771 E:30776 ||| NN
.  ||| S:30776 E:30778 ||| .
ECFP ||| S:30778 E:30782 ||| NNP
/ ||| S:30782 E:30783 ||| NNP
EYFP  ||| S:30783 E:30798 ||| NNP
fluorescence  ||| S:30798 E:30811 ||| NN
changes  ||| S:30811 E:30819 ||| NNS
with  ||| S:30819 E:30824 ||| IN
respect  ||| S:30824 E:30832 ||| NN
to  ||| S:30832 E:30835 ||| TO
time  ||| S:30835 E:30840 ||| NN
for  ||| S:30840 E:30844 ||| IN
regions  ||| S:30844 E:30852 ||| NNS
of  ||| S:30852 E:30865 ||| IN
interest  ||| S:30865 E:30874 ||| NN
corresponding  ||| S:30874 E:30888 ||| NN
to  ||| S:30888 E:30891 ||| TO
an  ||| S:30891 E:30894 ||| DT
area  ||| S:30894 E:30899 ||| NN
of  ||| S:30899 E:30902 ||| IN
Golgi  ||| S:30902 E:30908 ||| NNP
membrane  ||| S:30908 E:30917 ||| NN
were  ||| S:30917 E:30932 ||| VBD
determined  ||| S:30932 E:30943 ||| VBN
by  ||| S:30943 E:30946 ||| IN
calculating  ||| S:30946 E:30958 ||| VBG
the  ||| S:30958 E:30962 ||| DT
F  ||| S:30962 E:30975 ||| NN
t  ||| S:30975 E:30977 ||| VBD
/ ||| S:30977 E:30978 ||| CD
F  ||| S:30978 E:30991 ||| NN
0  ||| S:30991 E:30993 ||| CD
,  ||| S:30993 E:30995 ||| ,
where  ||| S:30995 E:31001 ||| WRB
F  ||| S:31001 E:31014 ||| NN
t  ||| S:31014 E:31016 ||| NN
is  ||| S:31016 E:31019 ||| VBZ
the  ||| S:31019 E:31023 ||| DT
background-  ||| S:31023 E:31035 ||| JJ
and  ||| S:31035 E:31049 ||| CC
bleach-corrected  ||| S:31049 E:31066 ||| NNP
ECFP  ||| S:31066 E:31071 ||| NNP
or  ||| S:31071 E:31074 ||| CC
EYFP  ||| S:31074 E:31079 ||| NNP
fluorescence  ||| S:31079 E:31092 ||| NN
at  ||| S:31092 E:31095 ||| IN
time  ||| S:31095 E:31100 ||| NN
=  ||| S:31100 E:31102 ||| SYM
t  ||| S:31102 E:31114 ||| FW
and  ||| S:31114 E:31118 ||| CC
F  ||| S:31118 E:31131 ||| NNP
0  ||| S:31131 E:31133 ||| CD
is  ||| S:31133 E:31136 ||| VBZ
the  ||| S:31136 E:31140 ||| DT
background-corrected  ||| S:31140 E:31161 ||| JJ
ECFP  ||| S:31161 E:31166 ||| NNP
or  ||| S:31166 E:31179 ||| CC
EYFP  ||| S:31179 E:31184 ||| NNP
fluorescence  ||| S:31184 E:31197 ||| NN
at  ||| S:31197 E:31200 ||| IN
time  ||| S:31200 E:31205 ||| NN
=  ||| S:31205 E:31207 ||| SYM
0  ||| S:31207 E:31209 ||| CD
s ||| S:31209 E:31210 ||| NNS
.  ||| S:31210 E:31212 ||| .
Fluorescence  ||| S:31212 E:31225 ||| NNP
was  ||| S:31225 E:31239 ||| VBD
normalized  ||| S:31239 E:31250 ||| VBN
to  ||| S:31250 E:31253 ||| TO
the  ||| S:31253 E:31257 ||| DT
F  ||| S:31257 E:31270 ||| NN
0  ||| S:31270 E:31272 ||| CD
value ||| S:31272 E:31277 ||| NN
,  ||| S:31277 E:31279 ||| ,
which  ||| S:31279 E:31285 ||| WDT
resulted  ||| S:31285 E:31294 ||| VBD
in  ||| S:31294 E:31297 ||| IN
F  ||| S:31297 E:31310 ||| NN
t  ||| S:31310 E:31312 ||| VBD
/ ||| S:31312 E:31313 ||| CD
F  ||| S:31313 E:31326 ||| NN
0  ||| S:31326 E:31328 ||| CD
representing  ||| S:31328 E:31341 ||| VBG
the  ||| S:31341 E:31345 ||| DT
fraction  ||| S:31345 E:31354 ||| NN
of  ||| S:31354 E:31357 ||| IN
total  ||| S:31357 E:31373 ||| JJ
cell  ||| S:31373 E:31378 ||| NN
fluorescence  ||| S:31378 E:31391 ||| NN
at  ||| S:31391 E:31394 ||| IN
Golgi ||| S:31394 E:31399 ||| NNP
.  ||| S:31399 E:31401 ||| .
Final  ||| S:31401 E:31407 ||| JJ
images  ||| S:31407 E:31414 ||| NNS
were  ||| S:31414 E:31419 ||| VBD
produced  ||| S:31419 E:31438 ||| VBN
using  ||| S:31438 E:31444 ||| VBG
Adobe  ||| S:31444 E:31450 ||| NNP
Photoshop ||| S:31450 E:31459 ||| NNP
.  ||| S:31459 E:31489 ||| .
Calcium  ||| S:31489 E:31497 ||| JJ
imaging  ||| S:31497 E:31515 ||| NN
MDCK  ||| S:31515 E:31520 ||| NN
cells  ||| S:31520 E:31526 ||| NNS
grown  ||| S:31526 E:31532 ||| VBN
on  ||| S:31532 E:31535 ||| IN
MatTek  ||| S:31535 E:31542 ||| JJ
plates  ||| S:31542 E:31549 ||| NN
were  ||| S:31549 E:31554 ||| VBD
quiesced  ||| S:31554 E:31573 ||| JJ
overnight  ||| S:31573 E:31583 ||| JJ
in  ||| S:31583 E:31586 ||| IN
serum-free  ||| S:31586 E:31597 ||| JJ
medium ||| S:31597 E:31603 ||| NN
,  ||| S:31603 E:31605 ||| ,
washed  ||| S:31605 E:31612 ||| VBN
with  ||| S:31612 E:31617 ||| IN
HHBSS  ||| S:31617 E:31633 ||| NNP
containing  ||| S:31633 E:31644 ||| VBG
1  ||| S:31644 E:31646 ||| CD
mM  ||| S:31646 E:31649 ||| JJ
probenecid  ||| S:31649 E:31660 ||| NN
and  ||| S:31660 E:31664 ||| CC
incubated  ||| S:31664 E:31674 ||| NN
with  ||| S:31674 E:31679 ||| IN
5  ||| S:31679 E:31681 ||| CD
μM  ||| S:31681 E:31694 ||| JJ
Fura2-AM  ||| S:31694 E:31703 ||| NNP
( ||| S:31703 E:31704 ||| -LRB-
Calbiochem ||| S:31704 E:31714 ||| NNP
)  ||| S:31714 E:31716 ||| -RRB-
in  ||| S:31716 E:31719 ||| IN
HHBSS ||| S:31719 E:31724 ||| NNP
,  ||| S:31724 E:31726 ||| ,
1  ||| S:31726 E:31728 ||| CD
mM  ||| S:31728 E:31731 ||| JJ
probenecid ||| S:31731 E:31741 ||| NN
,  ||| S:31741 E:31743 ||| ,
and  ||| S:31743 E:31747 ||| CC
1 ||| S:31747 E:31748 ||| CD
%  ||| S:31748 E:31760 ||| NN
DMSO  ||| S:31760 E:31765 ||| NN
for  ||| S:31765 E:31769 ||| IN
45  ||| S:31769 E:31772 ||| CD
min  ||| S:31772 E:31776 ||| NN
at  ||| S:31776 E:31779 ||| IN
37°C ||| S:31779 E:31783 ||| CD
.  ||| S:31783 E:31785 ||| .
Cells  ||| S:31785 E:31791 ||| NNS
were  ||| S:31791 E:31796 ||| VBD
then  ||| S:31796 E:31801 ||| RB
washed  ||| S:31801 E:31808 ||| VBN
with  ||| S:31808 E:31823 ||| IN
HHBSS  ||| S:31823 E:31829 ||| NNP
containing  ||| S:31829 E:31840 ||| VBG
1  ||| S:31840 E:31842 ||| CD
mM  ||| S:31842 E:31845 ||| JJ
probenecid  ||| S:31845 E:31856 ||| NN
and  ||| S:31856 E:31860 ||| CC
imaged  ||| S:31860 E:31867 ||| NN
after  ||| S:31867 E:31873 ||| IN
a  ||| S:31873 E:31875 ||| DT
30  ||| S:31875 E:31888 ||| CD
min  ||| S:31888 E:31892 ||| JJ
incubation  ||| S:31892 E:31903 ||| NN
for  ||| S:31903 E:31907 ||| IN
de-esterification  ||| S:31907 E:31925 ||| JJ
of  ||| S:31925 E:31928 ||| IN
the  ||| S:31928 E:31932 ||| DT
Fura2-AM ||| S:31932 E:31940 ||| NN
.  ||| S:31940 E:31952 ||| .
Single-cell  ||| S:31952 E:31964 ||| JJ
imaging  ||| S:31964 E:31972 ||| NN
was  ||| S:31972 E:31976 ||| VBD
performed  ||| S:31976 E:31986 ||| VBN
on  ||| S:31986 E:31989 ||| IN
the  ||| S:31989 E:31993 ||| DT
Olympus  ||| S:31993 E:32001 ||| JJ
system  ||| S:32001 E:32018 ||| NN
described  ||| S:32018 E:32028 ||| VBD
above ||| S:32028 E:32033 ||| RB
,  ||| S:32033 E:32035 ||| ,
but  ||| S:32035 E:32039 ||| CC
using  ||| S:32039 E:32045 ||| VBG
a  ||| S:32045 E:32047 ||| DT
40× ||| S:32047 E:32050 ||| NNP
,  ||| S:32050 E:32052 ||| ,
1.35  ||| S:32052 E:32057 ||| CD
NA  ||| S:32057 E:32060 ||| JJ
oil  ||| S:32060 E:32064 ||| NN
immersion  ||| S:32064 E:32084 ||| NN
objective  ||| S:32084 E:32094 ||| NN
and  ||| S:32094 E:32098 ||| CC
a  ||| S:32098 E:32100 ||| DT
Fura2  ||| S:32100 E:32106 ||| JJ
dichroic  ||| S:32106 E:32115 ||| JJ
mirror  ||| S:32115 E:32122 ||| NN
and  ||| S:32122 E:32126 ||| CC
emission  ||| S:32126 E:32135 ||| JJ
filter  ||| S:32135 E:32152 ||| NNS
( ||| S:32152 E:32153 ||| -LRB-
Chroma ||| S:32153 E:32159 ||| NNP
) ||| S:32159 E:32160 ||| -RRB-
.  ||| S:32160 E:32162 ||| .
Fura2  ||| S:32162 E:32168 ||| NNP
image  ||| S:32168 E:32174 ||| NN
pairs  ||| S:32174 E:32180 ||| NN
illuminated  ||| S:32180 E:32192 ||| NN
at  ||| S:32192 E:32195 ||| IN
340  ||| S:32195 E:32199 ||| CD
and  ||| S:32199 E:32203 ||| CC
380  ||| S:32203 E:32207 ||| CD
nm  ||| S:32207 E:32220 ||| NNS
were  ||| S:32220 E:32225 ||| VBD
taken  ||| S:32225 E:32231 ||| VBN
at  ||| S:32231 E:32234 ||| IN
1  ||| S:32234 E:32236 ||| CD
Hz ||| S:32236 E:32238 ||| NNP
.  ||| S:32238 E:32240 ||| .
The  ||| S:32240 E:32244 ||| DT
[ ||| S:32244 E:32245 ||| -LRB-
Ca  ||| S:32245 E:32248 ||| NNP
2+ ||| S:32248 E:32250 ||| NNP
]  ||| S:32250 E:32263 ||| -RRB-
i  ||| S:32263 E:32265 ||| FW
increase  ||| S:32265 E:32274 ||| NN
is  ||| S:32274 E:32277 ||| VBZ
expressed  ||| S:32277 E:32287 ||| VBN
as  ||| S:32287 E:32290 ||| IN
the  ||| S:32290 E:32294 ||| DT
ratio  ||| S:32294 E:32310 ||| NN
of  ||| S:32310 E:32313 ||| IN
the  ||| S:32313 E:32317 ||| DT
background-corrected  ||| S:32317 E:32338 ||| JJ
Fura2  ||| S:32338 E:32344 ||| CD
fluorescence  ||| S:32344 E:32357 ||| NN
at  ||| S:32357 E:32360 ||| IN
340  ||| S:32360 E:32364 ||| CD
and  ||| S:32364 E:32378 ||| CC
380  ||| S:32378 E:32382 ||| CD
nm  ||| S:32382 E:32385 ||| NNS
[  ||| S:32385 E:32387 ||| -LRB-
42  ||| S:32387 E:32390 ||| CD
]  ||| S:32390 E:32392 ||| -RRB-
.  ||| S:32392 E:32422 ||| .
Measurement  ||| S:32422 E:32434 ||| NN
of  ||| S:32434 E:32437 ||| IN
AA  ||| S:32437 E:32440 ||| NN
release  ||| S:32440 E:32458 ||| NN
The  ||| S:32458 E:32462 ||| DT
protocol  ||| S:32462 E:32471 ||| NN
for  ||| S:32471 E:32475 ||| IN
determining  ||| S:32475 E:32487 ||| VBG
AA  ||| S:32487 E:32490 ||| NN
release  ||| S:32490 E:32498 ||| NN
is  ||| S:32498 E:32501 ||| VBZ
essentially  ||| S:32501 E:32523 ||| RB
as  ||| S:32523 E:32526 ||| RB
described  ||| S:32526 E:32536 ||| VBN
[  ||| S:32536 E:32538 ||| -LRB-
15  ||| S:32538 E:32541 ||| CD
21  ||| S:32541 E:32544 ||| CD
]  ||| S:32544 E:32546 ||| -RRB-
.  ||| S:32546 E:32548 ||| .
MDCK  ||| S:32548 E:32553 ||| NNP
cells  ||| S:32553 E:32559 ||| NNS
stably  ||| S:32559 E:32566 ||| VBP
expressing  ||| S:32566 E:32587 ||| VBG
EGFP-cPLA  ||| S:32587 E:32608 ||| JJ
2  ||| S:32608 E:32610 ||| CD
were  ||| S:32610 E:32615 ||| VBD
plated  ||| S:32615 E:32622 ||| VBN
in  ||| S:32622 E:32625 ||| IN
12-well  ||| S:32625 E:32633 ||| CD
plates  ||| S:32633 E:32640 ||| NN
at  ||| S:32640 E:32643 ||| IN
5  ||| S:32643 E:32645 ||| CD
×  ||| S:32645 E:32657 ||| CD
10  ||| S:32657 E:32660 ||| CD
3cells ||| S:32660 E:32666 ||| CD
/ ||| S:32666 E:32667 ||| CD
cm  ||| S:32667 E:32670 ||| CD
2and  ||| S:32670 E:32675 ||| CD
incubated  ||| S:32675 E:32685 ||| NN
in  ||| S:32685 E:32688 ||| IN
growth  ||| S:32688 E:32695 ||| NN
medium  ||| S:32695 E:32702 ||| NN
overnight ||| S:32702 E:32711 ||| RB
.  ||| S:32711 E:32723 ||| .
Cells  ||| S:32723 E:32729 ||| NNS
were  ||| S:32729 E:32734 ||| VBD
then  ||| S:32734 E:32739 ||| RB
washed  ||| S:32739 E:32746 ||| VBN
twice  ||| S:32746 E:32752 ||| RB
with  ||| S:32752 E:32757 ||| IN
serum-free  ||| S:32757 E:32768 ||| JJ
medium  ||| S:32768 E:32775 ||| NN
and  ||| S:32775 E:32789 ||| CC
incubated  ||| S:32789 E:32799 ||| NN
with  ||| S:32799 E:32804 ||| IN
0.25  ||| S:32804 E:32809 ||| CD
μCi  ||| S:32809 E:32813 ||| NNS
[  ||| S:32813 E:32815 ||| -LRB-
3H ||| S:32815 E:32817 ||| NNP
] ||| S:32817 E:32818 ||| -RRB-
-AA ||| S:32818 E:32821 ||| NNP
/ ||| S:32821 E:32822 ||| NNP
well  ||| S:32822 E:32827 ||| RB
in  ||| S:32827 E:32830 ||| IN
serum-free  ||| S:32830 E:32851 ||| JJ
medium  ||| S:32851 E:32858 ||| NN
overnight ||| S:32858 E:32867 ||| RB
.  ||| S:32867 E:32869 ||| .
U0126  ||| S:32869 E:32875 ||| NNP
or  ||| S:32875 E:32878 ||| CC
vehicle  ||| S:32878 E:32886 ||| NN
was  ||| S:32886 E:32890 ||| VBD
added  ||| S:32890 E:32896 ||| VBN
to  ||| S:32896 E:32899 ||| TO
each  ||| S:32899 E:32904 ||| DT
well  ||| S:32904 E:32919 ||| RB
and  ||| S:32919 E:32923 ||| CC
the  ||| S:32923 E:32927 ||| DT
cells  ||| S:32927 E:32933 ||| NNS
were  ||| S:32933 E:32938 ||| VBD
then  ||| S:32938 E:32943 ||| RB
incubated  ||| S:32943 E:32953 ||| VBN
for  ||| S:32953 E:32957 ||| IN
15  ||| S:32957 E:32960 ||| CD
min  ||| S:32960 E:32964 ||| NN
at  ||| S:32964 E:32967 ||| IN
37°C  ||| S:32967 E:32972 ||| CD
in  ||| S:32972 E:32985 ||| IN
5 ||| S:32985 E:32986 ||| CD
%  ||| S:32986 E:32988 ||| NN
CO  ||| S:32988 E:33002 ||| NNP
2  ||| S:33002 E:33004 ||| CD
.  ||| S:33004 E:33006 ||| .
Cells  ||| S:33006 E:33012 ||| NNS
were  ||| S:33012 E:33017 ||| VBD
washed  ||| S:33017 E:33024 ||| VBN
to  ||| S:33024 E:33027 ||| TO
remove  ||| S:33027 E:33044 ||| VB
unincorporated  ||| S:33044 E:33059 ||| NNS
[  ||| S:33059 E:33061 ||| -LRB-
3H ||| S:33061 E:33063 ||| NNP
] ||| S:33063 E:33064 ||| -RRB-
-AA  ||| S:33064 E:33068 ||| JJ
and  ||| S:33068 E:33072 ||| CC
then  ||| S:33072 E:33077 ||| RB
incubated  ||| S:33077 E:33087 ||| VBN
in  ||| S:33087 E:33090 ||| IN
HHBSS  ||| S:33090 E:33106 ||| NNP
supplemented  ||| S:33106 E:33119 ||| NN
with  ||| S:33119 E:33124 ||| IN
0.05 ||| S:33124 E:33128 ||| CD
%  ||| S:33128 E:33130 ||| NN
BSA  ||| S:33130 E:33134 ||| NN
with  ||| S:33134 E:33139 ||| IN
either  ||| S:33139 E:33146 ||| DT
U0126  ||| S:33146 E:33152 ||| NNP
or  ||| S:33152 E:33155 ||| CC
vehicle ||| S:33155 E:33162 ||| NN
.  ||| S:33162 E:33174 ||| .
Cells  ||| S:33174 E:33180 ||| NNS
were  ||| S:33180 E:33185 ||| VBD
stimulated  ||| S:33185 E:33196 ||| VBN
with  ||| S:33196 E:33201 ||| IN
the  ||| S:33201 E:33205 ||| DT
agonist  ||| S:33205 E:33213 ||| NN
of  ||| S:33213 E:33216 ||| IN
choice  ||| S:33216 E:33223 ||| NN
and  ||| S:33223 E:33227 ||| CC
the  ||| S:33227 E:33241 ||| DT
medium  ||| S:33241 E:33248 ||| NN
was  ||| S:33248 E:33252 ||| VBD
collected  ||| S:33252 E:33262 ||| VBN
at  ||| S:33262 E:33265 ||| IN
appropriate  ||| S:33265 E:33277 ||| JJ
time  ||| S:33277 E:33282 ||| NN
points ||| S:33282 E:33288 ||| NNS
.  ||| S:33288 E:33290 ||| .
The  ||| S:33290 E:33304 ||| DT
medium  ||| S:33304 E:33311 ||| NN
was  ||| S:33311 E:33315 ||| VBD
centrifuged  ||| S:33315 E:33327 ||| VBN
at  ||| S:33327 E:33330 ||| IN
500  ||| S:33330 E:33334 ||| CD
g  ||| S:33334 E:33336 ||| NN
for  ||| S:33336 E:33340 ||| IN
5  ||| S:33340 E:33342 ||| CD
min ||| S:33342 E:33345 ||| NN
,  ||| S:33345 E:33347 ||| ,
and  ||| S:33347 E:33351 ||| CC
the  ||| S:33351 E:33355 ||| DT
amount  ||| S:33355 E:33372 ||| NN
of  ||| S:33372 E:33375 ||| IN
radioactivity  ||| S:33375 E:33389 ||| NN
in  ||| S:33389 E:33392 ||| IN
the  ||| S:33392 E:33396 ||| DT
supernatant  ||| S:33396 E:33408 ||| NN
was  ||| S:33408 E:33412 ||| VBD
determined  ||| S:33412 E:33423 ||| VBN
by  ||| S:33423 E:33436 ||| IN
scintillation  ||| S:33436 E:33450 ||| JJ
counting ||| S:33450 E:33458 ||| NN
.  ||| S:33458 E:33460 ||| .
Cells  ||| S:33460 E:33466 ||| NNS
were  ||| S:33466 E:33471 ||| VBD
scraped  ||| S:33471 E:33479 ||| VBN
in  ||| S:33479 E:33482 ||| IN
0.5  ||| S:33482 E:33486 ||| CD
ml  ||| S:33486 E:33489 ||| CD
0.1 ||| S:33489 E:33492 ||| CD
%  ||| S:33492 E:33504 ||| NN
Triton  ||| S:33504 E:33511 ||| NNP
X-100  ||| S:33511 E:33517 ||| NNP
for  ||| S:33517 E:33521 ||| IN
determining  ||| S:33521 E:33533 ||| VBG
the  ||| S:33533 E:33537 ||| DT
total  ||| S:33537 E:33543 ||| JJ
cellular  ||| S:33543 E:33562 ||| JJ
radioactivity ||| S:33562 E:33575 ||| NN
.  ||| S:33575 E:33608 ||| .
Authors ||| S:33608 E:33615 ||| NNP
'  ||| S:33615 E:33617 ||| POS
contributions  ||| S:33617 E:33639 ||| NNS
JHE  ||| S:33639 E:33643 ||| VBP
carried  ||| S:33643 E:33651 ||| VBN
out  ||| S:33651 E:33655 ||| RP
the  ||| S:33655 E:33659 ||| DT
Ca  ||| S:33659 E:33662 ||| NNP
and  ||| S:33662 E:33666 ||| CC
FP  ||| S:33666 E:33669 ||| NNP
imaging  ||| S:33669 E:33677 ||| NN
studies ||| S:33677 E:33684 ||| NNS
,  ||| S:33684 E:33694 ||| ,
participated  ||| S:33694 E:33707 ||| VBD
in  ||| S:33707 E:33710 ||| IN
the  ||| S:33710 E:33714 ||| DT
design  ||| S:33714 E:33721 ||| NN
and  ||| S:33721 E:33725 ||| CC
coordination  ||| S:33725 E:33738 ||| NN
of  ||| S:33738 E:33741 ||| IN
the  ||| S:33741 E:33745 ||| DT
study ||| S:33745 E:33750 ||| NN
,  ||| S:33750 E:33760 ||| ,
and  ||| S:33760 E:33764 ||| CC
drafted  ||| S:33764 E:33772 ||| VBD
the  ||| S:33772 E:33776 ||| DT
manuscript ||| S:33776 E:33786 ||| NN
.  ||| S:33786 E:33788 ||| .
DJF  ||| S:33788 E:33792 ||| NNP
performed  ||| S:33792 E:33802 ||| VBD
the  ||| S:33802 E:33806 ||| DT
AA  ||| S:33806 E:33809 ||| NN
release  ||| S:33809 E:33825 ||| NN
and  ||| S:33825 E:33829 ||| CC
Western  ||| S:33829 E:33837 ||| JJ
blot  ||| S:33837 E:33842 ||| JJ
studies  ||| S:33842 E:33850 ||| NNS
and  ||| S:33850 E:33854 ||| CC
participated  ||| S:33854 E:33867 ||| VBD
in  ||| S:33867 E:33870 ||| IN
the  ||| S:33870 E:33874 ||| DT
design  ||| S:33874 E:33881 ||| NN
and  ||| S:33881 E:33893 ||| CC
coordination  ||| S:33893 E:33906 ||| NN
of  ||| S:33906 E:33909 ||| IN
the  ||| S:33909 E:33913 ||| DT
study ||| S:33913 E:33918 ||| NN
.  ||| S:33918 E:33920 ||| .
CCL  ||| S:33920 E:33924 ||| NNP
conceived  ||| S:33924 E:33934 ||| VBD
of  ||| S:33934 E:33937 ||| IN
the  ||| S:33937 E:33941 ||| DT
study ||| S:33941 E:33946 ||| NN
,  ||| S:33946 E:33956 ||| ,
participated  ||| S:33956 E:33969 ||| VBD
in  ||| S:33969 E:33972 ||| IN
its  ||| S:33972 E:33976 ||| PRP$
design  ||| S:33976 E:33983 ||| NN
and  ||| S:33983 E:33987 ||| CC
coordination ||| S:33987 E:33999 ||| NN
,  ||| S:33999 E:34001 ||| ,
and  ||| S:34001 E:34013 ||| CC
participated  ||| S:34013 E:34026 ||| VBD
in  ||| S:34026 E:34029 ||| IN
writing  ||| S:34029 E:34037 ||| VBG
the  ||| S:34037 E:34041 ||| DT
draft ||| S:34041 E:34046 ||| NN
.  ||| S:34046 E:34048 ||| .
All  ||| S:34048 E:34052 ||| DT
authors  ||| S:34052 E:34060 ||| NNS
read  ||| S:34060 E:34065 ||| VBP
and  ||| S:34065 E:34077 ||| CC
approved  ||| S:34077 E:34086 ||| VBD
the  ||| S:34086 E:34090 ||| DT
final  ||| S:34090 E:34096 ||| JJ
manuscript ||| S:34096 E:34106 ||| NN
.  ||| S:34106 E:34123 ||| .
